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Abstract
E. coli 0157:H7 causes serious human disease including haemolytic uraemic
syndrome and haemorrhagic colitis. Cattle are a known reservoir for E. coli
0157:H7, but despite often-large levels of carriage, appear unaffected by the
organism. Two important factors in the ability of E. coli 0157 to cause disease
are i) the possession of a 35Kbp pathogenicity island known as the locus of
enterocyte effacement (LEE) and ii) the production of verotoxin. The products of
the LEE interact bringing about intimate attachment to gut eneterocytes via the
formation of attaching and effacing (AE) lesions.
The role of the bovine intestinal microbiota and immune system in protection
against E. coli 0157 associated disease is unclear. PCR and monoclonal
antibodies were used to compare the distribution of the five E. coli LPS core
types (R1-R4 + K12) within two populations of faecal isolates from healthy
humans and cattle. To study the immune response in cattle LPS antigens were
prepared and recombinant Intimin280 and EspB were cloned into the pGEX-4t2
expression vector. The GST tagged proteins were purified by affinity
chromatography. ELISA and immunoblot were used to examine the sera of
healthy and experimentally infected cattle for antibodies reactive to antigens
from E. coli 0157:H7.
E. coli possessing R1 core LPS were most frequently detected in both human
and cattle populations (50% and 40% respectively). Compared to the human
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isolates a significantly higher level of bacteria with R3 core LPS was detected
among the bovine commensal £. coli (p<0.05). In each population the highest
level of antibody detected was reactive to the R4 core. In cattle the level of anti-
R3 core antibody was significantly higher than the level of anti-R1, R2 and K12
antibody (p<0.01). This was not observed in humans.
Healthy adult cattle were found to have little or no antibody reactive to Int280.
Prior to experimental challenge with E. coli 0157, a number of calves had little
or no detectable antibody to either Int280 or EspB; all other calves had
detectable levels. The period of experimental infection did not alter the level of
response in these animals. LPS was the only antigen found to elicit a response
in any of the calves. The ability of the E. coli 0157 inoculum to colonise the
calves appeared unaffected by the levels of anti-lnt280, EspB and LPS antibody
detected. The antibodies present in the sera of the experimentally infected
calves did not prevent the formation of AE lesions on HeLa cell monolayers
Antibody detected in calves prior to experimental infection may have been
acquired from colostrum. However the lack of systemic responses to Int280
observed in healthy adult cattle would suggest that the response detected in
calves originates from exposure to these antigens at birth. It is possible that the
maturation of the commensal flora and local mucosal immunity in the calf
reduces the level of systemic exposure to antigens such as Int280 and EspB
and as a result the systemic response diminishes. Despite the presence of
xiv
antibodies reactive to Int280, EspB and LPS, E. coli 0157 is still able to colonise
calves yet disease is not recognised. The role of the bovine immune system in
protection against E. coli 0157 disease remains unclear.
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Introduction
1.1 Escherichia coli a brief history
Escherichia coli is a Gram-negative facultative anaerobic organism, forming
large circular smooth colourless colonies on nutrient agar. Escherich first
isolated 'Bacterium coli' in 1885 from the stools of infants, however the
organism was subsequently re-classified under the genus Escherichia in
1920 (Parker & Duerden, 1990). Kauffman (1947) proposed the technique of
typing E. coli upon the basis of the LPS (O-antigen), the capsule type
(K-antigen) and flagella type (H-antigen). E. coli isolates are now routinely
referred to on the basis of their 0,H and K types. Today there are over 170
E. coli serotypes recognised and the genomes of E. coli K12 MG1655, E. coli
0157:H7 EDL933 and E. coli 0157 Sakai have all been fully sequenced
(Blattner et al, 1997, Hayashi et al 2001,Ohnishi et al, 2001 and Perna et al,
2001).
1.2 Virotypes
E. coli implicated in diarrhoeal disease are often categorised into groups
known as virotypes (virulence and types). Each group is made up of
particular E. coli serotypes that share a common range of virulence
determinants (Levine, 1987, Joseph et al, 2002). Virotypes include
enterotoxigenic E. coli (ETEC), enteroinvasive E. coli (EIEC),
enteroaggregative E. coli (EAEC), enteropathogenic E. coli (EPEC) and
enterohaemorrhagic E. coli (EHEC).
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1.2.1 Enterotoxigenic E. coli (ETEC)
The ETEC are characterised by their ability to produce heat-labile (LT)
exotoxin and two heat stable-toxins (STa & b) causing non-inflammatory
diarrhoea (Joseph et al, 2002). The LT exotoxin is structurally similar and
acts in a similar way to the main toxin of Vibrio cholerae causing massive
fluid loss into the intestinal lumen (Guerrant et al, 1999).
1.2.2 Enteroinvasive E. coli (EIEC)
Disease caused by the EIEC shows similarities with shigellosis produced by
Shigella spp. Plasmid encoded cell invasion factors allow the E. coli to invade
and spread to adjacent cells (Joseph et al, 2002 and Guerrant et al, 1999).
1.2.3 Enteroaggregative E. coli (EAEC)
EAEC are so called due to their aggregative adherence patterns on Hep-2
cells (Joseph et al, 2002). Adherence is mediated by the plasmid encoded
aggregative adherence fimbriae I and II (AAFI, AAFII) (Guerrant et al, 1999).
EAEC are not known to secrete toxin but are associated with chronic or
persistent diarrhoea (Joseph et al, 2002). The diarrhoeic effects of the EAEC
may result from the production of a factor found to up-regulate interleukin-8
(IL-8) production in Caco-2 cells. The subsequent attraction of neutrophils
and macrophages into the intestinal lumen may disrupt the epithelial barrier.
1.2.4 Enteropathogenic E. coli (EPEC)
EPEC have the ability to bind intimately to the surface of host cells and, via a
type III secretion system, pass virulence determinants directly into the host
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cell (Vallance and Finlay, 2000) The subsequent interaction of these bacterial
proteins with the host cell lead to the formation of attaching and effacing
lesions. These lesions are characterised by the effacement of microvilli and
accumulation of polymerised actin beneath the site of bacterial adherence.
This massive cytoskeletal rearrangement leads to the formation of a pedestal
like structure (Vallance and Finlay, 2000). All of the components required to
bring about AE lesion formation have been mapped to a 35Kbp pathogenicity
island termed the locus of enterocyte effacement (LEE). The diarrhoea
caused by EPEC is acute and non-bloody (Guerrant et al, 1999).
1.2.5 Enterohaemorrhagic E. coli (EHEC)
EHEC possess the LEE and share the ability to cause AE lesions on gut
enterocytes. Since 1982 the EHEC have been implicated in a broad range of
human diseases as a result of foodstuffs contaminated with faeces from
animals colonised with EHEC and direct contact with infected animals
(Nataro and Kaper 1998; Poxton, 1999; Chapman et al, 2000). Conditions
arising as a result of EHEC infection include mild non-bloody diarrhoea,
haemorrhagic colitis (HC), haemorrhagic uraemic syndrome (HUS) and
thrombotic thrombocytopaenic purpura (Louie et al, 1999). As well as
possessing the same virulence determinants as the EPEC, the EHEC have
acquired the ability to produce verotoxin (section 1.3), which in some cases
increases the severity of disease.
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1.3 Escherichia coli 0157:H7
1.3.1 The emergence of a new pathogen
Since its isolation from a woman with bloody diarrhoea in 1975 (Riley et al,
1983) E coli 0157:H7 has become a major human pathogen. In 1982 two
outbreaks of severe abdominal cramps with initially watery, progressing to
grossly bloody diarrhoea affected at least 47 people. All were connected with
having eaten similar meals at the same fast-food chains in Oregon and
Michigan (Riley et al, 1983). Reports of similar sporadic outbreaks in both the
USA and Japan had failed to identify the aetiological agent. Stool samples
were examined for a variety of pathogens including Salmonella spp., Shigella
spp., Campylobacter spp., Clostridium difficile and E. coli (Wells et al 1983).
A rare serotype of E. coli, 0157:H7, was identified as the cause of the
Michigan haemorrhagic colitis outbreaks. Although no E. coli 0157:H7 was
recovered from a cooked hamburger taken from one of the restaurants
implicated in the outbreak, it was isolated from a frozen hamburger from the
same outlet. The mechanism by which this organism caused disease was
unclear. Since 1982 EHEC have been implicated in a number of large
disease outbreaks. Over the past 11 years the number of reported cases of
E. coli 0157 associated disease in England and Wales have risen sharply
from just over 200 reported cases in 1992 to over 1000 in 2001 (Figure 1.1).
There is a definite seasonal variation in the number of cases reported with
figures being higher in the spring and summer months than in the winter
(Figure 1.2). The seasonal variation seen in human disease outbreaks is
mirrored by the prevalence of E. coli 0157 in cattle during the same months
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(Hancock et al, 1994). This is possibly due to an increase in outdoor
activities, children's camps and barbeques during the spring and summer.
Owing to the elevated levels of E. coli 0157 carriage among cattle and
consequently the environment at this time, the risk of infection from either
source is greater. Poorly cooked food and or contaminated water can lead to
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Figure 1.1: The number of reported cases of E. coli 0157 infection over the last twelve
years in England and Wales. Data from 2001 are preliminary. Information obtained
from the Public Health Laboratory Service, UK (www.phls.co.uk)
1999 2000 2001
Year
Figure 1.2: The number of reported cases of E. coli 0157 infection over the last three
years in England and Wales. Data show the number of cases reported each quarter.
Data from 2001 are preliminary. Information obtained from the Public Health
Laboratory Service, UK (www.phls.co.uk)
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As detection techniques improve and people become more aware of the
organism it is inevitable that the number of reported cases will continue to
rise. Cases such as the UK's largest outbreak of E. coli 0157:H7, which
started on November 22nd 1996, attract massive media attention. A
butcher's outlet in Lanarkshire, Scotland was identified as the source of the
outbreak. Two hundred and seventy nine people were infected with the
organism and 22 died as a result of infection (Cowden et al, 2001).
There is considerable debate as to whether or not E. coli 0157 is an
emerging pathogen, or whether in the past it was simply undiagnosed. Since
the recognition of E. coli 0157 as the causative agent of HUS and HC,
collections of E. coli isolates associated with human disease prior to 1982
have been examined for the presence of E. coli 0157. The Public Health
Laboratory, UK reported only one E. coli 0157 isolate among 15,000 strains
typed between 1978 and 1982 (Day et al, 1983). Similar findings were
reported in Canada (Johnson et al, 1983, Griffin and Tauxe, 1991). It is clear
therefore that the rise in E coli 0157 associated disease since 1982 is real,
and due to the recent emergence of this pathogen. A study by Avery et al
(2002) used pulsed field gel electrophoresis and ribotyping to examine 207 E.
coli 0157 isolates. The combined use of the two techniques was able to
group the 207 isolates into 146 types. This emphasises the enormous
diversity that exists within the E. coli 0157 serotype.
7
Although possessing identical virulence determinants to those of the EPEC,
disease caused by EHEC is usually much more severe. Konowalchuk et al
(1977) examined a number of ETEC, EIEC, and non-toxigenic E. coli strains
and noted the ability of a number of ETEC strains to produce a toxin that had
a very different cytotoxicity profile from LT and ST. The toxin was found to
have a cytotoxic effect on Vero cells (African green monkey kidney cell line)
only and was named VT (toxic to Vero cells). The toxin has subsequently
been shown to be almost indistinguishable from the shiga-toxin of Shigella
dysentehae and hence is sometimes referred to as shiga-like toxin (SLT).
The genes for verotoxin production are phage encoded. These organisms
were grouped as the verotoxigenic Escherichia coli (VTEC). Since then a
large number of serotypes have been identified as producing VT although not
all have been associated with human disease. The EHEC are a further
subdivision of the VTEC. EHEC possess the LEE pathogenicity island and
the ability to produce one or more shiga-like toxin(s) (Perna et al, 1998).
1.3.2 Genetic diversity
The determination of the genome sequences of E. coli K12, 0157 Sakai and
0157 EDL933 have allowed detailed comparisons of the genomes of
different E. coli (Ohnishi et al, 2001). E. coli K12 MG1855, E. coli 0157 Sakai
and E. coli 0157 EDL933 all share around 4.1Mbp of DNA (Ohnishi et al,
2001). There is however considerable difference between the K12 strain and
the two 0157 strains, which is attributable to the large amount of strain
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specific sequence in both (1.5Mbp in 0157 Sakai and 1.34Mbp in 0157
EDL933).
1.3.3 Evolution
The evolution of the EHEC from a possible EPEC origin has been examined
in great detail. Feng et al (1998) proposed a model for the evolution of E. coli
0157.H7. Using multilocus enzyme electrophoresis, the relationship between
a number of 0157 strains and other E. coli was investigated. Among 46
representative isolates, 15 electrophoretic types were found and close
relationships between a number of 0157:H7 and EPEC like 055:H7 isolates
were noted.
Perna et al (1998) looked at sequence similarities between the LEE
pathogenicity island of E. coli 0157:H7 EDL933 and an EPEC strain. It was
evident that there were significant differences between the two LEE
sequences. While the average level of nucleotide identity was 93.9% many of
the key genes involved in the formation of AE lesions, for example tir,
(encoding the translocated intimin receptor), shared as little as 66%
homology. Other genes showed a high degree of conservation especially
those involved in type III secretion. This is strong evidence for the evolution
of the two strains from a common ancestor and lends weight to the possibility
that the EHEC evolved from the EPEC via the acquisition of the verotoxin
encoding phage.
9
Citrobacter rodentium causes murine colonic hyperplasia. In extreme cases
the disease is fatal but more often is associated with mild diarrhoea, coat
ruffling and retarded growth. C. rodentium, like the EPEC and EHEC,
possesses the LEE pathogenicity island and is able to produce AE lesions in
infected mice (Newman et al, 1999). In contrast to the LEE of both EPEC and
EHEC the LEE of C. rodentium (LEEc) was poorly characterised until very
recently. Deng et al (2001) sequenced the entire C. rodentium LEE providing
an insight into where the pathogenicity island may have come from. While
LEEc was virtually identical to the LEE from EHEC and EPEC, in addition to
insertion sequence elements at various point within LEEc, a number of genes
had unique orientation. They also found that the LEEc was flanked by
sequences that showed homology with a number of known plasmids. This
was suggestive of a number of things, either the LEE was plasmid encoded,
or the LEE had once been a mobile element in a plasmid and had become
integrated into the chromosome. The detection of a number of insertion
sequences within LEEc may suggest passage through a number of
organisms. Deng et al (2001) suggested that C. rodentium, EPEC and EHEC
had obtained the LEE pathogenicity island independently and by horizontal
transfer among AE pathogens.
1.4 Transmission routes
While infection after ingestion of contaminated foodstuffs is well documented
(Morgan et al 1993, Cowden et al, 2001, Keene et al, 1997), the question of
whether or not direct contact between humans and animals could result in
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infection has only recently been answered. Recent studies have utilised
molecular typing techniques along with more established methods of EHEC
typing such as phage typing, to investigate the transmission of EHEC strains
from cattle to humans.
Louie et al (1999) investigated a number of human and bovine EHEC strains
associated with disease outbreaks from two farms. Phage typing, verotoxin
typing, pulsed field gel electrophoresis (PFGE) and plasmid profiling were
used to identify any relationships between the outbreak isolates and a
number of bovine strains isolated from cattle on each of the farms. They were
able to show that a number of human isolates were of the same PFGE type
as those isolated from cattle belonging to the outbreak farms. Chapman et al
(2000) reported an incidence of infection in two children aged three and four
after a visit to an inner city open farm. E. coli 0157:H7 was cultured from
faecal samples and swabs from cattle, pigs, sheep and goats. In addition,
environmental sampling at the farm revealed extensive E. coli 0157:H7
contamination. Molecular typing techniques confirmed that the strains
isolated from the two children were of the same type obtained from the farm
samples. It is clear therefore that direct transmission from animals to humans
does occur.
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1.5 The locus of enterocyte effacement (LEE)
The locus of enterocyte effacement (LEE) is a 35Kbp region of the genome
of pathogenic E. coli such as EPEC and EHEC. The G+C content of this
region (38.4%) is significantly lower than the rest of the genome and thus the
LEE is likely to have been exogenously acquired (Vallance & Finlay, 2000).
This pathogenicity island is responsible for the production of proteins crucial
to the formation of attaching and effacing (AE) lesions. The pathogenicity
island comprises 41 open reading frames which have been divided into five
operons, LEE1, LEE2, LEE3, LEE4 and tir the products of which interact
bringing about the intimate attachment of EPEC or EHEC to gut enterocytes
(Sperandio et a/, 2000). Figure 1.3 Shows the main features of the LEE and
their location within the pathogenicity island.
35Kbp
LEE1
f LEE2 LEE3 f Tir LEEA >
Translocated intimin
Type III secretion receptor and Intimin Secreted proteins




IH^) Translocated intimin receptor and Intimin
E. coli secreted protein
Figure 1.3: The locus of enterocyte effacement (LEE)





The genetic regulation of the LEE pathogenicity island is complex and poorly
understood. There are a number of differences between the LEE of EPEC
and of EHEC as discussed earlier. Briefly, while the LEE of EPEC and EHEC
share 94% nucleotide sequence homology, a number of the individual genes
can differ by up to 34% (Perna et al 1998). It is unclear however whether
observed differences in EHEC and EPEC pathology are due solely to the
sequence divergence of the LEE. EPEC and EHEC are known to differ at
several other loci as well. McDaniel and Kaper (1997) showed that isolation
of an EPEC 0127:H6 derived LEE in a K12 background conferred the ability
to produce AE lesions. It was concluded therefore that everything required to
regulate and express the proteins involved in AE lesion formation must be
contained within the LEE. Owing to the extensive sequence conservation
between the LEE of EPEC and EHEC, it was assumed that the same would
be true of the EHEC LEE. Elliott et al (1999) conducted the experiment and
isolated an EHEC 0157:H7 derived LEE in the same K12 background. They
found however that the AE lesion phenotype was not conferred upon the
recipient K12 strain. The inability of the EHEC LEE to confer the AE lesion
phenotype on a K12 strain could have resulted from subtle differences in
regulation between EPEC and EHEC LEE.
EPEC contain a large 70Kbp plasmid known as the EPEC adherence factor
plasmid, this plasmid encodes a regulator of virulence genes known as the
plasmid encoded regulator (Per) (Sperandio et al 1999). Per is known to
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regulate the first gene in the LEE1 operon, the LEE encoded regulator (Lei)
(Mellies et al, 1999). EHEC lack the EPEC adherence factor plasmid and
therefore the LEE may be considered to be under different regulation. Per
however is obviously not essential to the expression of the LEE genes as it
was not required to confer the AE lesion phenotype in the K12 background.
As well as controlling the expression of the type III secretion system,
secreted proteins, intimin and Tir, Ler is also thought to control the
expression of a number of other genes not involved in AE lesion formation.
Sperandio et al (1999) reported that quorum sensing also plays a role in the
regulation of the LEE operons in EHEC and EPEC. Although EHEC and
EPEC have a low infectious dose, quorum sensing molecules produced by
other commensal E. coli in vivo, may activate the LEE pathogenicity island.
Not only are there differences in regulation between the EPEC and the EHEC
but regulatory differences have also been noted in different EHEC strains.
McNally et al (2001) noted that the levels of secreted proteins expressed by
different E. coli 0157 strains were often very variable.
1.6 Type III secretion
The genes encoding the type III secretion system, responsible for
translocating the AE lesion effector molecules into the host cell are located
on the LEE pathogenicity island. Several genes termed sepA, B, C and D
were shown to have homology to the genes involved in type III secretion
systems of other organisms such as Shigella and Yersinia species (Jarvis et
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al, 1995). Subsequently a number of other genes involved in type III
secretion have been identified; these are the esc and ces genes (Elliott et al,
2000).
1.7 E. coli secreted protein A (EspA)
E. coli secreted protein A (EspA) forms long filamentous structures on the
surface of EHEC and EPEC connecting the type III secretion system directly
to the host cell, acting much like the needle of a syringe through which other
virulence determinants pass. Knutton et al (1998) showed that EspA was
able to form a large extracellular filamentous complex that is required to
translocate proteins from the bacterium to the host cell. By culturing EPEC
strains in Dulbecco's modified Eagle's medium (DMEM) large filamentous
structures that reacted with anti-EspA antibody were observed. Homology
between the coiled domains of bacterial flagellins, essential to the formation
of flagella, and the carboxy-terminus of the EspA protein also pointed to its
involvement in the formation of these large filamentous structures (Delahay
et al, 1999). The exact nature of the interaction between EspA and the
needle complex (NC) of the type III secretion system was unclear. By
comparing the NC preparations of Shigella with those of several EPEC,
Sekiya et al (2001) showed that it was evident that the EPEC NC was far
longer than that observed in Shigella. This was due to the association of
EspA proteins at the end of the needle complex, which resulted in the
formation of vast extended needles of almost 600nm in length (Figure 1.4).
By disrupting EscF, a protein crucial to the formation of the needle complex
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in type ill secretion, Sekiya et al (2001) were able to show that the formation
of the EspA filaments was completely disrupted. Thus in order to form the
long EspA filaments, association of EspA proteins with the type III secretion
apparatus, in particular the needle complex, is crucial.
Figure 1.4:The formation of EspA filaments and their association with the type III secretion
system. Adapted from Sekiya et al (2001)
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Neves et al (1998) investigated a number of EPEC strains and found that the
espA gene was heavily conserved between strains. One serotype was found
to contribute most of the diversity observed and when compared along side
the other EspA proteins was found to be less immunogenic and also when
polymerised at the bacterial surface, a lot shorter.
1.8 The translocated intimin receptor (Tir) and intimin
Intimin is a 94-97KDa outer-membrane protein largely responsible for the
attachment of EHEC (and other LEE containing organisms) to gut
enterocytes (Kenny et al, 1997). When first discovered no function was
assigned to intimin, but homology with the invasin of Yersinia implicated
intimin in a receptor-binding role (Frankel et al, 2001). The homology
between the two proteins was localised to the amino-terminus, this shifted
attention to the carboxy - terminus which possibly contained receptor binding
activity. Attention was focussed on a 280 amino acid region of the carboxy-
terminus, which was shown to interact with HEp-2 cells (Kelly et al, 1999).
This 280 amino acid fragment is widely known as intimin280 (Int280). As well
as binding to EHEC/EPEC activated HEp-2 cells, an EHEC/EPEC
independent binding of the truncated intimin fragment was also observed
implicating a cell bound receptor with a degree of specificity for the intimin
protein.
A 90KDa protein termed Hp90 was identified as the receptor for intimin. Hp90
was first assumed to be a host cell protein that had intimin binding activity but
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was soon recognised as a protein of bacterial rather than mammalian origin
(DeVinney et al, 1999). It was apparent that Hp90 like intimin, was a LEE
encoded protein that was exported via the type III secretion system, through
the EspA filament, to the host cell, where upon it became integrated into the
host cell membrane to act as a receptor for Hp90 was renamed the
translocated intimin receptor (Tir).
The structure of intimin280 (residues 658-939) has been determined as
comprising of three globular domains (Kelly et al, 1999). Domain 2 (D2;
residues 658-751), domain 3 (D3; residues 752-841) and domain 4 (D3;
residues 842-939) make up the extracellular portion of intimin that binds Tir
(Figure 1.5:Luo et al, 2000). More recently the binding domain was narrowed
to the terminal 150 amino acids at the carboxy-terminus (Kelly et al, 1999),
which encompasses the lectin like D4, which possesses the Tir binding
domain (Luo et al, 2000). A 76 amino-acid loop in D4 has been identified as
being essential for intimate attachment of EPEC/EHEC to cultured
mammalian cells (Frankel et al, 1994)
Analysis of the Tir sequence revealed that the protein had two
transmembrane domains. This implied that the protein took on a hairpin like
structure with the central portion possessing the intimin binding activity
(Frankel et al, 2001). Figure 1.5 shows how intimin and Tir interact to bring
about intimate attachment during AE lesion formation.
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Figure 1.5: The interaction of Intimin and the translocated Intimin receptor Tir
in the formation of AE lesions. Tir-M: Translocated intimin receptor middle
section.
Adapted from Luo et al (2000)
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1.9 Intimin types a p y 5 s
While intimin maintains a high degree of homology within the N-terminal
region, there is considerable variation within the carboxy-terminus leading to
the recognition of intimin types (Frankel et al, 2001j. At least five distinct
intimin types have so far been found. Intimin a, p, y, 8 and s have all been
found to associated with different EPEC and EHEC (Fitzhenry et al, 2002).
EPEC have evolved into two groups of related clones, termed EPEC 1 and 2
(Adu-Bobie et al, 1998). Each group spans a range of O-antigen types but
the flagella (H-antigen) types do not vary greatly. Intimin s was recently
identified as a new variant (Oswald et al, 2000).
Intimin a is associated with the group 1 EPECs (EPEC1) (Adu-Bobie et al,
1998). Intimin p was found in both EHEC and EPEC strains while intimin y is
expressed by E. coli 0157:H7. This apparent preferential association with
selected £. coli serotypes led to the suggestion that intimin type may
influence the pattern of colonisation and tissue tropism exhibited by a
particular LEE positive E. coli (Phillips et al, 2000). Phillips et al (2000) were
able to show that an EPEC strain expressing intimin a formed AE lesions on
in vitro organ culture proximal small intestine, distal small intestine and the
follicular associated epithelium of the Peyer's patch. However an EHEC
strain expressing intimin y was found to bind and cause AE lesions on the
follicular associated epithelium of the Peyer's patch. By deleting eae from an
E. coli 0157:H7 strain and complementing with either y or a eae, Fitzhenry et
al (2002) showed that the ability of E coli 0157:H7 to bind to various in vitro
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organ culture tissue explants, was dependent upon the intimin type.
Expression of intimin a allowed E. coli 0157 to bind to both Peyer's patch
and small intestine explants. intimin y expression however limited the binding
ability of the same E. coli 0157 to the Peyer's patch. Preferential binding of
EHEC/EPEC to the Peyer's patch may be the result of the expression of
microfold (M) cells. Their role as antigen sampling cells may act as a route
into the host (Fitzhenry et al, 2002).
The essential role intimin plays in disease was demonstrated by Dean-
Nystrom et al (1998). Colostrum deprived calves received either intimin
positive or intimin negative strains of E. coli 0157:H7. It was found that the
presence of the eae gene was crucial to the organism's ability to cause
disease.
1.10 The immunogenicity of intimin280
Adu-Bobie et al (1998) were able to elucidate which regions of the carboxy
terminal 280 amino acids of intimins a and (3 were immunogenic. In the first
instance a human colostral IgA and rabbit polyclonal antiserum were used to
detect the immunodominant regions of the various Int280 fragments. Results
showed that there were two immunodominant regions. The first lay within the
first 80 amino acids and the second mapped to a 50 amino-acid segment
between residues 80 and 130 of both intimin types. Further investigation
identified the first 20 amino acids of Int280a and the terminal 20-80 residues
of Int280p as being the specific regions responsible for antibody reactivity. It
21
is possible that conformational changes induced by protein tags used in this
study affected the immunogenicity of a number of the protein fragments and
resulted in the observed differences.
1.11 Actin polymerisation
Characteristic of AE lesion formation is the accumulation of polymerised actin
beneath the site of EPEC/EHEC adherence (Celli et al, 2000). The
cytoskeletal rearrangements contribute to the formation of the pedestal-like
structure upon which the bacteria sit. Finlay et al (1992) investigated the
recruitment of microfilament-associated proteins within these pedestal
structures. Actin, a-actinin, talin and ezrin were all found localised beneath
areas of bacterial adherence. Talin and ezrin are two microfilament
associated proteins that have been implicated in linking actin filaments to
transmembrane receptors thus the results suggest that the polymerised actin
fibres may be associated with Tir (Finlay et al 1992).
Rosenshine et al (1996) showed that three proteins designated Hp39
(39KDa), Hp72 (72KDa) and Hp90 (90KDa: Tir) were all tyrosine
phosphorylated following HeLa cell infection with EPEC. Further work by
Rosenshine et al (1996) showed that this heavy accumulation of tyrosine-
phosphorylated proteins occurred directly beneath the site of EPEC
adherence. They postulated that this may be an important role in steps
leading to the polymerisation of actin and subsequent pedestal formation.
However Ismaili et al (1995) were able to demonstrate that in EHEC induced
pedestals there was no accumulation of tyrosine phosphorylated proteins
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beneath the surface of the adhered bacteria, yet the same cytoskeletal
rearrangements took place. Furthermore DeVinney et al (1999) confirmed
that the Tir of EHEC was not tyrosine-phosphorylated. These results show
that tyrosine-phosphorylation is not a necessary precursor to the formation of
EHEC induced pedestals in AE lesions.
1.12 E. coli secreted proteins
The LEE encoded secreted protein genes encode a number of proteins
crucial to signalling events leading to AE lesion formation. These signals
include activation of phospholipase C-y, NF-kB induction and changes in
membrane potential (Taylor et al, 1998). The secreted proteins may be
detected in the culture supernate of certain E. coli strains (Wainwright et al,
1998). The secreted proteins are transported via the LEE encoded type III
secretion system, through the EspA filament and into the host cell whereupon
a number of events result in actin polymerisation and the formation of an AE
lesion (McNally et al, 2001).
1.12.1 EspBand D
EspB is an integral protein involved in AE lesion formation. Without EspB no
alterations in the host cell cytoskeleton or inositol phosphate flux are
observed (Tacket et al, 2000). Taylor et al (1998) reported that EspB was
targeted to the cytoplasm of HeLa cells in a mechanism that was clearly
dependent upon EspA and EspD function. Intimin knockout strains had no
affect on the ability of EspB to enter the HeLa cell and localise in the
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cytoplasm. This was confirmed by Wolff et al (1998) who showed that HeLa
cell contact via intimin and/or the bundle forming pilus was not required for
complete translocation of EspB, although translocation was not as efficient as
with the wild type strain. The mechanism by which EspB was able to be
translocated from the bacteria and accumulate in the cytoplasm of HeLa cells
was at the time unclear. Wainwright et al (1998) were able to show that in
common with the type III secretion systems of other organisms, for example
Yersinia and Shigella, a specific chaperone protein was required to effect
EspB and D secretion. By mutational analysis it was determined that a
protein termed CesD was absolutely required for the secretion of EspD and
its absence dramatically affected the level of EspB secretion. CesD showed
significant homology to a number of proteins already implicated in type III
secretion, for example SicA (salmonella invasion chaperone) from
Salmonella typhimurium and IpgC (Invasion plasmid gene) from Shigella
flexneri (Wainwright et al 1998). Since EspB secretion was still observed it is
likely that chaperone proteins are not solely responsible for the export of
these proteins and that other factors are involved.
Work by Wolff et al (1998) showed that espB mutants were unable to secrete
EspB even when complemented with a plasmid with the intact espB gene.
This implied that actual expression of the espB gene was required to allow
EspB translocation. The same study also expanded on work by Taylor et al
(1998) and proved that EspB was not only localised to the HeLa cell cytosol,
but could also be detected in the membrane fractions. Homology between
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EspB and the Yersinia outer membrane protein B (yopB) involved in the
formation of a translocation channel in the host cell membrane, suggests that
EspB could have a similar role (Frankel et al, 1998).
Analysis of the espD sequence revealed homology with a number of proteins
involved in type III secretion for example IpaB of Shigella and SipB of
Salmonella (Wachter et al 1999). The structure of EspD is predicted to
contain two coiled-coil domains as well as two transmembrane domains
(Figure 1.6: Wachter et al 1999). Just as with the EspA protein, the coiled-
coil domains suggest a role in protein-protein interactions. Daniell et al (2001)














Figure 1.6: Structure of EspD showing the position of the coiled-coil domains (residues 145-
177 and 324-370) and the transmembrane domains (residues 180-204 and 234-256)
Adapted from Daniell et al (2001)
25
EPEC infection of HeLa cells by Wachter et al (1999) showed that like EspB,
EspD could be found integrated into the host cell membrane. By preparing
glutathione-S-transferase tagged EspB, Ide et al (2001) were able to show
that EspD interacted with EspB presumably via the coiled-coil domains. With
the use of electron and atomic force microscopy they were also able to
demonstrate the formation of pores in sheep red blood cell membranes and
revealed in exquisite detail the shape of the EspB/D pore structures. The
pores appear to result from the interaction of 6-8 units (Figure 1.7). The
opening of the pore was gauged at approximately 8nm, which would allow
the EspA filament complex at around 2-3nm, to be inserted into the pore.
~65nm
~8nm
EspB/D pore * ^
Figure 1.7: The EspB/D pore complex. Sizes shown were ascertained by atomic force
microscopy.
Adapted from atomic force microscopy image, Ide et al (2001)
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It is clear that the coiled-coil domains of EspA, B and D allow each of the
proteins to interact. Firstly the formation of the long EspA filament allows
effector proteins such as EspB and D to be translocated to the host cell were
upon they associate with one another and form a pore into which the EspA
filament engages. Intimin and/or bundle forming pilus mediated attachment
were important for full translocation efficiency (Wolff et al 1998, Taylor et al
1998).
Wolff et al (1998) hypothesised that attachment via intimin stabilised the
fragile EspA filaments and allowed effective translocation. However it is clear
that in order for intimin to bind, Tir must already have passed through the
EspA filament, into the host cell and have localised to the host cell surface, a
process downstream of, and dependent upon, EspB translocation (Kenny et
al 1997). In vivo there is therefore a requirement for EspB translocation
without intimin/Tir interaction. Therefore the ability of intimin to bind p-1
integrins (Frankel et al, 1996) may be vitally important for the initial
translocation of EspB/D prior to a stable intimin/Tir interaction.
1.12.2 E. coli secreted proteins F, G, C and P
There are a number of other proteins secreted by EHEC and EPEC about
which less is known, these include E. coli secreted protein F (EspF) involved
in the disruption of the tight junctions of gut enterocytes (Elliot et al, 2002),
and E. coli secreted protein G (EspG) which shows homology to the VirA
protein of Shigella flexneri (Elliot et al, 2001). Although the role of VirA in the
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pathogenesis of Shigella flexneri is unclear it is known to be important in cell
invasion and could play a similar role in E. coli.
E. coli secreted proteins C and P (EspC and EspP) are not associated with
the LEE pathogenicity island and their secretion is not dependent upon the
type III secretion system utilised by the LEE encoded secreted proteins
(Mellies et al 2001 and Brunder et al 1997). The gene encoding EspC has
been mapped to a region of the chromosome demonstrating the
characteristics of a pathogenicity island (Mellies et al, 2001). This region of
DNA was not found in either commensal or laboratory strains of E. coli. EspC
is a 110KDa protein and earlier work by Stein et al (1996) had identified
significant homology between EspC and a number of other proteins including
a group of immunoglobulin A protease-like proteins. The IgA proteases of
other organisms are known to mediate their own export from cells (Mellies et
al, 2001). These autotransported proteins comprise a large group of proteins
many of which are not IgA proteases, but do possess a serine protease motif
(Mellies et al, 2001). Stein et al (1996) reported that although EspC showed
IgA protease homology, it was unable to cleave human IgA. Also by mutating
espC, Stein et al (1996) showed that EspC was not required for the formation
of AE lesions by EPEC. The role of this protein is unclear.
EspP is a large protease (1300 amino-acids, 104 kDa) encoded by a 3.9Kbp
region of the £. coli 0157 virulence plasmid, p0157 (Brunder et al, 1997).
This 90Kbp plasmid also encodes the EHEC-haemolysin (Bauer and Welch,
28
1996). The role of EspP in disease is unclear, but anti-EspP IgG responses
detected in sera from patients infected with E. coli 0157, suggests that it is
expressed during infection (Brunder et al 1997).
1.13 Lipopolysaccharide
1.13.1 Structure
Lipopolysaccharide (LPS: endotoxin) is an integral part of the outer
membrane of all Gram-negative bacteria (Poxton, 1995). Exposure to
endotoxin can lead to potentially fatal systemic inflammatory reactions
(Erridge et al, 2002). The whole LPS structure of Escherichia coli (and other
related species) may be divided into three distinct regions (Figure 1.8), the
hydrophobic Lipid A moiety, responsible for the endotoxic properties of LPS
(Galanos et al, 1985) the core oligosaccharide and the O-polysaccharide
antigen (Erridge et al, 2002).
Lipid A ^ t Core > ^ O-polysaccharide
Figure 1.8 LPS schematic showing the three structural regions and the components of rough
form and smooth form LPS
LPS may occur in one of two forms, rough (R-form) or smooth (S-form)
(Poxton, 1995). S-form LPS comprises all three structural regions shown in
Figure 1.8, while R-form LPS is characterised by the loss of the
O-polysaccharide leaving just the Lipid A and the core region (Amor et al,
2000). Variability in the LPS structure ranges from the Lipid A region which is
highly conserved to the O-polysaccharide of which there are over 170 types
known in the E. coli alone (Amor et al, 2000). There are five known E. coli
core types denoted R1, R2, R3, R4 and K12. The core region may be divided
into inner and outer core. The inner core comprises three 3-deoxy-D-manno-
octulosonic acid (KDO) and three L-glycero-D-manno heptose (hep) residues
and displays little variation between each of the five core types. The variation
observed in the outer core region is responsible for the differences in the five
core types. Figure 1.9 shows in detail the structure of E. coli LPS. Complete
core LPS comprises the lipid A, three KDO and three heptose residues along
with five (six in the case of K12) variable sugars dependent upon core type
(Figure 1.9b), this is known as Ra complete core LPS. There are several
forms of incomplete core LPS denoted Rb, Rc, Rd and Re, each comprising
progressively less of the complete core structure. The components of Rb, Rc
and Re LPS are shown in Figure 1.9a. The high degree of conservation
within the membrane proximal parts is possibly due to the essential role that
core LPS plays in membrane stability (Heinrichs et al, 1998).
1.13.2 O-antigen
Exposed at the bacterial surface, the O-polysaccharide is easily accessible to
the host immune system and leads to the generation of O-specific immune
responses, thus the term O-antigen is commonly used (Erridge et al 2002).
The O-antigens appear at the cell surface as chains of varying length
(Poxton, 1995). This is demonstrated by the O-antigen 'ladder pattern'
observed when smooth-form LPS is resolved by polyacrylamide gel
electrophoresis. Each band in the ladder results from the addition of one
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extra O-antigen unit to the core (Poxton, 1995). The enzymes required to
assemble the O-antigen chains have been mapped to a region of the E. coli
chromosome known as the rfb locus (Schnaitman and Klena, 1993).
While core LPS is crucial to membrane stability, the O-antigen plays a vital
role in protection against the effects of a number of otherwise lethal
compounds and substances. The O-antigen provides an effective barrier
against hydrophobic antibiotics, phagocytosis, complement, free fatty acids
and detergent (Burns and Hull, 1998). There are over 170 E. coli O-antigen
serotypes recognised, yet only a few have been implicated in disease. These
include 01, 02, 04, 06, 07, 08, 015, 018 and 075 most often associated
with blood borne and urinary tract infection (Gibb et al, 1992, Burns and Hull,
1998). The ability of certain serotypes to cause disease is related to the
degree of serum resistance the O-antigen confers (Porat et al, 1992).
Complement mediated killing (serum sensitivity) requires that the membrane
attack complex has access to the bacterial membranes (Erridge et al, 2002),
various O-antigens appear to function well as barriers against this, while
others do not.
Porat et al (1992) compared the lengths of O-antigen side chains of serum
resistant E. coli and serum sensitive E. coli. By constructing liposome-
radioactive-chromium packages incorporated with O-antigen LPS derived
from serum sensitive and resistant strains, it was possible to determine the
complement resistance offered by each O-antigen type. They observed a
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correlation between the length of the carbohydrate side chains and the serum
resistance of particular O-antigens. O-antigens found to be serum resistant
had longer carbohydrate side chains than those that were serum sensitive. It
is possible that serum sensitivity and resistance of E. coli is far more complex
than simply a matter of which O-antigen is expressed and the length of
carbohydrate side chains. Other studies have reported only minor alterations
in serum sensitivity upon the loss of the O-antigen (Russo et al, 1995).
Being the dominant antigen at the bacterial cell surface, the O-antigen may
be expected to play an important role in adherence. However the role (if any)
of the O-antigen of E. coli 0157:H7 in enterocyte binding is unclear. Studies
by Bilge et al, (1996) showed that a mutant strain unable to express the O-
antigen was able to bind to HeLa cells. When the ability of the mutant to
synthesise the 0157 antigen was restored, the binding affinity was lost. They
concluded that the 0157 antigen somehow interfered with E. coli 0157:H7
binding to epithelial cells; the reason for this is unclear.
1.13.3 Antibody responses to LPS
A number of studies have examined the sera of patients convalescing from
E. coli 0157 infection for antibodies to E. coli 0157 LPS. In all cases most of
the sera examined were found to contain antibodies to 0157-LPS (Chart et al
1989, Greatorex and Thorne, 1994). As mentioned previously the O-
polysaccharide is exposed at the bacterial surface and the above studies
show that the LPS is indeed immunogenic. Polysaccharide antigens often
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generate igM responses only, and the study of Chart et al, (1989) showed
that most of the antibodies they detected were of the IgM class. However
LPS is often associated with large amounts of protein, this may facilitate the
generation of an IgG response. Greatorex and Thome (1994) reported both
IgM and IgG responses in the sera they examined. The response to whole
LPS must however be considered as the sum of the responses to both the
core and the O-antigen (Currie et al, 2001).
Currie et al (2001) used an inhibition ELISA to determine exactly how much
of the response to E. coli 0157 LPS was due to the core component. When
compared with the sera from convalescent patients the inhibitory effect of the
R3 core was greatest among the healthy controls. This suggested that in
health most of the response is directed towards the core LPS, and in
disease, exposure to the O-antigen generates a significant response. A
number of serotypes, for example 055, 091, 015, 086 and 0157 (Amor et
al, 2000, Currie and Poxton, 1999, Gibb et al 1992) are known to carry R3
core LPS. There are also many shared epitopes among all E. coli core types
as well as with the cores of LPS from other organisms, for example
Salmonella and Shigella (Currie et al, 2001). It is therefore likely that healthy
humans exposed to specifically R3 core LPS and core LPS of all types,
generate an anti-core LPS response that is largely cross-reactive with all five
£. coli core types and detectable at any time.
Whole gut lavage (WGL) with a non-absorbable cleansing fluid can be used
to detect IgA secreted into the gut. Currie et al (2001) used this technique to
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measure the IgA response to the 0157 antigen and the R3 core. They
reported that among convalescent patients who went on to make a full
recovery with no complications, the level of 0157 and R3 specific IgA was
significantly higher than in the healthy volunteers. The generation of the
mucosal response was a possible factor in the recovery of these patients and
may have helped prevent the development of serious complications. Hoque
et al (2000) utilised the same technique to compare the mucosal immune
responses of healthy volunteers from Edinburgh, UK and Dhaka, Bangladesh
to core LPS. They reported that the level of endotoxin incomplete-core
antibody (EndoCAb) was significantly higher among the group from Dhaka. It
is thought that increased exposure to core LPS in the developing world may
induce greater mucosal immunity and explain reduced levels of























































1.14 Antibody responses to E. coli 0157
1.14.1 Early findings
A number of studies have examined the immune response to surface and
secreted components of E. coli 0157:H7. While most of these studies have
focused on the human response to EHEC/EPEC infection, animal models
have been used to examine the potential for vaccine development. Studies of
this nature allow us to understand which antigens are recognised by the
immune system and therefore may help identify potential vaccine targets.
Early evidence for responses to EPEC infection was obtained by Levine et al
(1985). While investigating the effects of a 50-70Mda plasmid on EPEC
infection in human volunteers, a 94KDa protein unique to EPEC, was found
to elicit both serum IgA and IgG responses. These findings were confirmed
by Frankel et al (1996). They suggested that the 94KDa protein was most
likely intimin. Mice challenged with the organism responsible for murine
colonic hyperplasia, Citrobacter rodentium, which contains a pathogenicity
island homologous to the LEE, were found to mount IgA responses to both
intimin and EspB. These antibodies were predominant among those mice
that survived the challenge and were therefore implicated in protection
against infection. Lissner et al (1996) used a colostral immunoglobulin
preparation (lactobin®) to examine its potential as a therapeutic agent for the
treatment of EHEC disease. Antibodies reactive to EHEC haemolysin and
verotoxin 1 and 2 B subunits [albeit truncated Vt1/2-GST fragments as
prepared by Gunzer and Karch, (1993)] were detected in the colostral
preparations. The study went on to show that these antibodies were
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functional and were able to neutralise the Vero cytotoxic effects of the
verotoxin and also the haemolytic activity of the haemolysin. The studies by
Frankel et al (1996) and Lissner et al (1996) showed that antigens involved in
the pathogenesis of EPEC/EHEC disease were antigenic and could give rise
to functional antibodies.
1.14.2 Experimental EPEC infection in humans
The first study to investigate the role of pre-existing antibody in protection
against EPEC disease was conducted by Donnenberg et al (1998). Two
experiments looked at the ability of human experimental EPEC challenge to
confer protection against a subsequent rechallenge with both heterologous
and homologous strains. The heterologous challenge comprised an initial
infection of 17 human volunteers with EPEC strain 055:H6, followed 27 days
later by rechallenge of eight of the original 17 volunteers along with a further
six naive individuals, with EPEC strain 0127:H6. In the second study, 13
(plus nine naive individuals) volunteers received either an initial challenge
with EPEC 0127:H6 or an eae mutant of the same strain, followed 70 days
later by a rechallenge with EPEC 0127:H6. The results obtained failed to
provide evidence for the generation of a protective antibody response. There
was no significant difference in the incidence or severity of diarrhoea
between any of the groups. It is possible that oral challenges of 1x109 or
9x108 cfu E. coli are too large to assess the effectiveness of any antibody
response.
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It is clear that intimin is a crucial component in the formation of AE lesions,
thus an antibody reactive to intimin could prevent the formation of AE lesions.
The existence of a number of intimin types (a, p, y, 5, s) (Adu-Bobie et al,
1998) may provide EHEC/EPEC organisms with the ability to avoid the
neutralising capacity of these antibodies. Voss et al (1998) provided the first
evidence for an immune response specific to an intimin type. They found that
while patients convalescing from E. coli 0111:1-1- infection reacted well to
intimin from that particular strain, no reaction to the intimin of E. coli 0157:H7
EDL933 was noted. Perna et al (1998) established that the eae sequences of
E. coli 0157 EDL933 and EPEC 0126:H6 were 87.23% similar. The strains
used by Voss et al (1996) showed a similar degree of eae homology (88.6%).
Further analysis by Voss et al (1996) revealed that the terminal 200 amino
acids of intimin contributed most of the variation seen in the whole protein.
Since only a small region intimin appears to be variable it is unclear why
Voss et al (1996) were unable to detect antibody responses to the large
highly conserved N-terminal region of intimin.
To compensate for the variation in the Tir binding domain of intimin, Paton et
al (1998) recognised distinct variations in Tir from different EPEC and EHEC
strains. This was confirmed at the DNA level by Perna et al (1998) who
identified significant divergences in tir sequences from the LEE of an EPEC
and an EHEC strain. While convalescent sera from patients with HUS
investigated by Paton et al (1998) reacted with all the Tir types tested, it is
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unclear if these responses were to the conserved regions of the molecule or
whether, as with the Tir binding domain of intimin, specific neutralising
antibodies exist.
Studies by Li et al (2000) and Jenkins et al (2000) used recombinant
antigens to investigate further the human response to EHEC infection. Upon
admission to hospital sera from patients infected with E. coli 0157 were
collected, followed by convalescent samples eight and sixty days after
admission. Li et al (2000) investigated these sera for antibodies reactive to
GST-tagged EspA, intimin, Tir and EspB. In each case the response at day
zero (sample obtained upon admission) showed little reactivity to any of the
fusion proteins. However by day eight strong reactions to Tir, intimin, EspA
and EspB were noted. These responses were still detectable 60 days after
infection. Jenkins et al (2000) extended this study further by examining the
response to three separate Tir domains; Tir-N (N-terminal region), Tir-M
(region located between two transmembrane domains with intimin binding
capacity) and Tir-C (C-terminal region),as well as Int280, EspB, EspA. They
were able to detect antibodies reactive to all the recombinant antigens except
Tir-N and Tir-C. The lack of any detectable antibody response to these two
Tir domains may have resulted from the low homology between tir used in
the generation of the recombinant C and N fragments and the tir from the
strain infecting the patients tested (Jenkins et al 2000). It is also likely that
due to the intracellular localisation of the Tir-N and C domains that their
inaccessibility to the immune system resulted in the lack of any detectable
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antibody. Although the intimin binding domain of Tir was strongly reactive
with five of the eight patient sera tested it is possible that within this 24KDa
Tir fragment that there is a smaller variable domain required to recognise and
bind the five intimin types. In both studies by Li et al (2000) and Jenkins et al
(2000) EspB generated the weakest response. This may be due to its initial
role as an intracellular signalling activator within the host cell, followed by its
eventual role as a pore at the end of the needle complex, which may render
the protein inaccessible to the immune system.
1.14.3 Vaccine potential
A study by Ghaem-Maghami et al (2001) investigated the potential
effectiveness of an intimin-based vaccine in murine colonic disease caused
by C. rodentium. Mice challenged orally with C. rodentium were found to
mount cross-reactive serum IgG and IgA responses against EPEC EspA,
EspB and TirM (IgG only). C. rodentium expresses intimin |3 and as such an
intimin p specific immune response was detected in these animals that did
not cross react with EPEC intimin a. The study went on to try and establish
whether or not acquired immunity to EPEC pathogenicity factors could induce
protection as inferred by Donnenberg et al (1998). Two groups of mice were
challenged either with wild type C. rodentium. Three months later
convalescent mice and a group of naive mice were rechallenged with either
wild type C. rodentuium or an eae mutant of the same strain expressing
EPEC intimin a via a plasmid. Convalescent mice were found to have
significantly lower levels of infection than the naive group. This demonstrated
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that the development of acquired immunity was able to confer protection.
While the results appeared to suggest that immunity to heterologous intimin
types could result from a prior exposure to any of the five intimin types, it is
likely that this arises from the large number of antibodies cross reactive to
components involved in AE lesion formation. Thus anti-intimin antibodies are
only part of the protective antibody repertoire. Indeed subsequent
experiments by Ghaem-Maghami et al (2001) showed that immunisation with
the carboxy terminal 280 amino acids of intimin a (Int280a) could protect
mice from infection with C. rodentium expressing Int280a but did not confer
protection against the wild type C. rodentium.
1.15 Verotoxin
1.15.1 Types
Karmali et al (1983) reported the vero cytotoxic activities of a toxin produced
by E. coli isolated from the stools of patients with HUS. The toxin was named
verotoxin. We now know that the toxin is phage encoded and is the cause of
HC and HUS. O'Brien et al (1982) and subsequently Strockbine et al (1986)
showed that antiserum raised against the Shiga toxin (ST) of Shigella
dysenteriae could neutralise the effects of the verotoxin. This led to the
designation of the term 'shiga-like toxin' (SLT) still used today. Since then a
number of SLT variants have been described. SLT 1 is identical to ST (Tesh
et al 1993, Strockbine et al, 1988). SLT 2 is antigenically distinct from SLT 1
but does share significant sequence homology with ST (Jackson, 1990).
There are a number of recognised variants of SLT 2. SLT 2e is associated
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with oedema in pigs (Valdivieso-Garcia et al, 1996 and Obrig, 1997). SLT 2c
shares 99.6% and 94.8% homology with the structural components (A and B
subunits) of SLT 2 (Furst et al 2000). Molecular typing techniques can be
used to further divide SLT 2c into 2 groups known as SLT2vh-a and SLT2vh-
b (Pierard et al, 1998). EHEC are known to produce one or two toxins, SLT1
or SLT2 (or both) (Mukherjee et al, 2002)
1.15.2 Structure
Verotoxin is a member of a group of toxins that share structural similarities.
Like the toxins of V. cholerae and S. dysenteriae, the verotoxin produced by
EHEC comprises a single active (A) subunit and five identical binding (B)
subunits, denoted an AB5 structure (Figure 1.10: Nataro & Kaper, 1998). The
32KDa A subunit is responsible for the activity of the toxin and is itself
activated upon partial cleavage into subunits Ai and A2 that remain bound via
a disulphide bond. The enzymatic activity is localised to the 27KDa Ai
subunit and the 4KDa A2 subunit forms the site of attachment to the five B
subunits (Nataro & Kaper, 1998). As previously mentioned the B subunits
associate with one another to form a pentameric structure with a molecular
mass of 38.5KDa, each individual subunit being 7.7KDa. This region is the






Figure 1.10: 70KDa Verotoxin, showing the classical AB5 structure. The 32KDa active
subunit and five 7.7KDa binding subunits are labelled
1.15.3 The verotoxin Receptor Gb3
With the exception of Vt2e the receptor for verotoxin is the glycolipid
globotriaosylceramide (Gb3) (Vt2e:Gb4). Gb3 is known to occur in great
abundance in the cortex of the human kidney, predominantly on the surface
of cortical tubular epithelial cells (Lingwood, 1994 and Hughes et al, 1998).
Indeed the levels of Gb3 found on these cells are 50-100 fold higher than
levels found on Vero cells a well established VT sensitive cell line (Lingwood,
1994). This is compelling evidence for the role of VT in the development of
HUS. The B subunit of verotoxin is responsible for engaging and binding to
the Gb3 receptor thus allowing the A subunit access to the cell. Crystal
structure analysis of the verotoxin B subunit revealed three potential binding
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sites for Gb3 on each monomer (Stein et al, 1992). Solution structure analysis
conducted by Shimuzu et al (1998) subsequently revealed that only one of
these binding sites was occupied by the Gb3 receptor. The presence of
multiple binding sites on the B subunit indicates that the process of binding to
Gb3 may be very complicated, it may also infer differential binding site usage
by different VT types (Peter & Lingwood, 2000).
Lingwood (1994) conducted an extensive examination of both human adult
and infant renal tissue for the presence of the Gb3 receptor. Glomerular
binding of VT1 in adult samples was not observed. However, there was clear
binding of the toxin to proximal and distal tubules. In contrast, although
paediatric samples showed decreased binding overall, in samples from
infants less than two years old, all the glomeruli were found to bind VT1,
however by two and a half years the level of binding had reduced to 50% of
samples observed. The Gb3 receptor has also been found in the
gastrointestinal tract (Peter & Lingwood, 2000). These are important
observations in terms of HUS as the apparent reduction in glomerular Gb3
receptor expression at 2.5 years corresponds to the upper age limits of HUS
(Rowe et al, 1991). The observed reduction in Gb3 expression in the adult
glomerulus appears not to correspond with the frequency of HUS among
elderly adults.
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1.15.4 Entry into the cell
Once bound the toxin must enter the cell in order to exert its actions. The
entry of verotoxin into cells has been the subject of much work and will be
described briefly here. Verotoxin enters cells via receptor mediated
endocytosis (Sandvig et al, 1992). The presence of Gb3 on a cell surface
does not however predict that that cell will be sensitive to verotoxin. Factors
other than Gb3 binding are required for toxicity. A number of cells (for
example epidermoid carcinoma A431 cells) are known to bind and internalise
VT and are yet unaffected (Johannes & Goud 1998). Shiga toxin is
internalised via clathrin coated pits and is then transported to the Golgi
apparatus (Sandvig et at, 1992 and Johannes & Goud 1998). It is then
thought that the verotoxin is released from the Golgi into the cytoplasm.
1.15.5 Mode of action
Verotoxin is a potent inhibitor of protein synthesis able to inactivate 60 S
ribosomal subunits selectively (Obrig et al, 1987 and O'Brien et at, 1992).
The ability of Shiga toxin to inhibit protein synthesis in rabbit reticulocyte
lysates was noticed by Brown et al (1980). Furthermore they established that
this inhibitory effect could be enhanced by the addition of proteolytic
enzymes and reducing agents. Proteolytic digestion would have released the
Ai fragment which has potent protein synthesis inhibition activity.
Shiga toxin causes ribosomal inactivation by preventing interaction with
elongation factors-1 and 2 (EF-1 and EF-2) and therefore arrests protein
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translation at the aminoacyl-tRNA binding step (Obrig et al, 1987, Endo et at,
1988). Obrig et al (1987) investigated the specifics of EF-1 and 2 inhibition by
Shiga toxin. They found that shiga toxin prevented the enzymatic binding of
radiolabeled tRNA to ribosomes obtained from rabbit reticulocytes. This is
achieved via the N-glycosidase activity of the Ai subunit which removes an
adenine residue from the 28 S rRNA of the 60 S ribosomal subunit, thus
preventing interaction with EL-1 and EL-2 (O'Brien et al, 1992).
1.16 Disease in cattle
It is widely accepted that carriage of E. coli 0157 by cattle leads to outbreaks
of human disease. Despite this however, adult cattle remain unaffected by
this particular serotype (Cray and Moon, 1995) while infection in calves
usually results in mild diarrhoea (Wales et al, 2001). The VTEC 026 has
been associated with both human and bovine disease (Gunning et al, 2001).
In humans disease symptoms often include diarrhoea, bloody diarrhoea, HC
and HUS while in calves, E. coli 026 causes diarrhoea (Gunning et al, 2001).
Examination of post-mortem tissue samples from the intestines of two calves
naturally colonised with E. coli 026 revealed the presence of AE lesions
(Gunning et al, 2001). In another case, E. coli 026 were found intimately
attached via AE lesions in the colon of an eight-month old heifer with bloody
diarrhoea (Pearson et al, 1999). The reason for the lack of E. coli 0157
associated disease in adult cattle is unclear, although the expression of
variant intimin types may play a role.
Studies to examine the susceptibility of various bovine tissues have revealed
interesting results. Studies by Dean-Nystrom et al (1998) demonstrated the
ability of E. coli 0157:H7 to produce AE lesions in vivo. It is important to
realise however that animals used in these experiments were neonatal
colostrum deprived calves. As such they are susceptible to infection by E.
coli 0157. It does prove however that bovine ileal cell types are not
intrinsically resistant to AE lesion formation.
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These findings were expanded upon by Baehler et al (2000). They focused
on the ability of E. coli 0157 to produce AE lesions in adult bovine rectal and
colonic tissue explants. After 6-9h incubation periods the tissue explants
were examined by electron microscopy for the presence of AE lesions.
Lesions were observed on all inoculated cells along with associated
destruction of the microvillus ultrastructure. AE lesion formation on the
surface of the bovine tissue explants was comparable to the prolific formation
of AE lesions seen on HeLa cell monolayers. It was clear therefore that AE
lesion formation was as likely to occur on adult tissue as it was on neonatal
tissue. The work also showed that the bovine ileum, colon, caecum and
rectum, were all susceptible to AE lesion formation. The results presented by
Dean-Nystrom et al (1998) are highly suggestive that the bovine immune
system plays an important role in the protection against EHEC disease.
The role (if any) verotoxin plays in bovine EHEC colonisation is unclear.
Toxin expression is known to occur in vivo and has been detected in the
faeces of colonised animals (Donkersgoed et al, 1999). A number of studies
have used PCR/DNA probes to determine which toxin type(s) a bovine
isolate carries. Blanco et al (1996), China et al (1996), Chapman et al (1997)
and Orden et al (1998) have all demonstrated the prevalence of VTEC
among cattle populations.
A study by Pruimboom-Brees et al (2000) demonstrated that tissue from the
gastrointestinal tract of newborn calves was devoid of the verotoxin receptor,
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Gb3. Gb3 expression was observed in the kidney and brain however. Further
more, ligated ileal loop experiments in calves revealed that E. coli 0157:FI7
was not enterotoxic. The lack of gastrointestinal Gb3 was thought to explain
the apparent resistance to the effects of verotoxin demonstrated by cattle.
Hoey et al (2002) expanded on this study, by examining rumen, jejunum,
ileum, caecum, colon and kidney tissue samples from one and ten month old
cattle. VT1 was found to bind to the crypt cells adjacent to the submucosa
from the jejunum, ileum, caecum and colon samples from both age groups.
Gb3 was successfully extracted from the mucosal tissue samples confirming
the presence of verotoxin receptors in bovine gastrointestinal tissue. The
pattern of Gb3 receptor distribution in bovine kidney (collecting ducts and
tubules) was similar to that observed by Lingwood (1994) in human renal
tissue. These findings were contradictory to those of Pruimboom-Brees et al
(2000). In contrast to human endothelial cells that have previously been
shown to possess Gb3 and bind verotoxin (Jacewicz et al, 1999), no
verotoxin binding to bovine endothelial cells was reported by either Hoey et al
(2002) or Pruimboom-Brees et al (2000). This difference in Gb3 expression
may explain the verotoxin susceptibility differences between humans and
cattle.
Recent evidence has begun to suggest that cattle colonisation by E. coli
0157:H7 may be directed to a specific tissue type. Grauke et al (2002)
carried out extensive post-mortem investigations of sheep and cattle
experimentally infected with E. coli 0157 to determine the gastrointestinal
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location of E. coli 0157 colonisation. Tissue and digesta samples were taken
from the rumen, abomasum, duodenum, lower ileum, caecum,
ascending/descending colon and rectum of experimentally infected sheep at
weekly intervals up to 43 days post infection. E. coli 0157 were
predominantly isolated from the digesta of the lower gastrointestinal tract,
and no E. coli 0157 were isolated from any of the tissue samples taken.
Similar results were seen in the experimentally infected cattle. Rumen and
duodenum digesta samples showed that beyond 16 days post infection no E.
coli 0157 could be isolated from the samples collected. However up to 34
days post infection E. coli 0157 could be detected in the faeces of the
infected animals. This was highly suggestive of the fact that E. coli 0157 may
preferentially localise to the lower regions of the gastrointestinal tract.
Recently Naylor et al (unpublished data) have been able to characterise
further the region of E. coli 0157 colonisation in both experimentally infected
and naturally colonised animals. Their data provide support for the findings of
Grauke et al (2002) and have narrowed the colonisation region to an area of
stratified squamous epithelium unique to the terminal rectum. This tissue
appears to persist for only a number of centimetres, but levels of E. coli 0157
isolated from here far exceed levels elsewhere in the bovine digestive tract.
Whether or not this phenomena is the result of tissue tropism exhibited by E.
coli 0157 is yet to be clarified. If confirmed this may have important
implications for our understanding of how E. coli 0157 interact with the
bovine host.
51
Hypothesis and aims of this thesis
It is unclear what role (if any) the bovine immune response plays in protection
against EHEC associated disease. It is possible that antibody responses
mounted against a number of antigens present on E. coli 0157 offer a
degree of protection. It is hypothesised that cattle are exposed to R3 core
LPS more frequently than humans and consequently develop an immune
response against this LPS core type that could afford protection against
EHEC infection. It is also hypothesised that this increased exposure to R3
core LPS also leads to an increase in exposure to antigens encoded upon
the LEE pathogenicity island from which an antibody response may develop.
The introduction to this thesis cited a number of factors, shown to be
immunogenic in other species, which are worthy of investigation. LPS is the
dominant antigen of the Gram-negative outer membrane and as such is likely
a very important component of any immune response. Studies have proved
an association between R3 core LPS and the VTEC virotype and a
proportion of bovine VTEC isolates have also been shown to harbour the
LEE pathogenicity island. The frequency with which R3 core LPS appears
among the bovine commensal E. coli flora may influence the level of
response-mounted against this antigen.
The LEE pathogenicity island presents the bovine host with an array of
antigens against which an immune response may be mounted with the
ultimate aim of preventing intimate adherence. However it is unclear which
LEE antigens cattle are exposed to and whether or not detectable immune
responses result from exposure. It is likely though that a number of the LEE
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components are immunogenic in cattle and that these antibodies have the
potential to block intimate adherence.
Therefore the aims of this thesis were as follows:
1) To determine the distribution of the five LPS core types of E. coli
within two populations of faecal E. coli isolates from healthy humans
and cattle.
2) To examine sera from healthy adult human volunteers and healthy
adult cattle for antibodies reactive to each of the five core types and to
investigate a link between core LPS exposure and anti-core LPS
antibody levels.
3) To clone, express and purify recombinant intimin280 (Int280), E. coli
secreted protein B (EspB) and Verotoxin 2 B subunit (Vt2B).
4) To use Immunoblot and ELISA to detect antibodies to recombinant
Int280, EspB and Vt2B and LPS in the sera and faecal antibody
preparations of calves experimentally challenged with E. coli 0157.
5) To determine whether any antibody detected in the sera of
experimentally infected calves inhibits the formation of attaching





All Escherichia coli strains used in this study were supplied by the Zap Lab,
Medical Microbiology, The University of Edinburgh unless otherwise stated.
Table 2.1 summarises the strains used.
Table 2.1: Strains used throughout this study
Technique (section reference) Escherichia coli strain
PCR (section 2.2) Zap 26, EDL933
Sequenced strain
Competent cell preparation and Cloning E. coli AECC 185
(section 2.3 & 2.6)
Outer membrane preparations
(section 2.16)




Zap 3 Lothian Red House dairy
outbreak strain (cattle isolate)
*Zap 198 Walla 3, outbreak strain
Verotoxin Negative
*Zap 196 Walla 1, outbreak strain
Verotoxin Positive
* Walla strains originated from food poisoning outbreaks in Washington State. Walla 3
is identical to Walla 1 but has lost the verotoxin 2 encoding phage and does not carry
any other verotoxin genes
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Dr Fiona Thomson-Carter of The University of Aberdeen and Dr Michael
Pearce of the Wellcome Trust IPRAVE study provided healthy adult bovine
commensal E. coli isolates for use in the LPS core typing studies (section
2.2). Isolates represented cattle from around Scotland. Human commensal E.
coli isolates were obtained from 197 healthy volunteers aged approximately
20yrs at the University of Edinburgh. All isolates were sub-cultured on
Columbia agar supplemented with horse blood overnight at 37°C. Individual
colonies were then transferred to nutrient agar slopes, after overnight
incubation at 37°C isolates were stored at 4°C until required.
2.2 PCR
2.2.1 DNA Template preparation
All recombinant antigens were generated by primary PCR from E. coli
0157:H7 EDL933 (Table 2.1). Overnight 5ml cultures were grown in Luria
Bertani (LB: 10g peptone from casein, 5g Yeast extract, 10g Sodium
chloride, Merck Darmstadt, Germany) broth at 37°C in containment level 3
with shaking. Volumes (10pl) of the overnight cultures were used to inoculate
10Optl sterile ultra pure water (Sigma-Aldrich Company Ltd, Poole, Dorset,
UK). Subsequent heating at 100°C for 10 min ensured complete lysis of all
the bacteria. The resultant lysate formed the template from which all
reactions proceeded. Other E. coli were sub-cultured on blood agar prior to
lysate preparation. DNA templates for the determination of LPS core type by
PCR were obtained as described above.
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2.2.2 Primers and reaction volumes
Primers used for the generation of recombinant Int280 and EspB were
supplied by the Zap lab, Medical Microbiology, The University of Edinburgh.
Dr David Gaily of the Zap lab designed primers for the amplification of the
verotoxin B subunit gene from the E. coli EDL933 sequence.
Primers for the determination of LPS core type were taken from published
sequences (Amor et al 2000; see Table 2.2 for details). Multiplex PCR was
not carried out. All isolates were initially screened for the presence of R1 core
specific genes. Those failing to generate any products were re-screened in
turn for R2, R3, R4 and K12 until each had been assigned a core type. Any
that remained unclassified were labelled as 'untypeable'
All reactions were done in a final volume of 50pl. Table 2.2 shows the primer
sequences and cycling conditions used in each reaction.
Each reaction mix contained the following:
10x PCR buffer (Roche) 5pl
dNTPs: 1.25mM: (Amersham) 2pl
Primers: (50pM): (MWGbiotech) 1pl




Table2.2.Primersequencesndactioncondi nustpro urec mb nantt idet r iLPSry es Primers1to6weredesigneda plifybothntigenfr mhLEEndverotoxinBubun t.ri76rus





















































Primers1and2usfothamplificationfInt ingeneea .ri ers34w rs plifytEs Be pnd56ru
toamplifyhegeneencodingt verot xinBsubu it.Primers7-14w rusdet cg ninvolvLPSc rtypbio y the is,f t charactersint eprimsuffixde othortyppecificgen set ct d
2.3 Determination of LPS core type by dot blot
E. coli were sub-cultured overnight at 37°C on Columbia agar supplemented
with horse blood. Single colonies were emulsified in 10Opil of water.
Nitrocellulose membranes were cut and marked into grids with squares of
dimensions 10mm x 10mm. The nitrocellulose grids were washed in Tris
buffered saline (TBS: 0.02M Tris-HCI, 0.5M NaCI pH7.5) and allowed to dry
at 37°C. Volumes (5pl) of each emulsified bacteria solution were applied to
each of the squares on the nitrocellulose membrane. Controls comprising
heat killed cells and PCP extracted core LPS representing core types R1, R2
and R3 (section 2.19) were included on each nitrocellulose grid.
Nitrocellulose was incubated at 37°C to dry. Membranes were blocked with
3% fish gelatin (v/v) in phosphate buffered saline (PBS pH7.4: Oxoid) for 45
min at room temperature. Monoclonal antibodies as described by Gibb et al
(1992) were used for the determination of LPS core type. Monoclonal
antibodies were diluted 1 in 50 in 1% fish gelatin + PBS (pH7.4) prior to use.
Nitrocellulose membranes were incubated in 30 ml of the appropriate
monoclonal antibody solution for 3h at room temperature. Membranes were
then washed twice in tween-Tris buffered saline (TTBS: 0.02M Tris-HCI,
0.5M NaCI, 0.025% tween 20 pH7.5) for 10 min. Rabbit anti-mouse IgG
horse radish peroxidase (HRP: Sigma) was diluted 1 in 1000 in 1% fish
gelatin + PBS and incubated with the nitrocellulose membranes for 1h 30
min. Membranes were washed twice in TTBS for 10 min, rinsed in H20 and
developed in HRP colour reagent (Bio-Rad, UK)
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2.4 Competent cell preparation
A single colony of E. coli AECC 185 was used to inoculate 20ml LB broth in a
250ml flask. The culture was grown at 37°C with shaking until the optical
density at 600nm (A^o) was 0.5. The 20ml culture was then diluted in 100ml
of LB broth and growth continued until A6oo=0.5. Finally 400ml of LB broth
was added to the culture and growth continued until A6oo=0.6. The flask was
placed immediately on ice. Bacteria were harvested by centrifugation at
4000g, 4°C for 10min. Cells were resuspended in 100ml ice cold sterile TFB1
(30mM KAc, 10mM CaCI2.2H20, 100mM KCI, 15% glycerol v/v, 50mM
MnCI2) and bacteria were harvested by centrifugation at 4,000g, 4°C for
10min. Harvested bacteria were resuspended in 20ml sterile ice cold TFBII
(75mM CaCI2l 10mM KCI, 15% glycerol v/v, 100mM Na-MOPS pH7).
Aliquots (1 OOpil) were frozen in liquid nitrogen and stored at -70°C until
required.
2.5 Agarose gel electrophoresis
PCR products and plasmids were resolved by agarose gel electrophoresis.
Gels were prepared by the addition of 1g agarose to 100ml Tris-acetic acid-
EDTA (TAE) buffer (40mM Tris-acetic acid pH8, 1mM EDTA). Each gel was
supplemented with 2nM (1.5pl at 10mgml"1) ethidium bromide to allow
visualisation of the DNA. Samples comprising 2pil of the PCR product along
with 2pl gel loading solution (Sigma) and 6pl ultra pure water (Sigma) were
loaded on to each gel. Products were run along side 2pl ready load 100bp
ladder (Invitrogen Life sciences, Paisley, UK) in order to achieve accurate
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sizing. Plasmid samples were prepared the same way and run along side the
appropriate marker to allow either sizing (1Kbp ladder) or quantification
(AJHindlll).
A voltage of 100V was applied until the products had achieved sufficient
resolution. Products were visualised under UV illumination and analysed by
Bio-Rad Quantity One software.
2.6 PCR and restriction product clean-up
Each successful PCR or restriction digest reaction was subjected to a
QIAquick® clean-up column (Qiagen, Crawley, W. Sussex, UK). Multiple
reactions of the same PCR were pooled up to the maximum capacity of the
column, cleaned, and then eluted in the required volume of elution solution
(30 or 50|J:10mM Tris-HCI, pH8.5). Product recovery from the column was
determined by agarose electrophoresis.
2.7 Transformation
Chemically competent E. coli AECC 185 were transformed by the following
method. Purified plasmid (5pl) was added to 10Opil chemically competent
cells for 30 min on ice. Bacteria were then heat shocked at 42°C for 30 s.
Immediately 1ml LB broth was added and the bacteria were incubated at
37°C for a further 2 hours with gentle shaking. Luria Bertani agar (Merck)
supplemented with 1.3^M ampicillin (LBamp) was inoculated with 10Opil of
the competent cell culture. Plates were incubated overnight at 37°C.
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2.8 Plasmid preparation.
After transformation approximately 10 colonies from the LBamp plates were
sub-cultured overnight at 37°C with shaking in 5ml LBamp broth. Bacteria
were harvested in a bench centrifuge at 3000g for 15 min. The supernate
was discarded. Plasmids were extracted using QIAprep® kits (Qiagen). In
each case the optional wash was performed and prior to plasmid elution, the
columns were incubated at 42°C for 5 min to ensure removal of residual
ethanol. Plasmids were eluted in 30pl of Qiagen elution solution. Plasmids
were visualised by agarose gel electrophoresis and ethidium bromide
staining as described in section 2.5.
2.9 Restriction digests
All plasmid DNA digests were carried out in a maximum 10pl reaction unless
otherwise stated. To 2pl of extracted plasmid DNA, 20U of restriction
enzyme, 1pl 10x buffer as supplied by the manufacturer and autoclaved ultra
pure water (Sigma) to a final volume of 10pil were added. The reaction was
allowed to proceed in a water bath at 37°C for 1 hour. The samples were
then removed, gently mixed, and pulsed in a microfuge and replaced in the
water bath for a further hour. Enzymatic reactions were cleaned as described
in section 2.6.
2.10 TOPO pCR®4 cloning
To ensure the primers had engineered functional BamH1 restriction sites,
PCR products were cloned into pCR®4 TOPO vectors (TOPO TA cloning kit,
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Invitrogen). Transformation and plasmid preparation were carried out as
described previously. Restriction enzyme, BamH1, was used to excise the
cloned fragment from the pCR®4 TOPO vector. The restriction products were
resolved by agarose electrophoresis (section 2.5).
2.11 Gel purification
Cloned fragments were extracted from plasmid DNA by large-scale restriction
digests and subsequent purification of the excised fragment directly from the
gel. Volumes of purified plasmid (20pl) were added to 60U restriction enzyme
along with 3pl of the recommended buffer (10x) and H20 to a final volume of
30pl. The reaction was allowed to proceed as described in section 2.8.
Products were resolved by agarose gel electrophoresis. To allow better
separation of the restriction fragments a 0.8% gel (0.8g agarose in 100ml
TAE buffer) was prepared. A UV trans-illuminator was used to visualise the
DNA bands in the gel. The BamH1 restricted cloned PCR product was cut
from the gel. The agarose piece was then placed in a QIAquick® column
(Qiagen) and heated to 65°C in a water bath to melt the agarose. Once
melted the Qiagen clean up protocol was used to purify the fragment. The
fragment was eluted in 30pl Qiagen elution solution.
2.12 pGEX-4t2 preparation and restriction
Chemically competent E. coli AECC 185 were transformed with the
commercial cloning vector pGEX-4t2 (Amersham Pharmacia Biotech, UK) as
described previously (section 2.7). Transformed colonies were sub-cultured
62
overnight at 37°C in 5ml LB broth supplemented with ampicillin (as described
in section 2.7). The plasmid was removed with a QIAprep® kit (Qiagen). The
plasmid was digested with the appropriate enzymes. The restricted, cleaned
and purified plasmid was then treated with 3U shrimp alkaline phosphatase
(SAP; Boehringer Mannheim) for 20 min to remove phosphate groups at the
digested ends of the DNA. The enzyme was denatured by incubation at 65°C
for 15 min.
2.13 DNA quantification and ligation
In order to ligate the gel-purified PCR products to the restricted, SAP treated
pGEX-4t2 vector, an approximate value for the amount of DNA present had to
be calculated. This was achieved by resolving the restricted vector and all the
PCR products by agarose gel electrophoresis alongside a DNA marker of
known quantity. In this case the marker used was ready-load XHindlll
(Invitrogen) (Figure 2.1). The amount of DNA present in each band is
detailed in Table 2.3. The quantity of the DNA present was assessed by
comparing the intensity of the sample bands to those in the marker. Each











Figure 2.1: the A.Hindlll marker
Table 2.3: XHindlll marker quantification











Ready-load AHindlll marker (Invitrogen) contains
0.1pgpr1DNA. The quantity of DNA in each band is
given per standard 2pl application
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To ensure efficient ligation three different molar vector: insert DNA ratios,
1:1, 1:3 and 3:1 were used. Using the figures obtained from the XHindlll
ladder the following calculation showed how much DNA was to be used in
each reaction.
ng of vector x Kb size of insert Insert
x molar ratio of = ng of insert
Kb size of vector vector
Wherever possible the total reaction volume was 20pl. T4 ligase and ATP
buffer (Invitrogen) were used as per the manufacturer's instructions. The
ligation of the restricted PCR product to the cut vector was done overnight at
16°C in a Phoenix thermocycler (Helena Biosciences). Chemically
competent AECC 185 E. coli were transformed with the ligate (section 2.6).
After overnight incubation on LBamp agar at 37°C, colonies were examined
for the presence of plasmid DNA with PCR product insert.
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2.14 Orientation analysis
To ascertain the orientation of the inserted gene, restriction sites within both
the vector and the inserted gene were used. Table 2,4 shows the restriction
enzyme used and the expected fragments in each orientation.







pGEX-4t2-lnt280 Pstl 4000, 1880 4800, 1000
pGEX-4t2-EspB EcoR1 304, 5580 631, 5253
pGEX-4t2-Vt2Bsub Hinfl 1213, 1184, 796,
517, 396, 338, 255,
191, 143, 75, 70, 55,
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1213, 1050, 796, 517,
396, 338, 255, 191, 183,
143, 75, 70, 50
2.15 Sequence analysis
Clones identified to have a correctly orientated insert were sequenced.
QIAprep® kits (Qiagen) were used as previously described, to produce
plasmid preparations for each of the clones to be sequenced. Where the
cloned fragment was longer than 500bp, the vector was sequenced in both
forward and reverse directions to ensure that a sequence for the whole gene
would be obtained. Sequencing was carried out by MWG-biotech (Germany).
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2.16 SDS-PAGE
Protein solutions were mixed with an equal amount of double strength SDS-
PAGE sample buffer and heated to 100°C in a boiling bath for 3 min. Proteins
were resolved on 10% slab gels using the buffer system of Laemmli (1970),
as described by Hancock and Poxton (1988). Details of all SDS-PAGE
buffers are given in Appendix 1. LPS was resolved on 14% slab gels in the
same buffer system without SDS in the gel buffers.
2.16.1 Coomassie Blue Staining
The proteins separated on SDS-PAGE gels were stained with Coomassie
blue stain R250 (Fisher Scientific, UK) as described by Hancock and Poxton,
1988.
2.16.2 Zinc chloride staining
To allow immediate visualisation of proteins resolved by SDS-PAGE, gels
were submerged in a 0.3M solution of ZnCI2 for 5 min.
2.16.3 Immunoblotting
The Tris-glycine transfer method as described by Towbin et al (1979), was
followed, (details of all immunoblotting buffers are given in Appendix 1).
Proteins or LPS resolved by SDS-PAGE, were transferred to a nitrocellulose
membrane (0.2pm pore size, Schleicher & Schuell, Germany) in Tris
(0.025M), glycine (0.192M), methanol (20% v/v) buffer, pH 8.3 at 5V and 40
mA for 18 h at 4°C.
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The following transfer procedures were carried out with gentle agitation. After
washing the nitro-cellulose in Tris buffered saline (TBS: 0.02M Tris, 0.5M
sodium chloride, pH 7.5) for 10 min the membrane was blocked with 15 ml of
3% (v/v) fish gelatin (Sigma) in TBS for 45 min. The nitrocellulose membrane
was incubated with appropriate anti-sera diluted in 1% (v/v) fish gelatin in
TBS. This was incubated at room temperature for 90min. For the detection of
antibodies to LPS, the blots were left to incubate overnight at room
temperature. After washing twice for 10 min in Tween TBS (0.02M Tris, 0.5M
sodium chloride, 0.025% Tween 20, pH 7.5) the membrane was incubated
with the appropriate antibody conjugate (HRP) diluted 1 in 2000 at room
temperature for 90min. After two further washes in Tween TBS as above, the
nitrocellulose membrane was washed three times in distilled water. The
nitrocellulose was placed into HRP developer (details given in Appendix 1)
and the colour developed. The development was stopped by several washes
in distilled water.
2.17 Outer membrane preparations
Overnight 5ml cultures of Zap 193 (Table 2.1) were used to inoculate (0.1%
v/v) 100ml LB broth. Cultures were grown at 37°C with shaking until A6oo=0.8.
Bacteria were harvested by centrifugation at 10,000g for 15min at 4°C, and
washed in 50ml sterile PBS and harvested as before. The bacteria were
resuspended in 9ml pyrogen free H20 (pfH20). Bacteria were lysed by three
rounds of sonication at 10pm for 30s with 30s rest. A volume (1ml) of a 7%
sarkosyl (Sigma) solution was added at room temperature and clearing of the
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opalescent solution observed. Cell debris was removed by centrifugation at
10,000g for 15min at 4°C. To harvest the outer membrane proteins the
supernate was subjected to ultra-centrifugation at 50,000g for 1h at 4°C. The
supernate was removed and the pelleted outer membrane proteins
resuspended in 10ml pfH20, and stored at -20°C until required.
2.18 Secreted protein precipitation with trichloroacetic acid (TCA)
E.coli 0157 Zap 193 (Table 2.1) was cultured overnight at 37°C on Columbia
agar supplemented with horse blood (Oxoid). A single colony was used to
inoculate 5ml sterile LB broth. The culture was incubated overnight at 37°C
with shaking. Volumes (1ml) of the overnight culture were added to 40ml
sterile minimal essential medium. The culture was incubated at 37°C with
shaking until A6oo=0.9. Volumes (20ml) of the culture were added to
polypropylene universals. Bacteria were harvested by centrifugation at
4,000g for 15 min at room temperature. The supernate was removed and
passed through a 0.2pm filter into a fresh polypropylene universal. TCA
(100%) was added to a final concentration of 10% (v/v). Proteins were left at
4°C overnight to precipitate. Precipitated proteins were harvested by
centrifugation at 4000g for 30 min at 4°C. The supernate was discarded and
the pellet allowed to dry completely. Harvested proteins were resuspended in
500pl 1.5M Tris-HCI (pH8.0). Proteins were stored at -20°C until required.
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2.19 LPS extraction by phenol chloroform petroleum and rapid aqueous
phenol methods.
Phenol chloroform petroleum (PCP) extracted LPS cores R1, R2, R3, R4 and
K12 were prepared by staff at the Microbial Pathogenicity Research
Laboratorty, Medical Microbiology, The University of Edinburgh by the
method of Galanos et al (1969).
Smooth LPS was extracted by the micromethod of Fomsgaard et al (1993).
Briefly E. coli were cultured overnight at 37°C on Columbia agar
supplemented with horse blood. Several colonies were emulsified in 500pl
pfH20 and subjected to the rapid aqueous phenol extraction protocol.
2.20 Production and purification of recombinant proteins
2.20.1 Protein induction
Overnight 5 ml cultures in LBamp of each clone were used to inoculate 1 litre
LBamp. Cultures were grown to mid-log phase, as determined by absorption
at 600nm, at 37°C with vigorous shaking (approx 4h). Isopropyl p-D-
thiogalactoside (IPTG; Fisher) to a final concentration of 1mM was added to
each flask and growth at 37°C (with shaking) was continued for a further 3
h, during which time protein production was induced. Bacteria were
harvested by centrifugation at 10,000g for 15 min.
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2.20.2 Protein purification and extraction.
Harvested bacteria were re-suspended in ice cold PBS. Bacteria were lysed
by three rounds of sonication at 10pm for 30 s with 30 s rest. Cell debris was
separated from the solution by centrifugation at 7,000g for 15 min. A sample
of the supernate and harvested cell debris were removed and subjected to
SDS PAGE (section 2.15). If the GST tagged protein was present in the
supernate then it was stored at -20°C until required. If the fusion proteins
had formed inclusion bodies, then further treatment was required to solubilise
them.
2.20.3 Urea denaturation of insoluble inclusion bodies.
Harvested cell debris was re-solubilised in 8M urea supplemented with 1mM
dithiothritol (DTT), insoluble debris was removed by centrifugation at 7,000g
for 15 min. The supernate was then transferred to 12-14,000 molecular
weight cut-off (mwco) dialysis tubing. The supernate was then progressively
dialysed against reduced concentrations of urea (6M, 4M, 2M, 1M) for 2 h at
a time. Each urea solution was supplemented with 1 mM DTT. Final dialysis
against PBS + 1mM DTT was used to remove the urea completely; this was
done for a further 2 h and then repeated. Precipitated proteins were removed
by centrifugation at 70,000g for 30 min. The supernate was removed and
stored at -20°C until required.
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2.20.4 Affinity chromatography.
To remove specifically the GST tagged proteins from the supernate, GSTrap
FF 1ml columns (Amersham) were used. The supernate was pumped on to
the columns using a peristaltic pump according to the manufacturer's
recommendations. Each column was equilibrated with five bed volumes PBS
and then the sample applied to bind the GST tagged proteins. The column
was again washed with PBS before the GST tagged proteins were eluted
with ten bed volumes 10mM reduced glutathione (Sigma) plus 50mM Tris,
pH8. Columns were washed with 6M guanidine HCI and 70% ethanol, and
stored at 4°C in 20% ethanol. SDS-PAGE was used to confirm that the GST
tagged proteins had been eluted from the column.
2.20.5 Protein Assay.
The level of protein in the pooled fractions from the GSTrap FF columns was
determined by a modification of the method of Lowry (Lowry et al, 1951) with
the following alterations. To reduce the amount of sample required for the
assay, the protocol was scaled down so that the procedure could be
performed on a microtitre plate. A bovine serum albumin standard curve was
used to calibrate the assay. Volumes (40pl) of each of the standards were
added in duplicate to the wells of a microtitre plate. The sample to be
assayed was diluted 1 in 4 prior to use and 40pl of each added in duplicate to
the microtitre plate. A negative control consisting of 40pil distilled water was
included. Volumes (120pl) of 12.5% aqueous Na2C03 were added to all the
samples including the standards followed by 20pl 0.1% CuS04.5H20. The
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plate was left for 1 h at room temperature. A solution of Folin's reagent was
then diluted 1 in 3 and 20pl added to each of the samples (including the
standards), the plate was left at room temperature for a further 25 min. The
plate was then read in an ELISA plate reader at 750nm.
2.21 LPS core type ELISA
2.21.1 Core-polymyxin conjugate
PCP extracted LPS cores R1, R2, R3, R4 and K12 (section 2.18) were
prepared as 1mgml"1 solutions with pyrogen free water (pfH20). Each LPS
solution was sonicated at 5pm for 30s to aid dispersal. Polymyxin-B sulphate
was prepared as a 1mgml"1 solution with pfH20. Volumes (1ml) of the LPS
solutions were added to an equal volume of the polymyxin-B sulphate
solution. The resultant solution was sonicated as before. The polymyxin-B
sulphate LPS core solution was then transferred to dialysis tubing (mwco
2000; Spectrapore). The core-polymyxin solution was dialysed overnight at
4°C with constant stirring, against two litres of pfH20 to remove any unbound
polymyxin-B sulphate.
2.21.2 Coating ELISA plates
Polymyxin B-sulphate- LPS core complexes are floccular upon recovery from
the dialysis tubing. Complexes were transferred to glass bijouxs and floccular
masses were dispersed by sonication at 5pm for 30s. Coating buffer (0.05M
sodium carbonate buffer pH9.6) was used to dilute the complexes 1 in 50
prior to coating the plate. To coat, 100pl of each complex was added to each
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well of a microtitre plate (Greiner medium binding strips, Labortechnik). The
coating solution was vortexed at regular intervals to prevent large LPS-
polymyxin complexes becoming coated on to the ELISA plate. Coating was
done overnight at 4°C.
2.21.3 Blocking
Plates were washed four times with PBS-Tween
NaCI, 0.05% Tween 20, pH7.4) and then blocked
+ 3% fish gelatin. Plates were then washed and
until required.
2.22 Serum preparation
2.22.1 Healthy human sera
Sera were obtained from healthy human volunteers at The University of
Edinburgh. Serum was diluted 1 in 400 in PBS dilution buffer pH7.4 (4%
polyethylene glycol 6000 w/v and 0.05% v/v Tween 20). Volumes (1 OOptl) of
the test sera were added in duplicate to the microtitre plate. Dilution buffer
only was applied to those wells used as negative controls.
2.22.2 Healthy bovine sera
Dr Chris Low of The Scottish Agricultural College, Edinburgh provided the
bovine test sera used in this study. Sera had been collected as part of the on¬
going screening of cattle for commercially important bovine disease. Sera
represented many animals from all over Scotland. Since bovine sera had not
(PBS, 2.6mM KCI, 0.13M
overnight at 4°C with PBS
dried and stored at -20°C
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been used for LPS core antibody investigations prior to this study the ELISA
had to be optimised.
2.22.3 Serum titration
For the determination of the optimal serum dilution for detection of anti-core
LPS antibodies, bovine serum samples were first diluted 1 in 400 to screen
for samples that have a median optical density reading. Each sample was
applied in duplicate to five plates each coated with the core LPS-polymyxin
conjugates as described in section 2.21.2. Samples were screened for a
median value against each of the core types. Median samples were then
titrated against each of the five core types. Sera was doubly diluted in PBS
dilution buffer (see section 2.22.1) and applied in duplicate to the microtitre
plate. Sera were incubated with the antigens for 90 min at 37°C. Antibody-
antigen complexes were detected with sheep anti-bovine IgG HRP antibody
conjugate. Colour was developed (Section 2.22.4) and plates were read at
450nm
2.22.4 HRP colour developing for ELISA
One tablet of tetramethylbenzidine dihydrochloride (Sigma) was dissolved
per 10ml 0.05M phosphate citrate buffer (25.7% (v/v) 0.2M dibasic sodium
phosphate, 24.3% (v/v) 0.1M citric cid, 50% (v/v) distilled H20, pH5.0). To
each 10ml volume of substrate solution 2jliI hydrogen peroxide was added.
Volumes (100pl) of the HRP substrate were added to each well of the
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microtite plate. The reaction was stopped with the addition of 50(il 2M
sulphuric acid. Plates were read at 450nm.
2.23 Total immunoglobulin content.
In order to quantify the level of immunoglobulin in each of the samples used,
radial immunodiffusion (RID) was used. Bovine immunolobulin (IgG and IgA)
kits (Bethyl Laboratories Inc, USA) were used to quantify the samples as
directed by manufacture's instructions.
2.24 ELISA for the detection of antibodies to recombinant proteins
2.24.1 Determination of optimal recombinant protein coating
concentration
The availability of goat anti-GST antibody (Amersham) allowed the optimal
level of GST coating to be determined. Coating was achieved by the dilution
of the sample protein in 0.05m sodium carbonate buffer pH9.6 to the required
concentration. Volumes (1 OOpil) of GST at various concentrations were used
to coat the microtitre plate overnight at 4°C. Negative controls received
coating buffer only. Plates were blocked and washed as described previously
(section 2.21.3). Goat anti-GST IgG (Amersham) was added at a dilution of
1 in 1,000 in 0.05M sodium phosphate buffer pH7.4, 0.85% w/v sodium
chloride, 0.05% v/v Tween 20 (antiserum conjugate diluent) and plates were
incubated for 90 min at 37°C. After washing, antibody antigen complexes
were detected by the addition of rabbit anti-goat IgG HRP (Sigma) at 1 in
20,000 dilution in antiserum conjugate diluent for 90 min at 37°C. Plates were
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then developed (section 2.22.4) and colour read at 450nm. Optimal coating
was determined as the lowest concentration of GST that achieved maximum
detection (i.e. max. OD).
2.24.2 Serum titration
Serum titration was carried out to determine the optimal dilution for detection
of antibodies to Int280 and EspB. The optimal dilution is defined as the
dilution that produces an optical density of half the maximum obtained. At this
dilution the ELISA is most sensitive to changes in antibody titre. Microtitre
plates were coated overnight at 4°C with the optimal concentration of GST
and either Int280-GST or EspB-GST as described previously (section 2.24).
Sera identified by immunoblot as having a median level of antibody reactive
to Int280 and EspB were used to determine the optimal dilution. Sera were
used neat, at a dilution of 1 in 100 and doubly thereafter to a final dilution of 1
in 6400 in 0.05M sodium phosphate buffer pH7.4 (Antibody buffer). Plates
were blocked and washed as described previously (section 2.21.3). Sera at
the appropriate dilution were incubated with the antigen for 90 min at 37°C.
Antibody antigen complexes were detected by the addition of sheep anti-
bovine IgG HRP at a dilution of 1 in 20,000 in antibody buffer. Colour was
developed as described in section 2.22.4. Plates were read at 450nm.
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2.24.3 Conjugate titrations
All Serotec antibody conjugates were titrated to determine the optimal dilution
for use. Microtite plates were coated with GST, Int280-GST and EspB-GST
at the optimal dilution. The same sera used in the serum titration assay
(section 2.24.1) were prepared as previously described and used at the
optimal dilution. The antibody was incubated with the antigen for 90 min.
Antibody conjugates were serially diluted and incubated with the plate for 90
min. Plates were developed and read as described in section 2.22.4. The
optimal dilution was determined as the lowest dilution that gave an OD
reading equivalent to the maximum obtained.
2.25 Experimental infection with Escherichia coli 0157
Calf challenges were performed at Moredun Research Institute (MRI) in
either containment level 2 (verotoxin negative strains) or 3 (verotoxin positive
strains) large animal housing facilities by staff at MRI. Calves were
conventionally reared until approximately two weeks post-weaning and
transported to MRI where they were acclimatized for approximately three
days prior to challenge. Faecal samples were taken at least twice from each
calf and confirmed negative for E. coli 0157 by immuno-magnetic separation
(IMS) prior to challenge. E. coli 0157 strains, selected for resistance to
nalidixic acid, were grown overnight in LB broth 37°C, with shaking) and
diluted in sterile PBS to achieve an inoculum of 109 cfu per animal in a total
volume of 10 ml. The inoculum was administered to the calves via a
stomach tube and washed down with 500 ml sterile PBS. Table 2.1 details
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the strains used in this experiment. Three strains of E. coli 0157 were used
to experimentally infect 22 male calves (Table 2.5)
Table 2.5: Experimental infections
Calf number Inoculation strain
c81 c303 Zap 198 (Walla 3),









c108 Zap 3, Lothian Red
c118 House Dairy outbreak
c121 strain (cattle isolate)
c140 Verotoxin positive






2.26.1 Bovine serum from experimentally infected cattle
Whole bovine blood from experimentally infected cattle was collected at
weekly intervals. Sera were removed and stored as previously described
(section 2.22.2),
2.26.2 Bovine faecal samples from experimentally infected cattle
Faecal samples for the detection of IgA were treated as follows using a
method adapted from Gaspari et al (1988). All procedures were carried out
in category 3 containment facilities. Two parts protease inhibitor solution
(soybean trypsin inhibitor 1mgml"1 in PBS and 50mM EDTA with 0.05%
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Tween 20), were added to approximately one part (3g) bovine faecal
material. 0.1M phenylmethylsulphonyl fluoride (PMSF; Sigma) in ethanol was
added to a final concentration of 1mM. The mixture was vortexed for 30s and
then centrifuged at 4,000g for 10 min to remove faecal debris. To the
supernate, 0.1M PMSF in ethanol was added to a final concentration of 2mM.
The supernate was vortexed again and left to stand on ice for 15 min. Heat
inactivated (54°C for 45 min) foetal calf serum was added to a final
concentration of 4% (v/v). The sample was transferred to screw-capped
eppendorf tubes and centrifuged at 16,000g for 5 min. The supernate was
carefully removed. Each sample was then filter sterilised by passage through
a 0.2pm filter membrane (Millipore). Samples were stored at -70°C until
required.
2.27 Detection of bovine antibody to recombinant antigens
2.27.1 ELISA
Microtitre strips (Greiner) were coated overnight at 4°C with recombinant
antigen diluted in coating buffer (Appendix 1). Plates were blocked as
previously described (section 2.19.3) Bovine test sera from experimentally
challenged cattle were diluted in antiserum conjugate diluent. Each sample
was applied in duplicate to the microtitre plates at the required concentration.
After incubation for 90 min at 37°C the plates were washed 4 times and the
appropriate antibody conjugate was applied at a dilution of 1 in 20,000. All
antibody conjugates were purchased from Serotec and were raised in sheep
against each of the bovine immunoglobulin types.
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2.27.2 Dot blot for the detection of IgA in faeces
Nitrocellulose membranes were cut into rectangles of dimensions
100 x 70mm and 2pl of recombinant protein applied with a micropipette.
Each membrane was blocked with 3% fish gelatin + PBS for 45 min at room
temperature. The membrane was then clamped into a 96 well manifold and
100pl of each faecal suspension diluted 1 in 4 in antiserum conjugate diluent,
applied to the membrane. The manifold was sealed to prevent evaporation
and left overnight. A vacuum was applied to the manifold to remove the
faecal suspension and the membrane was removed and washed twice in
TTBS for 10 min. Sheep anti-bovine IgA HRP or sheep anti-bovine lgG1 HRP
at a dilution of 1 in 1000 was applied to the membrane for 90 min at room
temperature. Colour was developed using HRP colour developer.
2.27.3 Immunoblot for the detection of antibodies to recombinant
proteins.
Recombinant proteins were resolved by 10% SDS PAGE. Proteins were then
transferred to nitrocellulose overnight. Nitrocellulose was removed and cut
into strips of dimensions 3 x 90mm. Each strip was use to test bovine serum
samples for the detection of antibodies to GST, EspB and Int280.
Nitrocellulose was first blocked for 45 min in 3% fish gelatin + PBS. Serum
was diluted 1 in 50 in 1% fish gelatin in PBS and incubated with each strip for
90min. Negative controls received foetal bovine serum diluted as per the
samples and positive controls received goat anti-GST at a dilution of 1 in
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1000. Nitrocellulose was washed twice in TTBS for 10 min. Sheep anti-
bovine IgG HRP was applied for 90 min at a dilution of 1 in 1000. Positive
controls received rabbit anti-goat IgG HRP at the same dilution. Colour was
developed using HRP colour developer.
2.28 Protocol to assess the function of bovine antibody in preventing
AE lesions
HeLa cells were cultured at 37°C with 5% C02 in 5ml tissue culture flasks in
Dulbecco's modified Eagle's medium (DMEM) supplemented with 5%(v/v)
foetal calf serum and non-essential amino acids (Sigma) used in accordance
with the manufacturer's instructions. Confluent HeLa cell monolayers were
harvested by trypsin-EDTA (Sigma) digestion and centrifugation at 1,500g for
10 min. Pellets were washed in 10 ml PBS and harvested by centrifugation at
1,500 g for 10 min. Cells were resuspended in 15ml DMEM and 1ml was
placed into each well of a four well chamber slide (Nunc). HeLa cells were
cultured overnight at 37°C with 5% C02 to allow confluent monolayers to
form.
Overnight 5ml cultures of toxin negative E. coli 0157 (Zap 193: See Table
2.1) were grown at 37°C with shaking in LB broth. Volumes (100pl) of the
overnight culture were used to inoculate 5ml DMEM supplemented with 5%
(v/v) foetal calf serum, non-essential amino acids and glutamine to a final
concentration of 25mM. Where appropriate serum obtained from
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experimentally infected calves (section 2.26.1) was pooled and added to a
final concentration of 1 in 20 or 1 in 200.
The culture was incubated at 37°C with shaking until A6oo=0.4. Volumes (8pl)
of the 5ml culture were used to inoculate 4ml fresh DMEM + supplements
(plus where appropriate, pooled serum from experimentally infected calves at
the required dilution as before). DMEM was removed from the HeLa cell
monolayers and replaced with 1ml of the diluted E. coli 0157 culture. HeLa
cell monolayers were incubated at 37°C with 5% C02 for a further six hours.
Media was replaced with fresh DMEM after 3 hours.
2.28.1 Fluorescent actin staining (FAS)
Cell monolayers were washed twice with PBS and then fixed by the addition
of 300pl 4% formalin for 20 min. Formalin was discarded and the cells were
permeabilised with 300pl 0.1% Triton X-100 for 5 min. After three washes
with 1 ml PBS 200pl of tetramethyl rhodamine isothiocyanate (TRITC) or
fluorescein-5-isothiocyanate (FITC) labelled phalloidin was added for 20 min.
Throughout the incubation with phalloidin cells were kept in the dark. Cells
were washed three times in PBS, mounted with fluorescent mounting
medium (Dako) and observed under a Leica fluorescent microscope. Images
were captured and processed using LeicaQFIuoro software.
2.29 Statistics
Data was analysed by Student t-test and Chi-squared test.
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Chapter Three.
Human and bovine faecal commensal Escherichia coli
lipopolysaccharide core type study.
Aims.
Lipopolysaccharide is the dominant surface antigen of all Gram-negative
bacteria. An anti-core LPS antibody response may afford some protection
against E. coli associated disease. There is a proven association between R3
core LPS and EHEC, therefore increased exposure to R3 core LPS may elicit
a protective immune response against this virotype. It is hypothesised that
cattle are exposed to more R3 E. coli and consequently generate an anti-R3
antibody response that may provide protection against EHEC associated
disease in comparison to humans who are not commonly exposed to R3
bacteria.
Therefore the aims of this chapter were:
1) To use PCR and monoclonal antibodies to determine the LPS core
type of faecal £. coli isolates from healthy human volunteers and adult
healthy cattle.
2) To determine the distribution of the five LPS core types within both
commensal populations.
3) To examine sera from healthy human donors and healthy cattle for
antibodies reactive to each of the five LPS core types.




3.1 LPS core type detection by PCR and dot blot
Human faecal isolates obtained from 197 healthy human volunteers were
screened for LPS core type by PCR. An E. coli colony from each of the
primary faecal cultures was selected and sub-cultured on Columbia Agar
supplemented with horse blood. Bovine commensal isolates were obtained
from the commensal E. coli collection of Dr Fiona Thomson-Carter of the
University of Aberdeen (n=100) and Dr Michael Pearce of the Wellcome
Trust IPRAVE study (n=100). Lysates of each of the commensal isolates
were prepared and used as the DNA template for the PCR. Monoclonal
antibodies were used to check the results from the PCR. Figure 3.1a and b
show an agarose gel upon which the products of a PCR for the genes
involved in R3 core LPS biosynthesis have been resolved and the
corresponding dot blot developed using the W4 434.07 R3 specific
monoclonal antibody (Gibb et al, 1992). The PCR gel (Figure 3.1a) shows 35
faecal E. coli, seven of which (lanes 8, 10, 19, 20, 24, 28 and 29) show a
band at 1.7Kbp indicative of an R3 E. coli. The R3 specific monoclonal
antibody was found to react with the same isolates and no others (Figure
3.1b). The controls show two positive results where R3 LPS and heat killed
whole R3 E. coli where used. R1 and R2 core LPS was used for the negative
controls; no reaction between the monoclonal antibody and these core types
was observed.
85
Figure 3.2 shows typical results obtained from the screening of the
commensal E. coli isolates for LPS core types R1, R2 and R4. Figure 3.2a
shows 15 commensal isolates that have been examined for the presence of
the gene coding for a specific enzyme involved in the biosynthesis of the R1
core. An R1 E. coli is denoted by the presence of a band at 551 bp, 10 of the
commensals shown are therefore R1 E. coli. The primers designed to detect
R2 E. coli amplify a region of the R2 core biosynthesis producing a band at
1141 bp (Figure 3.2b) whilst the R4 E. coli yield a band at 699bp (Figure
3.2c). The primers for the detection of R3 and K12 E. coli (data not shown)
yield bands of 1785bp and 916bp respectively. Extra bands that appear on
the gel are a result of non-specific primer binding due to the low annealing
temperatures.
It was found that E. coli with R1 core LPS was the most frequently isolated
commensal from both healthy humans and cattle (50% and 40%
respectively) (Figures 3.3 and 3.4). The numbers of R2 and R4 E. coli
isolated from the healthy human faeces were very similar, 12% being R2 and
14% being R4. The number of R4 E. coli detected among the bovine isolates
was higher (20%) than in the humans. It was apparent that in humans R3
and K12 core LPS was the least common of all the core types, each being
isolated in only 3% of cases. Of interest was the high level of R3 core LPS in
the bovine commensals (9%) as compared to the level in humans (3%). This
difference was statistically significant (p<0.05). Within both commensal
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populations many of the organisms failed to yield any PCR products (21%
humans and 19% bovines) and were consequently labelled as 'untypeable'.
a:
1 2 3 4 5 6 7 8 9 10 TV 12 1314 15 1617
1 7Kbp- -1.7Kbp
18 19 20 21.22 23 24 25 26 27 28 29 30 31 32 33 34 35








R3 LPS R3 HKC R1 LPS R2 LPS
Figure 3.1a and b: Thirty-five faecal E. coli investigated by a) PCR and b) dot blot for R3
core LPS. a : Faecal E. coli isolates investigated by PCR for the genes involved in R3 core
type biosynthesis. A band at 1.7Kbp denotes a R3 E. coli. Lanes 8, 10, 19, 20, 24 28 and 29
show R3 E. coli. b: The same faecal E. coli isolates investigated by dot blot analysis for R3
LPS. The R3 core LPS specific monoclonal, W4 434.07 was used to detect those strains
with R3 core LPS. Isolates 8, 10, 19, 20, 24 28 and 29 are shown to be R3
E. coli. HKC - Heat Killed cells.
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a:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
551 bp ► + 551 bp
b:




1 2 3 4 5 6 7 8 9 10 11 1213 1415 16
699bp ► -« 699bp
Figure 3.2: PCR for the genes involved in LPS core-type biosynthesis pathways,
a: A band at 551 bp denotes that the isolate tested carries the genes for R1 core synthesis.
Ten of the samples (lanes 3-8, 11, 12, 15 and 16) are R1 E. coli. b: The genes for R2 core
synthesis are detected by the presence of a band at 1141bp. Four of the samples (lanes 2, 9,
13, and 15) are R2 E. coli. c: Nine of the isolates (lanes 2, 6, 7, 9-13 and 16), show a band at









Figure 3.3: Pie chart showing the distribution of LPS core types among 197 human








Figure 3.4: Pie chart showing the distribution of LPS core types among 200 bovine
commensal E. coll isolates.
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3.2 O-antigen variation
In order to ensure that the isolates being used in this study were not merely
duplicates of the same organism, the O-antigen profiles of a selected number
were investigated. Samples representing each of the core types were chosen
and subjected to a rapid aqueous-phenol LPS extraction protocol based on
that of Fomsgaard et al (1993). Each sample was then resolved by 14%
PAGE and the LPS visualised by silver staining. Sixteen human isolates
(Figure 3.5) and 19 bovine isolates (Figure 3.6) can be seen along with an
E. coli 018 control for comparison. There appears to be considerable
variation in the O-antigens of the isolates selected. Some of the isolates do
however appear to have the same O-antigen profiles and are indeed likely to
be of the same serotype, for example lanes 13-17 of Figure 3.6 show 5
bovine isolates that probably have the same O-antigen profile. This may
reflect the limited number of serotypes that exist as commensals.
018 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Figure 3.5: Silver stain of a 14% PAGE gel showing the LPS profiles of 16 human
commensal E. coli
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Figure 3.6: Silver stain of a 14% PAGE gel showing the LPS profiles of 17 bovine E. coli
commensals
3.3 Bovine LPS titrations
In order to determine the optimal bovine serum dilution for the determination
of LPS core type antibodies, 47 samples were screened against each of the
core types. Samples were diluted 1 in 400 as per the protocol for human
sera. The sample with the median optical density (OD) for each of the core
types was used to create a titration curve. Figure 3.7 shows the range of
responses to each of the core types among these 47 healthy bovine
samples. The black line in each of the box plots represents the median value
(actual value is given beside the plot) and the green line the mean. The
highest median values were obtained with the R4 and R3 core LPS whilst the
R2 and K12 OD ranges were only slightly lower. All were markedly higher
than the range of optical densities against R1.
The sample from which the median value was obtained was then titrated
further to obtain an optimal serum dilution (Figure 3.8). This would be noted
as the dilution that produced an OD reading equivalent to half the maximum
reading obtained. Each bovine serum sample was doubly diluted and titrated
against the LPS core type for which it was found to have a median OD
reading. As each serum was diluted, the level of response to each core type
was rapidly lost. A dilution of 1 in 4800 was enough to reduce the OD reading
to background levels. Half the maximum OD reading was achieved at a
dilution of approximately 1 in 1000 in each of the sera. This was determined
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Figure 3.7 Range of antibody responses to the five E. coli LPS core types in 47 bovine
serum samples. The black line in each of the box plots represents the median value (actual
value is given beside the plot) and the green line the mean. Box plot for R2 shows only the
mean value, as both the mean and median are identical. The lower boundary of the box
represents the 25th percentile and the upper boundary the 75th percentile. The lines above
and below the box represent the 90th and 10th percentiles respectively. Values falling out with
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3.4 Core LPS antibody responses in healthy humans and cattle
Serum from healthy humans and cattle was used to test for the presence of
antibodies reactive to each of the five known LPS core types present in E.
coli, R1, R2, R3, R4 and K12. Core LPS-polymyxin complexes were coated
on to microtitre plates. Human serum diluted 1 in 400 and bovine serum
diluted 1 in 1000 was applied to microtitre plates. Antibody antigen
complexes were detected with the use of either mouse anti-human IgG HRP
(Sigma) or sheep anti-bovine IgG HRP. In all 91 human (Figure 3.9) and
bovine serum samples were screened, however owing to problems incurred
with the bovine standards on a number of the plates, the results obtained
from only 39 of the samples tested are presented here (Figure 3.10). It was
found that in both cases the level of anti-R4 core antibody was statistically
higher than the level of any other anti-core antibody (p<0.01). In humans
there was no statistical difference between the level of anti-R1, R2 and R3
core antibody (p=0.3 and 0.9). In both humans and cattle the level of anti-
K12 antibody was significantly lower than any other core type response
(p<0.01). Of particular note was the elevated level of anti-R3 core antibody
relative to the R1, R2 and K12 levels among the bovine sera tested. This was
found to be statistically higher (p<0.01) than the level of anti-R1 and R2 core



















Figure 3.9: Graph to show the range of antibody responses to each of the five E. coli LPS
core types. Tested by ELISA on 91 healthy human serum samples. Box plot parameters as
Figure 3.7
Table 3.1: P values, obtained by student t-test, showing the significance of the antibody
responses to the five E. coli LPS core types in 91 healthy human serum samples.
R2 R3 R4 K12
R1 0.3 0.9 <0.01 <0.01
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Figure 3.10: Graph to show the range of antibody responses to each of the five E. coli LPS
core types. Tested by ELISA on 39 healthy bovine serum samples. Box plot parameters as
Figure 3.7
Table 3.2: P values, obtained by student t-test, showing the significance of the antibody
responses to the five E. coli LPS core types in 39 healthy bovine serum samples
R2 R3 R4 K12
R1 <0.01 <0.01 <0.01 <0.01





A previous study by Currie and Poxton (1999) showed that E. coli 0157 and
most other non-0157 verotoxin producing E. coli carry the LPS core type R3.
The study looked at 28 verotoxigenic E. coli (VTEC) strains, of which 20 were
0157, five were 0111 with one each from serotypes 026, 0128 and 086. All
were found to carry R3 core LPS. More recently studies by Amor et al (2000)
have confirmed that R3 core LPS is indeed often associated with VTEC.
They reported that 81% of the VTEC isolates tested, were positive for R3
core LPS. This represented serotypes 026, 055, 091, 0103 and 0157. The
study also showed that not all the VTEC are associated with R3 core LPS, for
example several 0157 isolates were found to have R1 core LPS. So while
there is not a complete association of R3 core LPS with the VTEC, it is by far
the most common core type associated with the group.
Gibb et al (1992) used core specific monoclonals to determine which core
types were the most prevalent among blood, urine and faecal isolates. Of all
the isolates examined the only true indication of the core type distribution
among commensal E. coli can be obtained from the 21 faecal isolates
examined. R1 core LPS was found to be most common (11 isolates), four
isolates were found to carry R2 core LPS and two R3. Four were either R4 or
K12 but were assigned no core type due to the lack of any anti-K12 or R4
monoclonal antibodies. Appelmelk et al (1994) investigated the distribution of
LPS core types among 68 isolates from positive blood cultures. R1 core LPS
was most frequently detected. Nine, 12 and seven strains were found to carry
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R2, R3 and R4 core LPS respectively. Only 3 isolates were identified as
being K12. Amor et al (2000) examined 72 E. coli isolates from the E. coli
reference collection (ECOR) deemed representative of the genetic diversity
within the species to obtain a view of the core type distribution in an unbiased
population. R1 core LPS was found to be the most common core type. R2
and R3 core LPS was found in 11.1% of the isolates with R4 and K12 being
found in only 2.8% and 5.6% of the isolates respectively. However the results
presented by Appelmelk et al (1994) and those presented by Amor et al
(2000) (although representative of the whole E. coli species), may not
accurately reflect the distribution of core types within commensal flora. Subtle
relationships between LPS core type and virulence determinants required to
allow an organism to survive in a particular niche may affect the results.
While studies such as these have focused on the core types associated with
a particular group of E. coli for example the VTEC, the study undertaken here
was intended to show how the LPS core types were distributed among a
population of commensal E. coli from both healthy humans and cattle. The
results would reveal which core type humans and cattle were most frequently
exposed to in health and whether or not this had any influence on the level of
the anti-core LPS antibody response.
Currie et al (2001) showed that patients convalescing from 0157 infection
had elevated levels of IgA to 0157 LPS that could be attributed, in part, to
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the R3 core component. This implied an immune response to core LPS that
may play a role in protection.
A number of studies have examined the correlation between levels of anti-
endotoxin incomplete core antibody (EndoCAb) and the development of
postoperative complications. Bennett-Guerrero et al (1997) postulated that
endotoxin was one of the factors leading to pro-inflammatory responses in
patients recovering from major heart surgery. Strutz et al, (1999) showed that
low levels of anti-core LPS antibodies reduced the possibility of survival. In
this study however serum was obtained upon admission to the intensive care
unit, or upon diagnosis of sepsis, in which case the low antibody levels could
have been attributed to a 'moping up' effect of the antibody by the organism
causing sepsis. Bennett-Guerrero et al (1997) investigated links between
postoperative complications and the level of IgG and IgM EndoCAb levels in
301 cardiac patients prior to surgery. They found that patients with low levels
of IgM EndoCAb were more likely to suffer complications.
In a comparative study between healthy volunteers from Edinburgh, UK and
Dhaka, Bangladesh, Hoque et al (2000) showed that there were significant
differences in the levels of anti-core LPS antibodies between the two
populations. Of note was the higher level of antibody to the R1, R3 and R4
core LPS in the population from Dhaka as compared to those in Edinburgh.
This difference in antibody level may help to explain the higher levels of
inflammatory bowel disease in the developed world and suggests a role for
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both mucosal and systemic anti-core LPS antibodies in protection against
such conditions. Could an increase in exposure to various E. coli serotypes
lead to an increase in the level of antibody reactive to that core?
Among the human and bovine commensals examined here it was found that
R1 core LPS was the most frequently detected core type. Despite the
obvious abundance of R1 core LPS among our own commensals and those
of cattle, the associated antibody response was not significantly different
from the R2 response, and in both cases far lower than the response to the
R4 core. Of the human isolates tested, only 11% were found to carry R4 core
LPS as opposed to 20% of the bovine isolates; this was significantly lower
than the level of R1 LPS within both commensal populations.
This apparent contradiction in the light of other studies may be explained by
the serum sensitivity of these particular serotypes. Gibb et al (1992)
investigated the serum sensitivity of the isolates used in their study. They
found that 81% of the R1 isolates were serum resistant, while 68% of other
core types were found to be resistant (R4 and K12 core types not included).
This was thought attributable to the capsule (K1 or K5) associated with the
R1 isolates. The K1 and K5 capsules are poorly immunogenic due to the fact
that they are composed of molecules mimicking those of the host (Devine &
Roberts, 1994).
102
Devine and Roberts (1994) reported that the level of serum sensitivity of a
particular isolate was most likely linked to both capsule type and O-type. A
wide range of serum sensitivities was found among those isolates with K1
and K5 capsules. Interestingly serotypes 07, 018 and 075 (representing R1
and R2 core types) were found to be sensitive to killing by the alternative
complement pathway but not by the classical pathway. This may suggest that
exposure to the LPS core was blocked by a capsule preventing effective
antibody mediated-complement activation. Porat et al (1992) showed that the
serum sensitivity of various serotypes of E. coli depended upon the lengths of
the O-antigen polysaccharide side chains. It is possible therefore that R4 E.
coli are often without capsule or have O-antigens that do not provide serum
resistance. This would correlate with the finding here that while the frequency
of R4 carrying commensals is not significantly higher than the level of either
R1 of R2 isolates, there is a significantly higher antibody response to the R4
core. This could result from the antigen challenge delivered by a serum
sensitive R4 organism when destroyed by both innate and acquired
components of the immune system.
Using a chi-squared test it was possible to show that the level of R3 core
LPS among the bovine commensals was significantly higher (p<0.05) than
the level found in the human commensals. This would suggest that cattle are
exposed to more E. coli serotypes carrying R3 core LPS than humans. The
association of R3 core LPS with VTEC as demonstrated by Gibb et al (1992),
Currie & Poxton (1999) and Amor et al (2000) would imply that this increased
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R3 exposure would be due largely to a greater number of species related to
VTECs, EHECs and EPECs within the commensal populations of cattle. The
level of anti-R3 core antibody detected in the bovine sera was significantly
higher than the R1, R2 and K12 response. Whilst no direct comparisons
between the human and bovine results are possible, this trend was not seen
in the human samples tested. It is possible that cattle being exposed to more
R3 core LPS, generate a more significant response to this core type than
humans who are infrequently exposed.
Of concern was the possibility that the strains used in the bovine core type
study were duplicates of the same organism from the same animal. Any
observed increase in the level of a particular core type could therefore have
been due to the presence of these duplicates. In order to confirm that the
isolates were different, their LPS profiles were examined by PAGE and
visualised by silver staining. The O-antigen profiles of those strains selected
exhibited considerable variation and therefore suggested that the isolates
were not merely duplicates of the same organism although some appeared
the same.
Core LPS may be divided into inner and outer regions, the outer region
displaying more variation than the inner (Amor et al, 2000). Barclay (1995)
showed that incomplete (Rc) core LPS comprising the Lipid A portion, three
3-deoxy-D-/7?aA7A?o-oct-2-ulosonic acid (KDO) residues, three heptose
residues and a single glucose, was the minimum structure required to
104
produce antibodies cross reactive to a large number of core LPSs. The
variation in the outer core is often limited to differences in only one or two
sugar residues. For example R1 core LPS differs from R4 core LPS in a
single p(1—K3) linked Glc residue [p(1 —+4) linked Gal at the same position
in the R4 core] (Amor et al, 2000). This similarity between core types may
result in a large number of cross-reactive antibodies. Hence the differences
in antibody titre observed in this study (Figure 3.9 & 3.10) are possibly due
to these often-subtle differences between core types. In which case the high
level of anti-R4 core antibody observed in both healthy humans and cattle, is
due to the single sugar difference in the outer core.
The differences in antibody levels detected may result from differences in the
ability of each core type to coat to the wells of the microtitre plates. If, for
example, R4 core had more binding affinity with the plastic of the wells then
one would expect the amount of antibody detected would be much higher as
opposed to a poorly binding core type. However the addition of polymyxin
should even out these discrepancies.
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Chapter Four.
The cloning and production of antigens from Escherichia coli 0157
Aims
Results presented in chapter three show cattle to be more frequently
exposed to R3 core type LPS than humans. Previous studies demonstrating
an association between R3 core type LPS and VTEC suggest that this
increased exposure results from VTEC among the bovine commensal flora. It
has also been shown that a number of bovine VTEC isolates carry the LEE
pathogenicity island. It is possible that exposure to verotoxin and antigens
from the LEE result in a potentially protective immune response.
Recombinant protein technology was used to allow investigations into
immune responses to these antigens.
Therefore the aims of this chapter were:
1) To produce and purify the carboxy-terminal 280 amino acids of the
eae gene product, Intimin (Int280).
2) To produce and purify the espB gene product, E. coli secreted protein
B (EspB).
3) To produce and purify the B-subunit of Verotoxin 2 (Vt2B) from the




The eae280, espB arid verotoxin 2 B subunit (W2B) genes were amplified by
PCR from E. coli strain EDL933; Zap 26 (see Table 2.1). Figure 4.1 shows a
1% agarose gel upon which all PCR products have been resolved.
Comparison with the 100bp ladder shows Vt2B at 312bp, the eae280 gene at
844bp and the espB gene at 914bp.








Figure 4.1: Agarose gel (1%) showing all PCR products to be cloned into pGEX-4t2.
The expected size of each band may be compared against the actual size as
determined by the 100bp ladder (lanes 1 and 7). The sizes of each band are as follows:
Vt2B - 312bp (lane 2); eae280 - 844bp (lane 3) and espB - 914bp (lane 5). Lanes 4 and
6 are empty.
4.2 TOPO pCR®4 cloning
After transformation of chemically competent AECC 185 E. coli with the
ligated pCR®4 vector, colonies were examined for the presence of a cloned
PCR product. Approximately 10 colonies from each plate were screened.
Bacteria were grown up overnight in 5ml LBamp broth. Plasmids were
extracted from the colonies by QIAprep® kits. Restriction digest with EcoR1
excised any cloned PCR product. This makes use of the two ecoR1
restriction sites engineered either side of the cloning site on the vector, thus
the excised fragment is slightly larger (18bp) than the cloned PCR product.
Excised fragments were resolved by agarose gel electrophoresis. Ligation
and transformation was very efficient with almost 100% of colonies examined
having successfully taken up a ligated vector. Figure 4.2 shows a typical
screen of several colonies for the presence of the PCR insert. Lanes 2-6 and
12-14 show 8 colonies screened for the presence of the eae280 gene. The
EcoR1 excised fragment appears at 862bp after agarose electrophoresis.
Lanes 8-10 show three plasmids extracted from colonies transformed with
the pCR®4 vector with a cloned espB gene. Due to the presence of an ecoR1
site within the espB gene, this PCR product actually loses a large fragment of
around 300bp. The EcoR1 excised espB gene may be seen at around 600bp
in lanes 8 and 10. Figures 4.3a, b and c detail all stages in the cloning of the
primary PCR products into the TOPO pCR®4 vector. In each figure lane 1
shows the whole pCR®4 vector, the multiple bands visible are the result of
plasmid DNA super coiling. Lane 2 shows the fragments generated by
digestion with EcoR1. The eae gene (Fig 4.3a) can be seen at 862bp, the
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espB gene (Fig 4.3b) at 600bp with the 300bp fragment below and the Vt2B
gene (Fig 4.3c) at 330bp. Lane 3 shows the BamH1 digestion profile, in this
case the bamH1 site engineered by the primers used to generate the PCR
products allow the excision of the whole PCR product. Each gel shows the
BamH1 excised PCR product, the same size as those in Figure 4.1.
Figure 4.2: Agarose gel (1%) showing the lysate of eight colonies screened for a
cloned eae280 gene and three colonies for the espB gene. Lanes 1 and 15 show the
100bp ladder to allow sizing. Lanes 2-6 and 12-14 are TOPO pCR®4 vectors digested
with EcoR1 to excise any cloned eae280 genes. The excised fragment can be seen at
862bp, 18bp larger than is normal size. Lanes 8-10 show 3 plasmids digested with
EcoR1 to detect any cloned espB genes, 2 (lanes 8 & 10) are positive. The excised
fragment may be seen at approximately 600bp, 300bp smaller than the whole fragment.
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DNA markers are shown in lanes 1
and 5. The pCR®4 vector is shown in
lane 2, multiple bands are due to
plasmid super-coiling. Lane 3 shows
the EcoR1 digested plasmid (3.9Kbp)
and the excised eae280 fragment.
Lane 4 shows the BamH1 restricted
plasmid and the excised eaeA280
fragment at 844bp.
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DNA markers are shown in lanes 1
and 5. The pCR®4 vector is shown in
lane 2, multiple bands are due to
plasmid super-coiling. Lane 3 shows
the EcoR1 digested plasmid (3.9Kbp)
and the excised espB fragment at
600bp with a smaller fragment below
at 300bp owing to the EcoR1
restriction site within the espB gene.
Lane 4 shows the BamH1 restricted
plasmid and the excised espB
fragment at 914bp.
DNA markers are shown in lanes 1
and 5. The pCR®4 vector is shown in
lane 2, multiple bands are due to
plasmid super-coiling. Lane 3 shows
the EcoR1 digested plasmid (3.9Kbp)
and the excised Vt2B fragment at
330bp. Lane 4 shows the BamH1
restricted plasmid and the excised
Vt2B fragment at 312bp.
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The gel-purified restriction fragments from the TOPO pCR®4 vector were
resolved on a 1% agarose gel to quantify the amount of DNA present (Figure
4.4). This was done by running a IHindlll marker (Invitrogen) of known DNA
content (lane 1) alongside the BamH1 restricted pGEX-4t2 vector (lane 2)
seen at 4.9Kbp and the purified PCR products espB (914bp), eae280
(844bp) and Vt2B (312bp), in lanes 3, 4 and 5 respectively. The relative
intensities of the bands allow the amount of DNA to be quantified. It was
estimated that the pGEX-4t2 vector had a concentration of 10ngpl"1, the espB
gene 5ngpl"1 and both the eae280 and Vt2B genes 2ngpl"1.
4.4 Clone screening
After overnight incubation on LBamp plates, transformed AECC 185 colonies
were screened for the presence of the vector and a cloned PCR fragment.
Around 10 colonies from each plate were screened. Bacteria were grown up
overnight in 5ml LBamp broth and subjected to a QIAprep® kit to extract any
plasmid. The plasmid was then digested with BamH1 and the restriction
products resolved by agarose gel electrophoresis. Cloned PCR products
were also detected with the use of the original primers, this provided a rapid
method of screening a large number of colonies. On the whole the ligation of
the vector to the PCR products appeared to be very inefficient as many of the
colonies were found to contain no plasmid or re-ligated pGEX-4t2 only (a
result of incomplete SAP activity). Many colonies had to be screened to
obtain enough plasmids with ligated PCR products. Figure 4.5 shows the
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results of a successful ligation. Nine colonies were screened for cloned Vt2B
PCR products. Six of the nine colonies examined here show a band at 312bp
after PCR with the original primers used to amplify the verotoxin B subunit
gene. Ligation, transformation and screening were repeated until at least 10
colonies containing both vector and PCR insert were identified. The
orientation of the cloned PCR product in the vector was then examined.
4.5 Gene orientation
To ascertain the orientation of the cloned insert a number of restriction sites
within the PCR product and the vector were utilised. Each enzyme would
produce a unique fragment pattern dependent upon the orientation of the
insert. Figure 4.6 shows eight colonies that have been digested with Pst1 to
determine the orientation of the eae280 gene. This utilises the pst1 site within
the gene itself and one in the vector. The products of seven colonies (lanes
2-5 and 7-9) show a band at 4.7Kbp and a smaller band at 1Kbp, thus the
gene is incorrectly orientated. However lane 6 shows a different Pst1
restriction profile, the larger band appearing at 4Kbp and the smaller band at
1.8Kbp, this gene was found to be correctly orientated. All EspB and Vt2B
clones were examined to determine the orientation of the cloned PCR
product. EcoR1 was used to orientate the EspB genes and Hinfl to orientate
the Vt2B genes. Lane 2 of Figures 4.7a, b and c show a correctly orientated,
BamH1 excised PCR product from the pGEX-4t2 vector. Lane 3 shows the
restriction pattern obtained by restriction digest to determine the orientation
of the gene in the vector. Table 2.4 details the products expected. In Figure
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4.7a the eae280 gene excised from the pGEX-4t2 vector can be seen in lane
2 at 844bp. Digestion of this clone with Pst1 reveals two fragments at 4Kbp
and 1.8Kbp (lane 3), thus the gene is correctly orientated (see Appendix 2
for vector maps). Figure 4.7b shows the EspB gene removed from the vector
backbone by BamH1 digestion at 912bp (lane 2), digestion of this clone with
EcoR1 revealed two fragments, one at 300bp and one at 5.4Kbp
characteristic of a correctly orientated gene. Determination of the orientation
of the verotoxin B subunit clones required digestion with Hinfl. Correct
orientation yielded those fragments seen in lane three of Figure 4.7c.
Correct orientation was confirmed by lack of a band at 1050bp and the
presence of two bands at 1213 and 1184bp, which appear as one due to the
proximal sizes.
4.6 Sequence analysis
QIAprep® kits were used to extract the plasmids from each of the correctly
orientated clones. All plasmids were eluted in 50pl ultra pure H20 and
allowed to dry over night at room temperature. Plasmids were sent to MWG
Biotech for sequencing. There was 100% homology between the wild-type
EDL933 Vt2B subunit and Intimin nucleotide/amino acid sequence and that
obtained from the fragments cloned into the pGEX-4t2 vectors. Two errors
were made in the EspB sequence. A guanine substitution at 50bp changed
GIui7 to a Gly17, and a thymine at 580bp changed Thr196 to Ser196. Raw










Figure 4.4. Quantification of vector and gel purified PCR product DNA by MHindlll
comparison. Gel to show the quantification of DNA prior to ligation. Lane 1 shows the
A.Hindlll marker of known DNA quantity. Each band in the gel (lanes 2-5) is then
compared to the marker to obtain an approximate quantity. The values decided are as
follows: pGEX4t-2 (lane 2) 10ngpl"1, espB (lane 3) 5ngpl"\ eae280 (lane 4) 2ngnlml"1
and Vt2B (lane 5) 2ngpl'1. Lane 6 shows the 100bp ladder.
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312bp
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Figure 4.5: Screening for cloned Vt2B PCR products by PCR. Nine colonies were
examined for the presence of the verotoxin B subunit genes by PCR (lanes 2-10). A
band at 312bp indicates the presence of the gene. Six of the nine colonies were found
to be positive. The 100bp ladder is shown in lanes 1 and 11
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Figure 4.6: Orientation analysis of eight pGEX-4t2/eae280 clones. Pst1 digestion of
these clones determined the orientation. Lanes 2-5 and 7-9 show incorrectly orientated
genes with bands at 4.7Kbp and 1Kbp. Lane 6 shows the only gene to have inserted in
the correct orientation. The bands appear at 4Kbp and 1.8Kbp. A 1Kbp ladder is shown




Figures 4.7: Orientation analysis of bamH1 digested PCR products cloned into the
expression vector pGEX-4t2 Lane 1 in each gel shows the 1Kbp ladder. The BamH1
digested plasmid (lane 2) can be seen at just over 4Kbp in length with the excised PCR
products (eae280 at 848bp, espB at 900bp and vt2B at 309bp) below. Lane 3 shows the
restriction profile obtained by digestion with Pst1, EcoR1 or Hinfl to determine insert
orientation. Figures 4a and b show the 100bp ladder in lane 4.
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4.7 Protein expression, detection and purification
4.7.1 Protein expression and detection
Overnight 5ml cultures of each clone were used to inoculate 1 litre of LBamp
broth. Once cultures had reached mid-log phase protein expression was
induced by the addition of IPTG to a final concentration of 1mM. Bacteria
were harvested by centrifugation and subjected to sonication. After
centrifugation samples of the supernate and harvested cell debris were
subjected to SDS-PAGE (Figure 4.8a) to determine if there had been
expression of GST tagged proteins. Lanes 2 and 6 of Figure 4.8a show the
GST protein at 29KDa. Very low Vt2B expression was detected in lane 3 at
around 35KDa. Much larger levels of EspB (60KDa) and Int280 (55KDA) are
expressed in lanes 4 and 5 respectively. The resolved proteins were
transferred to nitrocellulose and the fusion proteins detected by Western blot
using a goat anti-GST IgG HRP (Figure 4.8b). All of the fusion proteins were
located in the pellet and were likely to have formed inclusion bodies. GST
expression was confirmed in lanes 1 and 5 of Figure 4.8b with a band at
29KDa, a faint band at 35KDa confirmed a low level of Vt2B expression, but
another band was seen below at around 26KDa. High levels of EspB (lane 3
60KDa), and Int280 (lane 4 55KDa) were detected. The multiple bands below
the major EspB/lnt280 GST fusions are the result of host cell degradation.
All the fusion proteins and the GST alone reacted with the anti-GST antibody.
The GST protein was soluble and required no further treatment.
Solubilisation of inclusion bodies was achieved by urea denaturation. Fusion
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proteins were re-suspended in 8M Urea + 1mM DTT and then the urea was
gradually removed by dialysis as described in chapter two (section 2.17.3).
A considerable amount of the insoluble inclusion body was released into the
supernate as a result of urea denaturation and subsequent re-folding. Figure
4.9 shows a 10% SDS PAGE upon which the original pellet sample and the
urea re-natured fusion proteins have been resolved. Each insoluble fusion
protein can be seen in its respective preparations in lane 2 (Int280, 55KDa),
lane 5 (EspB, 60KDa) and lane 8 (Vt2B, 35KDa). No fusion protein was
detected in the post sonicate supernate as seen in lanes 3, 6 and 7. By urea
denaturation and subsequent re-naturation by slow dialysis most of the
inclusion body was recovered from the cell debris. Lanes 4, 7 and 9 show the
re-natured fusion protein after removal of precipitated protein by
centrifugation at 70,000g.
4.7.2 Protein purification
Affinity chromatography columns (GSTrap FF 1ml columns, Amersham) were
used to remove the GST tagged proteins. Bound fusion proteins were eluted
in 20 ml 10mM reduced glutathione (sigma) plus 50mM Tris pH8. Fractions
(1ml) were collected from the column and analysed by SDS-PAGE for the
presence of GST tagged proteins. Volumes (5pl) of each of the fractions
(1ml) eluted from the GSTrapFF column were resolved by 10% SDS-PAGE
(Figure 4.10). The Int280 GST tagged protein can be seen in each of the first
five fractions, no more Int280-GST was detected after the eighth fraction
(data not shown). A number of proteins of lower molecular weight than the
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major Int280/GST band (55KDa) are revealed upon Coomassie staining.
Many of these are the result of fusion protein degradation within the host cell.
Other proteins are contaminants non-specifically bound to, and eluted from,
the column. EspB and Vt2B fusion proteins were eluted and collected the
same way. SDS PAGE analysis of the fractions revealed the presence of
EspB in the first 10 fractions (data not shown), however Vt2B failed either to
bind, or elute from the column. No protein was detected by either SDS-PAGE
or Western blot. The fractions were pooled and concentrated in 4ml Vivaspin
tubes (Vivascience, Sartorius).
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Figure 4.8: SDS PAGE and Western blot analysis of post sonicate cell debris, a: GST
and GST fusion protein expression by IPTG induction detected in the supernate (lanes
2 and 6) and post sonicate pellet (lanes 3-5) b: GST fusion proteins detected by
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Figure 4.9: SDS-PAGE (10%) showing insoluble fusion protein before and after re-
solubilisation by urea denaturation. Lanes 2, 5 and 8 show the post sonicate pellet with
the large insoluble GST fusion protein inclusion body. Lanes 3, 6 and 9 show the post
sonicate supernate. Lanes 4, 7 and 10 show the re-natured fusion protein now soluble









Figure 4.10: SDS PAGE (10%) showing 5pl samples of each of the first five Int280-
GST fractions eluted from the GSTrapFF column. Lanes 3-7 show the protein content
of progressive fractions eluted from the GSTrapFF columns. The major Int280-GST
band can be seen at 55KDa, most lower molecular weight bands are the result of
fusion protein degradation. Other bands are contaminants non-specifically bound to
and eluted from the column. Lane 1 shows the molecular weight marker and lane 2 un-
transformed E. coli AECC 185 (control).
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4.7.3 Protein assay
Fractions eluted from the GSTrapFF columns were pooled giving a total of
20ml, which was reduced to approximately 1ml by concentration in a
Vivaspin® tube (Sartorius). Prior to the assay the GST fusion protein
concentrates were diluted 1 in 4 to reduce amount used. The level of protein
obtained in each of the column eluates varied considerably. Figure 4.11
shows the results obtained from the protein assay after concentration in 4ml
(10,000mwco) Vivaspin® tubes (Vivascience, Sartorius). It was found that
approximately 20mgmr1 of the GST protein had been purified. The amount
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Figure 4.11: Determination of fusion protein concentration by protein assay.
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4.8 Discussion
Primary PCR from the EDL933 EPEC template successfully generated
products from the eae280, espB and Vt2B subunit genes. Each primer had a
bamH1 site engineered at both the 5' and 3' ends of the product to allow
cloning into an expression vector. Initial attempts to digest the ends of the
products with BamH1 to allow direct cloning into the pGEX-4t2 vector were
unsuccessful. This probably resulted from the restriction enzyme's (BamH1)
requirement for a reasonable length of DNA upon which to sit before binding
and restriction of the cleavage site (Pingoud & Jeltsch, 2001). As a result the
products were cloned into the commercial cloning vector pCR®4 (Invitrogen).
Almost all of the colonies examined had been successfully transformed with
a ligated plasmid using this kit. Equally successful was the excision of the
cloned PCR fragment from this vector using either BamH1 or EcoR1. In this
case the pCR®4 vector would have provided a large amount of non-specific
DNA upon which the restriction enzyme could 'sit' prior to cleavage.
The efficiency with which the pCR®4-excised PCR products were ligated to
the BamH1 restricted and SAP treated pGEX-4t2 was poor. Many colonies
had to be screened before enough clones had been identified for orientation
analysis. A major problem was the propensity of the restricted plasmid to re-
ligate despite the use of SAP. This gave rise to many false positives on the
LBamp agar plates. The p-lactamase gene encoded on the pGEX-4t2 allowed
E. coli transformed with the vector to secrete a p-lactamase into the agar, this
prevented the ampicillin in the agar having any effect upon those colonies.
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However the secretion of the p-lactamase allowed the growth of 'satellite'
colonies around the transformed E. coli. These were often the cause of the
false positives.
The orientation of the cloned PCR fragments in the vector was ascertained.
Since both ends of the PCR product and the vector had been digested with
BamH1, the PCR product could insert either way round. In the incorrect
orientation the gene would not be transcribed properly. In more than 50% of
the plasmids examined the gene cloned the wrong way. Only two correctly
orientated espB genes and one eae280 gene were identified that had cloned
in the correct orientation. This trend was particularly noticeable when
attempting to clone the W2B gene. A very large number of colonies had to be
screened before a correctly orientated verotoxin B subunit gene was found.
There appeared to be a selection pressure against the gene cloning in the
desired orientation.
Previous studies by Gunzer and Karch (1993) showed that the cloning and
production of this antigen was difficult. They found that cloning of the A
subunit of the gene was lethal to the cell and that in order to obtain any
amount of the B-subunit the 5' leader sequence had to be removed and
primers were designed to amplify the region downstream of this. The result
was large quantities of a truncated 4KDa verotoxin B subunit fused to GST.
The loss of the 3KDa fragment would undoubtedly affect the immunogenicity
of the B-subunit and therefore this approach would have been undesirable.
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Acheson and Breucker (1994) showed that production of recombinant
verotoxin B-subunit was possible even with the leader sequence attached.
However they reported that the amount of toxin they were able to purify was
well below levels achieved for other proteins. It appeared that the high level
of protein expression achieved under the tac promoter, led to toxic amounts
of the B-subunit accumulating in the host E. coli eventually causing lysis. The
pGEX-4t2 vector used here also contains a tac promoter, however cell lysis
was not observed. E. coli transformed with a pGEX-4t2 vector ligated to a
correctly orientated Vt2B gene did appear to grow less well than E. coli
transformed with other pGEX-4t2 plasmids. In an attempt to reduce the
possibility of lysis the induction temperature was reduced to 35°C slowing the
growth of the E. coli and hence the rate of transcription. Despite this we were
unable to induce large amounts of the verotoxin 2 B-subunit.
Byun et al (2001) utilised Bacillus brevis as a secretion-expression system to
obtain recombinant verotoxin 1 and 2 B subunit. The promoter and signal
peptide-encoding region of a cell wall protein of B. brevis in the pNU212
vector used, allowed secretion of the recombinant protein into the culture
supernate. Despite successfully extracting Vt2B from the supernate it was
found that the recombinant protein was unable to bind to its receptor
globotriaosylceramide3 (Gb3). Indeed subsequent mouse immunisation
experiments by Byun et al (2001) showed that unlike the recombinant Vt1B,
the recombinant Vt2B failed to generate an immune response. It is possible
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that conformational changes in the recombinant Vt2B produced by this
system affected the antigenicity of the protein.
Western blot showed the Vt2B-GST as a very faint band at 35KDa.
Associated with this band was another at 26KDa, which due to its strong
reaction with the goat anti-GST IgG was identified as GST. Figure 4.12
shows a Western blot in which the proteins transferred to the nitrocellulose
were incubated along with an anti-GST antibody. The GST protein is shown
as a band at 29KDa, while the Vt2B-GST fusion appears at 35Kda. The
smaller band that appears below this reacted well with the anti-GST antibody.
In its natural state GST exists as a 26KDa protein, however when expressed
from a parental vector such as pGEX-4t2 will appear as a 29KDa protein. The
band at 26KDa below the Vt2B-GST protein is GST as it occurs naturally.
This would imply that the 26KDa fragment was the result of a truncated read-
through of the whole fusion protein or that the fusion protein was being
cleaved, releasing GST. This would explain the low level of Vt2B-GST
transcription seen at 35KDa, as not all the proteins transcribed are likely to
be degraded. If the fusion protein was being broken down we might have
expected to see a smear on the western blot relating to all the GST









Figure 4.12: Detection of Vt2B fusion proteins after IPTG induction. Western blot
showing GST at 29KDa as induced from pGEX-4t2 by IPTG and recombinant Vt2B
subunit at 35KDa with a smaller 26KDa GST fragment below.
Vt2B could not be bound or eluted from the column. Sequence analysis of
the cloning region on the pGEX-4t2 plasmid showed that the 312bp fragment
ligated to the pGEX-4t2 plasmid had 100% homology with the Vt2B gene from
the E. coli strain EDL933. It is likely that the 36KDa GST protein when
passed through the affinity purification (GSTrap FF) column, binds the
glutathione substrate attached to the Sepharose 4B in the columns. The
binding capacity of the columns is very low (~1mg) and hence it would only
take a small amount of GST to occupy all the binding sites or at least out
compete the Vt2B-GST fusion. If half the Vt2B were bound and the rest lost
in the flow through then this would probably reduce the level of Vt2B present
to below the limits of SDS-PAGE and immunoblot detection. Alternative
methods of purification may have to be considered in order to obtain good
yields of the B subunit fusion from this clone. One approach is to bind the
Vt2B to Gb3 conjugated to sepharose (Nakajima et al, 2001). This would
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abolish the problems associated with the 26KDa GST fragment. Another
would be to transform a VTEC strain of E. coli such as E. coli 0157 with the
pGEX-4t2-Vt2B vector. It is possible that these VTEC strains may be better-
suited cope with the production of Vt2B.
Despite problems with the purification of the recombinant verotoxin B-
subunit, there were no such difficulties with either Int280 or EspB. Once
correctly orientated clones had been identified, production and purification
was relatively simple. In fact transcription of the recombinant proteins was so
efficient that it resulted in the formation of inclusion bodies. In order to extract
the recombinant protein it had to be denatured using urea. The recovery of
the re-natured recombinant protein from the supernate was highly effective
with almost 80% of the protein being recovered. While the actual
conformation assumed by the recombinant proteins after re-naturation could
not be determined, it was hoped that the removal of the urea by slow dialysis
and the inclusion of dithiothritol (DTT) allowed correct folding. The GST
appeared to bind well to the affinity purification columns suggesting that the
folding of the protein was correct. The production of recombinant Int280 and
EspB is well documented in the literature. Most prefer to produce
recombinant proteins vectors that result in recombinant His-tagged proteins.
Jenkins & Chart (2000) used pET-28 vectors (Novagen) to generate His-
tagged Int280, EspB, Tir and EspA. The advantage of their system is that
purification is achieved with the use of a small tag. The size of the tag (6-10
His residues) is unlikely to have as much of an effect upon the overall
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conformation of the recombinant protein as the large 26KDa GST moiety.
Attempts were made to clone into the pET-28a however this was
unsuccessful.
Chapter Five
Antibody responses to surface and secreted components of
Escherichia coli 0157:H7 in experimentally infected calves.
Aims
Recombinant antigens generated in chapter four along with outer membrane
and secreted protein preparations will be used to examine sera from
experimentally infected calves for the presence of antibodies reactive to a
number of antigens from E. coli 0157.
Therefore the aims of this chapter were:
1) To detect antibody responses in the sera of experimentally infected
calves to two recombinant proteins, Intimin280 (Int280) and EspB.
2) To detect antibody responses to the outer membrane proteins of
Escherichia coli 0157
3) To detect antibody responses to the secreted proteins of Escherichia
coli 0157
4) To detect responses to the LPS of Escherichia coli 0157
5) To detect IgA responses to Int280 and EspB in faecal antibody




5.1.1: Detection of antibody responses to GST, Int280 and EspB in
experimentally infected calves
Recombinant GST, Int280-GST and EspB-GST were resolved by SDS-
PAGE. Staining with zinc chloride allowed the proteins to be visualised prior
to transfer to nitrocellulose. The Int280-GST (Figure 5.1) appears as a
50Kda band with associated smaller proteolytic fragments beneath. The
recombinant EspB-GST (Figure 5.2) appears as five bands on the gel. The
first band (approximately 53KDa) is the whole EspB-GST fusion; those below
are the result of protein degradation. The GST appears as a single band at
29KDa (data not shown)
The GST, Int280 and EspB fusion proteins were transferred to nitrocellulose.
The nitrocellulose was cut into strips (3mm x 90mm) and each strip used to
detect antibodies to GST, Int280-GST or EspB-GST in the sera of
experimentally infected calves. Sera were diluted 1 in 50 in antibody diluent
prior to incubation with the nitrocellulose. Antibody-antigen complexes were
detected with the use of sheep anti-IgG HRP. Each calf in the experiment
was bled prior to and weekly for four weeks after an oral challenge with 109
E. coli 0157. Figure 5.3 shows the level of antibody reactive to GST in 11
experimentally infected calves. All of the calves examined had an apparent
low level of antibody reactive to GST. The level of the response did not
change as the experiment progressed. In some of the animals there are
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bands that do not appear in the positive control and are therefore
contaminating proteins that have been eluted from the column along with the
GST.
Figure 5.4 shows the level of antibody reactive to the Int280-GST fusion in
the same 11 animals. The positive controls (lanes 2 and 14) pick out the
bands of interest. The major band at around 50KDa represents the whole
Int280-GST fusion. The minor bands beneath this are a result of fusion
protein degradation during production in the host cell. The negative control
shows no significant bands although there are very faint reactions to some of
the Int280-GST proteins. All the animals tested had antibodies that reacted to
the major Int280-GST fusion. The lack of a response to GST alone would
suggest that these are antibodies specific to Int280. A number of the smaller
proteolytic Int280 fragments appear to be immunogenic in some of the
calves. For example c108 (lane 7) and c121 (Lane 11) appear to have
different anti-lnt280 IgG profiles. To show that the immune response to
Int280 did not vary at all during the experimental challenge, the sera of
several of the animals from each week of the experiment were tested for
antibodies to both GST and Int280. Figure 5.5 shows the immune response
in calf c81 to Int280 at weekly intervals during a four-week experimental
challenge. The positive control shows all the Int280 fusion proteins present
on the nitrocellulose. The pre-bleed anti-lnt280 IgG status of c81 is shown by
the blot in lane 1. There are good reactions to most of the bands shown in
the positive control. A number of the smaller proteolytic Int280/GST
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fragments have not reacted with the sera. After experimental infection and
over the next four weeks, there was no change in the immune response. This
trend was seen with the other animals examined. No response to GST alone
was observed.
The EspB-GST fusion can be seen in lanes 3, 15 and 16 of Figure 5.6
(positive controls) at just over 50KDa with a number of minor bands below.
These result from the degradation of the whole EspB-GST fusion. Two
negative controls were included here. Lanes 1 and 2 show the negative
controls obtained with foetal calf serum and antibody diluent. None of the
EspB-GST proteins can be seen to react with either the foetal calf serum or
the antibody diluent. The sera from these animals was already shown to have
a negligible level of antibody to GST (Figure 5.3), hence any band seen on
the test strips that is also present on the positive control strips, must be
attributable to anti-EspB IgG. The apparent level of response to EspB is
markedly lower than to Int280. Many of the animals, for example c81, c111
and c117, fail to show any response to EspB at all. Calf c140 appears to
have antibodies to EspB both before and after challenge. The level of
response in this animal appears not to have increased over the experimental
period. Calves c108 and c121 show an antibody response to a contaminating
protein eluted from the column. Calf c95 (lane 6) appears to have generated
an antibody response to EspB. The pre-bleed from this animal shows no
visible reactivity to any of the EspB-GST proteins, but the 4-week post











Figure 5.1: Purified Int280-GST resolved by SDS PAGE prior to transfer to
nitrocellulose Purified recombinant Int280-GST resolved by 10% SDS-PAGE The
whole Int280-GST fusion protein appears as a single band at 50KDa. The faint








Figure 5.2: Recombinant EspB resolved by 10% SDS PAGE prior to transfer to
nitrocellulose. Purified recombinant EspB-GST resolved by 10% SDS-PAGE.
EspB-GST appears as five bands on the Gel. The first band at just over 50Kda is the
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Figure 5.5: The immune response to Int280 in calf c81 at each week during an
experimental infection. The series of blots in lanes 1 to 5 represent the anti-lnt280
IgG status of calf c81 during a four-week experimental infection with E. coli 0157.
Lane 1 shows the animal's status prior to challenge and lanes 2-5 the status each
week thereafter. The positive control (lane 6) shows all the Int280 bands. The
negative controls (lanes 7 and 8) show no significant reactions.
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5.2 The immune response to surface antigens of E. coli 0157
Outer membrane preparations of a toxin negative E. coli 0157 (Zap193) (see
Table 2.1 for details) were prepared. Samples of the preparations were
resolved by 10% SDS-PAGE, and proteins transferred to nitrocellulose.
Nitrocellulose was cut into strips (3mm x 90mm) and used to examine sera
from experimentally infected calves for the presence of antibodies to
components present on the outer membrane of E. coli 0157. This experiment
used a different set of 12 animals each receiving an oral challenge of 109 E.
coli 0157 and monitored for a period of four weeks. Sheep anti-IgG HRP was
used to detect antibody antigen complexes on the nitrocellulose. The results
of the blots are shown in Figures 5.7 (complete results can be seen in
Appendix 3). The animals chosen are representative of the range of
responses observed in all the animals examined.
None of the animals' immune responses appear to have been stimulated
during the period of experimental infection. In most cases the basal level of
antibody (as shown by the pre-bleed sample) is high and no change is
observed in antibody levels over the following three weeks. In calves where
the basal level is low, for example c310 or c312, there is also no change in
the antibody levels over the period of experimental infection.
All of the animals appeared to respond to the major proteins visible on the
SDS-PAGE gel. The proteins at the 36KDa marker elicit the best response in
all the animals. A number of the high molecular weight proteins appear to be
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immunogenic in some of the animals but are undetectable in others. Calves
c296 and c303 show the best immune response to the high molecular weight
material. Both animals respond well to the 36KDa protein(s). There are a
number of low molecular weight bands to which the bovine sera react. All the
animals appear to react well to components of the unresolved material in the
gel front. C310 and c312 show the weakest immune response of all. The pre
and week-one sera of c310 failed to show any reaction to the proteins at
around 55KDa but weak reactivity can be seen in the week two and three
samples. All of the blots appear to have a very blurred background; this is
likely due to anti-LPS antibodies. The immune response to LPS will be
discussed later.
5.3 The immune response to the secreted proteins of E. coli 0157.
The secreted proteins of Zap 193, toxin negative E. coli 0157 were obtained
by TCA protein precipitation from the culture supernate. The precipitated
proteins were resolved by SDS-PAGE. The proteins were then transferred to
nitrocellulose and the immune responses of several experimentally infected
calves examined by Western blot. Figure 5.8 shows the protein profile
obtained from the TCA precipitated E. coli 0157 secreted proteins and the
immune response to these proteins in three experimentally infected calves.
(Complete results can be seen in Appendix 3) The series of three blots
shown are representative of the results seen in all the animals tested. There
was considerable variation in the range of response as compared with the
outer membrane proteins. Most of the proteins seen on the Coomassie
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stained SDS-PAGE gel appear to elicit an immune response in most of the
animals. The proteins of interest are pointed out on the SDS-PAGE gel and
show the translocated intimin receptor (Tir) at 74KDa, the EspB/D complex at
around 36KDa and the small filamentous protein EspA at 22KDa. In many of
the animals the basal level of antibody (as shown by the pre-bleed status) to
some or all of these proteins is high. It appears that the initial level of
antibody is unaffected by the period of experimental infection and none of the
secreted proteins appears to have stimulated an immune response above the
basal level during the experimental period (week-four samples were
unavailable for analysis). Calves c313 and c322 show a good response to
the EspB/D proteins and also to a slightly smaller protein at about 31KDa.
Calf c324 however fails to respond well to these proteins. EspA appears only
to have generated a response in c313. The translocated intimin receptor
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5.4 Detection of antibodies reactive to E. coli 0157 LPS in
experimentally infected calves
The LPS of E. coli 0157 was resolved by 14% PAGE and transferred to
nitrocellulose for immunoblot. Nitrocellulose was cut into strips (3mm x
90mm). The nitrocellulose strips were used to detect antibodies reactive to
the LPS of E. coli 0157 in pre-challenge and week-four post challenge sera
from a number of experimentally infected calves. Foetal calf serum and
antibody buffer were used as negative controls. No reaction to E. coli 0157
LPS was detected in either. The positive controls were generated using
serum from a rabbit previously shown to have antibodies to E. coli 0157
LPS. The blots (Figure 5.11) show reactivity to both the high molecular
weight O-antigen repeating units of the LPS and the low molecular weight
core region. The response to the O-antigen results in a ladder pattern
characteristic of an LPS response (complete results can be seen in
Appendix 3).
Of the ten animals tested four (calves c87, c108, c117 and c121) had little or
no antibody to E. coli 0157 LPS. The blots representing the pre-challenge
and week-four IgG status of these animals appear no different from the
negative controls. Two calves c106 and c140 have antibody reactive to E.
coli 0157 LPS in both the pre-challenge and week-four post challenge
samples. The level of this response appears to have been unaffected by the
period of experimental infection with E. coli 0157, as the intensity of the
bands does not change.
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The remaining four calves c81, c95, c111 and c118 have all responded to the
LPS of E. coli 0157. There is little or no antibody present in the pre-challenge
sera of these calves, however there is a marked LPS response in each of the
animals after four weeks experimental infection. The response is particularly
notable in c81. The pre-challenge sample from this animal is devoid of any
detectable IgG reactive to E. coli 0157 LPS. In the week four-post challenge
sample, the characteristic ladder pattern denoting an O-antigen response is
clearly visible along with a significant response to the core region. The
responses in c111 and c118 are less well defined, but still clearly visible. The
response in calf c95 is weak and appears to be directed towards the O-
antigen only.
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5.5 The mucosal immune response to Int280 and EspB
Various volumes of Int280 and EspB at a concentration of 1mgml"1 were
spotted on to nitrocellulose to determine the optimal amount for detection.
Nitrocellulose was blocked and then goat anti-GST IgG at a dilution of 1 in
1000 in antibody diluent was incubated with the nitrocellulose for 90min at
37°C. The nitrocellulose was then washed twice in TTBS for 10min and then
rabbit anti goat-IgG HRP (Sigma) at a dilution of 1 in 10,000 in antibody
diluent was added for 90min at 37°C. Colour was developed with HRP colour
developer. It was found that there was little difference in the level of reaction
between 1pl and 4pl of the Int280 or EspB fusion proteins (data not shown).
To reduce the possibility of leakage of antigen across the nitrocellulose it was
decided that 2pl of antigen gave a clearly detectable spot without spreading
too far through the nitrocellulose. In all subsequent blots 2pl of antigen was
used. Faecal samples taken from experimentally infected calves were
prepared in category 3 containment facilities. From a starting sample of
around 3g (wet weight) bovine faeces, around 3ml of purified, sterile faecal
extract was obtained. Faecal antibody extracts obtained from calves c296,
c303, c310, c312, c315 and c323 were examined for anti-lnt280 and EspB
IgA prior to and at weeks one and two post challenge (Figure 5.10a). Calves
c295, c299, c307, c313, c322 and c324 were examined for anti-lnt280 IgA
only, prior to and every week for four weeks post challenge (Figure 5.10b).
Negative controls were generated using foetal calf serum. No Int280 or EspB
specific IgA was detected in the negative controls. Positive controls were
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generated using an anti-GST antibody and show the presence of a GST-
tagged protein on the surface of the nitrocellulose.
Very little IgA was detected in the faeces of these animals. A number of the
pre-challenge samples, for example c310 (both anti-lnt280 and EspB IgA)
and c307 (anti-lnt280 IgA) yielded detectable amounts of IgA. All calves in
Figure 5.10a except c303 had detectable levels of both anti-lnt280 and EspB
IgA prior to challenge with E. coli 0157. In general, the level of IgA appears
to fall as the experiment progresses, by week-two post infection the level of
Int280 IgA has fallen to below the limits of detection in this assay (Figure
5.10a). However calf c296 does have a very low level of IgA detectable in
both the one and two week post challenge samples. No anti-lnt280 IgA was
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5.6 Discussion
A number of antigens from E. coli 0157 were resolved by SDS-PAGE and
transferred to nitrocellulose. The transferred antigens were used to analyse
the antibody response of calves experimentally challenged with E. coli 0157.
It was evident that the sera of most of the animals examined contained
antibodies to Int280 prior to challenge with E. coli 0157. Immune responses
to Int280 detected before experimental infection did not change as the
experiment progressed. A number of calves failed to react to some of the
fusion fragments visible below the whole Int280-GST fusion protein band. It is
possible that the immunogenicity of the fusion fragments generated during
recombinant antigen preparation varies. Adu-Bobie et al (1998) were able to
identify regions of the C-terminal region of Intimin that possessed greater
immunogenicity than others. It is possible therefore that the difference in
serum reactivity observed in the experimentally challenged calves to Int280
and associated fragments reflects the immuno-variance of Int280. It is also
possible that the loss of certain fragments affects the folding of the fusion
protein and therefore the recognition of the protein. Conformational epitopes
are both lost and gained during the cleavage of fragments from the fusion
proteins, this may lead to cross-reactive responses from antibodies already
present in the serum of the experimental calves.
The poor responses to EspB can in part be attributed to the mis-reads and
errors within the EspB fusion protein. These errors were noted after
sequence analysis of the cloned fragments was obtained and possibly had
an effect on the structure of the fusion protein. However a number of sera
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obtained from the experimentally challenged calves did produce visible
reactions to the EspB-GST fusion (Figure 5.6). For example responses to
the whole EspB-GST fusion and associated fragments were noted in the
week-four post challenge sera of both calves c95 and c121 and in both the
pre-and week-four post challenge samples from calf c140. In many cases the
addition of the HRP developer solution to the EspB immunoblots led to a high
level of background colour that may have masked some of the more faint
antibody responses. The intensity of the background was considerably
reduced after drying.
In each case there appeared to be no relationship between the level of
antibody reactive to either Int280 or EspB and the amount of E. coli 0157
shed in the faeces of the experimentally challenged calves over the four-
week experimental period. For example calf c121, which had a particularly
strong response to Int280, shed consistently high levels of E. coli 0157 over
the course of the experimental infection while calf c106 which failed to
excrete any detectable E. coli 0157 had a response to Int280 that by
immunoblot appeared as good as that observed in c121. However, there
were differences in the responses detected in the sera from both these
animals. While it is possible that antibodies to various fragments of Int280
present in the sera from some of the calves may offer protection from
colonisation by E. coli 0157 it is unclear whether the immunoblot data
presented here supports such a conclusion. Graphs showing the full
complement of shedding results from each of the calves tested may be found
in Appendix 4.
Outer membrane preparations derived from strain Zap 193 (Table 2.1) were
used to look for antibody responses to surface components of E. coli 0157.
Responses to many of the surface proteins were noted in all the animals
tested (Figure 5.7). In all cases antibodies reactive to outer membrane
components were observed in sera obtained from calves prior to
experimental infection and the response did not change as the experiment
progressed. A number of calves, for example c310 and c312, exhibited
particularly weak responses to the outer membrane protein preparations
throughout the four-week period. Two proteins in particular reacted well with
the sera tested. These proteins have an apparent molecular weight of around
35 and 21KDa respectively.
Immune responses to LPS are also evident on a number of the outer
membrane preparation immunoblots. For example sera from calf c303 was
found to react well with a number of the outer membrane proteins but also
showed a considerable background 'smudge' characteristic of an immune
response to both the O-antigen and core LPS regions. There appeared to be
no relationship between the levels of E. coli 0157 shed in the faeces of the
animals tested and the immune response to the outer membrane
components. Animals that showed weak antibody responses, for example
calf c310, were found to shed high levels bacteria throughout the whole
experimental period, while others with equally low antibody responses shed
significantly lower numbers over the same period. By way of contrast, calf
c296 had high levels of antibody and shed very low amounts of E. coli 0157
while calf c303, which shed much higher levels of organisms was found to
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have a strong response to the outer membrane preparation. The reason for a
lack of correlation between the levels of antibody to outer membrane
components and the amount of E. coli 0157 shed during experimental
infection is unclear. It is possible that antibodies detected in this immunoblot
assay are cross reactive and are binding to common antigens present on the
surface of all E. coli and therefore offer no specific protection against E. coli
0157.
Sera were also examined for responses to the secreted proteins of E. coli
0157. Most of the animals tested had antibodies reactive to a number of the
secreted proteins (Figure 5.8), but there was considerable variation in the
responses detected. A number of animals, for example calf c324, produced
weak responses to the secreted proteins while others such as calf c322,
exhibited very strong responses. The reason for the variation in the response
is unclear. It is known that different strains of E. coli 0157 secrete different
amounts of proteins (McNally et al, 2001), and it is possible that exposure to
low and high secretor strains results in the observed differences in antibody
responses.
Lipopolysaccharide from E. coli 0157 was used to detect antibody responses
in the sera of experimentally challenged calves. A number of animals were
found to have mounted an immune response to LPS during the course of the
experimental infection. Sera taken prior to experimental challenge from
calves c81, c111 and c118 were found to have little or no antibody reactive to
E. coli 0157 LPS. However sera from the same animals taken four weeks
post challenge showed a significant response to LPS. It is unclear whether
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this response played a role in protection against colonisation by E. coli 0157.
While no E. coli 0157 was detected in the faeces of calf c81 throughout the
four-week experimental infection, calf c111 shed E. coli 0157 consistently for
the entire four weeks. Thus any relationship between the presence of
antibody reactive to LPS and the level of E. coli 0157 shed in the faeces of
experimentally infected calves is unclear.
Attempts to extract IgA from the faeces of the experimentally challenged
calves were largely unsuccessful. Despite attempts to prevent the
degradation of IgA with the addition of protease inhibitors, delays in obtaining
and processing faecal samples may have led to the loss of significant
amounts of IgA through proteolytic cleavage.
Much of the ELISA data to be presented in chapter six was based upon
results obtained from the immunoblot analysis of the calf sera. As such, the
discussion of chapter six is intended to span both chapters five and six as the
work is closely related.
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Chapter Six
Detection of immune responses to Int280 and EspB by ELISA.
Aims
Immunoblot analysis in chapter five showed qualitatively that a number of
experimentally infected calves had detectable levels of antibody to antigens
from E. coli 0157 prior to challenge. The response over time was determined
more quantitatively with the use of an ELISA. An attempt to neutralise AE
lesion formation on HeLa cell monolayers using bovine serum may help
determine a role for the antibody in protection against EHEC associated
disease in cattle.
Therefore the aims of this chapter were:
1) To optimise an ELISA for the detection of bovine antibody reactive to
the recombinant GST fusion proteins Int280 and EspB.
2) To detect antibody reactive to Int280 in the sera of healthy adult cattle
3) To detect antibody to Int280 and EspB in the sera of calves
experimentally infected with E. coli 0157.
4) To detect IgA reactive to Int280 and EspB in faecal antibody
preparations from calves experimentally infected with E. coli 0157.
5) To use sera from experimentally challenged calves to inhibit the




6.1.1 Determination of optimal coating concentration.
Recombinant GST was diluted to 10Ojug, 10pg, 1(ig and O.lpgmr1 in coating
buffer and 10O^il applied in duplicate to the wells of a microtitre plate. Plates
were left to coat overnight at 4°C. Goat anti-GST IgG was diluted 1 in 1000
and added to the plate. Antigen-antibody complexes were detected with
rabbit anti-goat IgG HRP. Colour was developed and read at 450nm. Figure
6.1 shows the graph obtained using 10 fold dilutions of GST. At a dilution of
O.lfagmr1 the level of detection was very low. GST concentrations of
100pgmr1 and lOpgmr1 gave maximum OD readings. A concentration of
lOOpgrnl"1 was in excess of the amount required to coat the plate. It was
decided that 10pgml"1 was the optimal coating concentration as this was the
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Figure 5.1: Determination of the optimal coating concentration of GST.
6.1.2 Serum titration
In order to ascertain the optimal dilution of bovine serum for the ELISA the
bovine sera had to be titrated. The immunoblots (Figures 5.4 and 5.6) gave
an indication as to which samples had median antibody titres. Samples from
calves c95, c106 and c108 were chosen. Samples from calf c95 (pre-bleed
and week 4 samples) were the only sera titrated against EspB. Sera was
used neat, 1 in 100 and then doubly thereafter until a final dilution of 1 in
6,400. The dilution producing an optical density reading of half the maximum
would be considered optimal. This is the dilution at which the ELISA is most
sensitive to changes in antibody level. It was found that the half maximum
value was obtained at a dilution of 1 in 200 for both the Int280 and EspB
titrations. All sera for use in ELISA were diluted 1 in 200.
6.1.3 Conjugate titration.
Sheep anti-bovine Ig HRP (Serotec) conjugates were used throughout to
detect antigen antibody complexes. For economical reasons all conjugates
were titrated to find an optimal dilution. All conjugates were found to have an
optimal dilution of 1 in 20,000.
6.2 Adult bovine sera screen.
To see how the results obtained from the experimentally challenged calves fit
in with the healthy adult bovine population, a number of healthy adult bovine
samples were screened for antibodies to Int280. Sera were obtained from Dr
Chris Low of the Scottish Agricultural College (SAC) and Dr Michael Pearce
of the Wellcome Trust IPRAVE study. The sera represented the immune
status of 263 (40 from SAC, 223 from IPRAVE) adult cattle. Microtitre plates
coated with GST and Int280-GST were used to detect antibodies to Int280 by
ELISA. Each sample was screened for background binding to GST, which
was subtracted from the Int280-GST readings to leave values representing
the level of antibody specific to Int280 alone. Figure 6.2 Illustrates the results
from the 40 samples obtained from SAC. The graph shows three populations
of results. The first population (black) is the range and frequency of
occurrence of the optical densities (OD) obtained against the Int280-GST
fusion protein. The second population (light grey) is the range of ODs and
frequency of occurrence of each OD obtained against the GST protein. The
final population (dark grey) is the effective range and frequency of optical
densities representing the anti-lnt280 IgG status of the animals. Figure 6.3
shows the range of optical densities representing IgG reactive to Int280
obtained from the 223 serum samples and the frequency with which each
range occurred. Many different plates were used in this assay therefore a
sample from the first plate with a median optical density value was included
on all subsequent plates so that results could be normalised and compared.
No comparisons between the data from the IPRAVE sample and SAC
samples can be made as the two populations of results were not
standardised to each other. Most of the animals tested had little or no
antibody (IgG) reactive to Int280. This was particularly notable among the
samples from the IPRAVE study with 173 of 223 samples having low/no
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antibody. Most of the samples obtained from SAC had levels of antibody that
gave OD values in the range 0.2-0.29. In a few of the sera tested very high
levels of anti-lnt280 IgG were detected.
■■■ anti intimin280/GST IgG
I I anti GST IgG
i i Effective anti intimin280 IgG
Figure 6.2: Graph to show the range and frequency of optical densities obtained from
40 adult bovine serum samples tested by ELISA for anti- GST, Int280-GST and Int280
IgG.
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Figure 6.3: Graph to show the range and frequency of optical densities obtained from
223 adult bovine serum samples tested by ELISA for anti-lnt280 IgG.
6.3 Detection of antibodies to Int280 and EspB in calves experimentally
challenged with Escherichia coli 0157.
Microtitre plates were coated with recombinant GST, Int280-GST and EspB-
GST fusions at lOpgrnl"1. The GST background was subtracted from the
Int280-GST and EspB-GST OD readings leaving an OD for the level of
antibody specific for Int280 and EspB. Figures 6.4-6.11 show examples of
the results obtained (all results can be seen in Appendix 4).
The amount of E. coli 0157 shed by each of the animals over the four-week
experimental infection period is shown in Figures 6.4-6.11. No E. coli 0157
was detected in the faeces of any of the animals prior to the experiment.
Most of the animals shed E. coli 0157 at some point during the experimental
infection, however there was considerable variation in the shedding patterns
from each of these animals. For example, calf c106 (Figure 6.5) did not shed
any E. coli 0157 while calves c117 and c108 (Figures 6.6 and 6.8) shed
consistently over the whole period. Calves c87 and c146 (Figures 6.4 and
6.11) displayed an enormous amount of variation in the level of E. coli 0157
shed. On day 14 approximately 3x105 cfu E. coli 0157 gram"1 faeces was
detected in c87 (Figure 6.4) despite no E. coli 0157 being detected on day
three, and relatively low amounts detected on all other days. Calf c108
(Figure 6.8) had a similar shedding pattern, with high levels (9x103 - 1.2x104
cfu gram"1 faeces) of E. coli 0157 detected on days three, 10, 17 and 21 and
very low levels detected in the intermediate samples (30-350 cfu gram "1
faeces).
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The amount of E. coli 0157 shed by calf c117 (Figure 6.6) was consistently
low. On days three, 14, 17, 21 and 24, only 1cfu gram"1 faeces was detected.
Levels were seen to rise on days seven and ten but only to 30 cfu gram"1
faeces. The highest level of E. coli 0157 shedding was exhibited by c121
(Figure 6.10). From day three onwards the level shed was high, peaking at
approximately 4.5x105 cfu gram"1 faeces. Results for this calf only extend as
far as day 21 as the animal was put down on day 23 due to a respiratory
illness.
The ability of the E. coli 0157 inoculum to colonise the calves appeared
unaffected by the level of antibody present. For example calves that did not
shed any E. coli 0157 were found to have both high and low anti-lnt280 or
EspB antibody levels. The same was true of animals that were colonised by
the inoculum. Of the animals that were colonised by the inoculum, shedding
of E. coli 0157 progressed for approximately one month.
Figures 6.4-6.7 show the level of anti-lnt280 immunoglobulin in four
experimentally challenged calves over a four-week period. On average the
level of anti-lnt280 antibody appears not to change. Many of the calves have
antibodies to Int280 prior to challenge however calf c87 (Figure 6.4) has very
little anti-lnt280 antibody prior to challenge and the level of antibody does not
change as the experiment progress. While the levels of antibody reactive to
Int280 were almost identical in the pre-challenge and week four post
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challenge samples, small fluctuations in antibody levels were detected in the
intermediate samples, although these readings tend to have larger errors
associated with them. In all of the animals the level of lgG1, lgG2 and IgM
appears low when compared with the total level of IgG.
The EspB antibody status in four of the 11 animals tested can be seen in
Figures 6.8-6.11.The basal level (the pre-bleed status) of anti-EspB IgG in
some of the animals was high, for example calf c95 (Figure 6.9) had a high
level of anti-EspB IgG prior to challenge with 0157. Other animals, for
example c146 (Figure 6.11) had or very low (or virtually no detectable) levels
of anti EspB antibody throughout the experiment. Despite the obvious
colonisation and consistent shedding of the E. coli 0157 inoculum in many of
the animals no change in the immune response was noted. The levels of
lgG2 and IgM in each of the animals were negligible and no response was
noted. It is apparent that experimental infection with E. coli 0157 failed to
stimulate an immune response in any of the animals.
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Days post challenge
Figure 6.4: Calf c87. Level of E. coli 0157 shed from an experimentally infected calf
over a four week period (left axis), and the level of anti-lnt280 immunoglobulin over the
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Figure 6.6: Calf c117. Legend as for Figure 6.4.
Days post challenge




























Figure 6.8: Calf c108. Level of E. coli 0157 shed from an experimentally infected
calf over a four week period (left axis), and the level of anti-EspB immunoglobulin



















































Figure 6.9: Calf c95. Legend as for Figure 6.8.
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Days post challenge









































Figure 6.11: Calf c146. Legend as for Figure 6.8.
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6.4 ELISA to determine the level of specific IgA present in the faeces of
experimentally infected calves
ELISA was used to provide an accurate picture of the level of anti-lnt280 and
EspB IgA in the faeces of the experimentally infected calves over a four-week
period.
6.4.1 Determination of the optimal faecal antibody preparation dilution
In order to determine the optimal dilution of the faecal antibody extract to
maximise IgA detection, a titration of the extract was set up. Faecal extract
diluted 1 in 2 and doubly thereafter to a final dilution of 1 in 8192 was used to
optimise the ELISA. Microtitre plates were coated overnight at 4°C with either
Int280 or EspB at lOpgrnl"1. Plates were blocked as described previously.
The pre-challenge sample from calf c312 was judged to have given a median
reaction by dot blot and was used in this titration experiment. Volumes
(100pl) of each faecal extract dilution were incubated with the appropriate
antigen for 90min at 37°C. Plates were washed and sheep anti-bovine IgA
was used to detect the antigen antibody complexes. Colour was developed
and read at 450nm. The titration curve is shown in Figure 6.12. From an
initial dilution of 1 in 2 the level of IgA detection was very quickly diluted out.
At a dilution of 1 in 32 the IgA in the faecal extract had been diluted to
beyond the limits of detection. It was decided that the optimal dilution of the
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6.5 Detection of IgA in faecal antibody preparations from experimentally
infected calves.
Microtitre plates were coated with GST and either Int280-GST or EspB-GST
at 10pgml"1. Plates were blocked as described previously. Faecal antibody
preparations from the experimentally infected calves were diluted to the
optimal dilution as determined previously. Volumes (1 OOjj.1) of each sample
were added to the wells of the microtitre plate for 3h at 37°C. An extended
incubation time was used to improve detection. Plates were washed and the
antigen antibody complexes detected with the use of sheep-anti bovine IgA
HRP.
The level of E. coli 0157 shed from four experimentally infected calves is
shown on Figures 6.13-6.16 (complete results may be seen in Appendix 4).
There is considerable variation in the level of shedding from each calf. Calf
c299 (Figure 6.13) shows a consistently high level of E. coli 0157 shedding
throughout the whole experiment. By day three the level of E. coli shed was
approximately 4.5x104 cfu gram"1 faeces, this rose to a maximum of 6x105
cfu by day ten. The level of shedding dropped off slightly towards the end of
the experiment but was still high. No £. coli 0157 was detected on day 28.
By way of contrast calf c313 (Figure 6.14) excreted the highest levels of E.
coli 0157 of any calf, but this was sustained for a period of only ten days.
The level of E. coli 0157 shed peaked on day ten at 1.3 x106 cfu gram"1
faeces. By day 21 no more E. coli 0157 was detected. Calf c307 (Figure
6.15) shows a similar pattern of shedding with a maximum of 3.6x104 cfu
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gram"1 faeces being detected on day 14, this rapidly falls off and by day 17
no more E. coli 0157 was detected in this animal.
Figures 6.13-6.16 also show the level of anti-lnt280 and EspB IgA in four
different animals over a four-week experimental infection. Results shown are
representative of all the animals tested (complete results may be seen in
Appendix 4) There is very little variation in the level of anti-lnt280 and anti-
EspB IgA during the four-week experimental infection. Levels of IgA detected
in the pre-challenge sample did not alter as the experiment progressed. A
number of the calves, for example c313 (Figure 6.14) had virtually no
detectable IgA to either antigen. Generally the level of IgA reactive against
either Int280 or EspB was low. Results from the dot blot analysis of these
faecal extracts, showed that very little anti-lnt280 or EspB IgA was present in
these samples and this was confirmed by the ELISA results.
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Figure 6.13: The level of E. coli 0157 shed from an experimentally infected calf
(c299) over a four-week period and the level of anti Int280 IgA over the same
period.







Figure 6.14: c313. Legend as 6.13
Figure 6.15: The level of E. coli 0157 shed from an experimentally infected calf
(c307) over a four-week period and the level of anti Int280 IgA over the same
period.














































Figure 6.16: c324. Legend as 6.15
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6.6 Total immunoglobulin
Both faecal antibody preparations and serum samples from the
experimentally infected animals were assayed by radial immunodiffusion
(RID) to ascertain the total IgG and IgA content of each sample. Volumes
(5pl and 10pl respectively) of serum and faecal antibody preparations were
loaded onto each agarose plate. The plates were incubated at room
temperature for at least 18h to allow the immuno-precipitation rings to form. A
high, medium and low bovine IgA and IgG standard of known
immunoglobulin content was assayed along side all the samples. Each
animal was found to have a consistent level of immunoglobulin over the four-
week period of infection. The IgG content of the bovine serum samples
ranged from 890 to 2100mgdl"1. The level of IgA present in the faecal
antibody preparations was determined the same way. The level of IgA found
in those samples that gave a good reaction by dot blot was below the level of
the lowest standard. All the faecal antibody preparations were found to have
less than 15mgdl"1. Immuno-precipitation had occurred around the well of
each of the samples indicating the presence of very low amounts of IgA.
Serum samples from the experimentally infected calves were assayed for
serum IgA. The results were similar to those for the faecal antibody
preparations in that each sample was found to have an IgA concentration
lower than that of the lowest standard (<15mgdT1).
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6.7 The role of anti-lnt280 and EspB antibodies in preventing AE
lesions.
Bovine serum from experimentally infected calves was used to prevent AE
lesion formation by E. coli 0157 on HeLa cell monolayers. HeLa cells were
infected with E. coli K12 as a negative control. The phase contrast image
(Figure 6.17a) is representative of all the fields examined. No adherent
bacteria can be seen and fluorescent actin staining (Figure 6.17b) with
TRITC-phalloidin reveals no actin polymerisation characteristic of AE lesion
formation. The merged phase and TRITC images (Figure 6.17c) show the
cytoskeleton of a normal HeLa cell monolayer. As a positive control HeLa
cells were infected with E. coli 0157, Zap 193. The x100 phase contrast
image (Figure 6.18a) shows a number of E. coli 0157 adhered to a HeLa
cell. Fluorescent actin staining of this cell (Figure 6.18b) reveals areas of
dense actin polymerisation. The merged image (Figure 6.18c) shows that
the actin polymerisation occurs directly beneath the site of bacterial
adherence. The E. coli 0157 bound to the HeLa cell has induced AE lesion
formation.
Bovine serum from experimentally infected calves, known to have antibodies
to both Int280 and EspB (as determined previously) was pooled and was
used to try and prevent AE lesion formation by E. coli 0157 Zap 193.
Bacteria were first cultured in Dulbecco's modified Eagle's medium (DMEM)
supplemented with pooled bovine serum diluted to 1 in 20 or 1 in 200.
Bacterial were then diluted in fresh DMEM supplemented with bovine serum
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at the appropriate dilution to give an effective infectious dose of 1 cfu HeLa
cell"1. The addition of bovine serum appeared to have no effect upon the
ability of E. coli 0157 Zap 193 to form AE lesions (Figure 6.19). Any micro-
colonies observed under phase contrast were large (Figure 6.19b).
Observation under fluorescence showed that the micro-colonies and had
formed large numbers of AE lesions beneath the site of adherence (Figure
6.19c). In both the positive control and inhibition assay areas of the HeLa cell
monoloayers were devoid of AE lesions, this tended to correspond to those
regions that were totally confluent. AE lesion formation was better observed
in areas of partial confluence.
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6.8 Discussion
A number of calves were experimentally challenged with an oral dose of
109 cfu E. coli 0157 via a feed tube straight to the rumen. Over a four-week
period the level of E. coli 0157 shed in the faeces of each animal was
monitored. Blood and faecal samples were taken so that the level of
antibodies to a number of surface and secreted components could be
examined over the same four-week period. ELISA and Western blot were
used to detect immune responses to a wide range of antigens.
The level of E. coli 0157 shed from these calves over the four-week
experimental infection was highly variable. A number calves (c85 and c106)
failed to shed any E. coli 0157, while others shed consistently high levels
throughout the experimental period. This is consistent with the findings of
others (Cray & Moon, 1995, Besser et al, 1997). Brown et al (1997) reported
that diet might affect the level of shedding observed. While no definite
relationship between diet and shedding was described, the level of E. coli
0157 shed from a number of calves increased when food was withheld. It is
likely that diet and other factors, for example age and health, influence the
level of E. coli 0157 shed from experimentally infected calves, and that the
influence of these factors varies between calves.
Work by Besser et al (2001) looked at the potential for calves experimentally
colonised with a low dose E. coli 0157 inoculum, to infect other calves (E.
coli 0157 negative) in the same isolation pens. By day 21 post-inoculation,
all calves, including those previously uninfected were excreting the challenge
strain. This may explain why the shedding figures from some of the calves
can dramatically increase during the course of the experimental infection.
The generation of recombinant EspB and Int280 allowed the detection of
bovine antibody specific to these proteins. In each case the background level
of antibody reactive to GST had to be considered and subtracted from the
recombinant fusion protein readings. It was found that most of the animals
examined had detectable levels of antibody that bound to GST. Analysis by
western blot showed that the level of antibody binding to GST was very low.
ELISA however demonstrated that the response was far more pronounced in
the sera from the latter half of the experiment. The reason for this is unclear;
indeed the reason for any antibody showing reactivity to GST is also unclear.
Work by Li et al (2000) used GST tagged Int280, EspB, EspA and Tir to
detect antibodies in the sera of patients infected with E. coli 0157.
Immunoblot analysis of the sera showed that there was a considerable
response to these recombinant antigens but no significant response to the
GST alone. Glutathione S-transferases belong to a group of detoxification
enzymes (Sommer and Nimtz, 2001). The GST used in the pGEX gene
fusion system originates from the parasite Schistosoma japonicum (Smith
and Johnson, 1988). It has been postulated that the GST proteins may offer
parasites the ability to modulate the host immune system (Sommer and
Nimtz, 2001). If true, GST proteins could induce an immune response in
animals exposed to such parasites. This may explain the low level affinity of
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some bovine antibodies to GST. No bovine anti-GST lgG2 or IgM was ever
detected and the level of IgA from the faecal preparations reactive to GST
was also low. It is possible that the IgG and lgG1 conjugates used, had some
cross reactivity to the GST component of the protein fusions. This however
does not explain the apparent increase in anti-GST titre in the latter half of
the experiment. One interesting observation, particularly in the Int280-GST
ELISAs was the variation in the negative controls. The background to GST
alone was consistently higher than the background to the Int280 fusion
protein (and to a lesser extent the EspB fusion). It is thought that the fusion of
either Int280 or EspB to the GST may occlude an epitope to which some of
the bovine antibodies react. It is important to remember that when GST alone
is used it is an entirely different protein in terms of conformation, to a GST
fusion protein.
There are therefore a number of problems associated with the subtraction of
the GST background from the fusion protein results to obtain a reading for
the level of antibody reactive specifically to Int280 or EspB. Firstly, owing to
the fact that both the GST and GST fusions bound to the purification columns
with reasonable affinity, we can assume that the active site of the enzyme
must at least be in the correct conformation. It is however impossible to
predict the shape of the remainder of the protein. Any change in
conformation may have a dramatic effect upon the immunogenicity of the
protein. Despite this however it is important to remember that both ELISA
and immunoblot rely on a degree of denaturation to either coat (ELISA) or
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resolve (immunoblot) proteins. In which case some of the epitopes will be
lost. It is entirely possible that antibodies detected by these methods are not
in actual fact the antibodies that offer protection in vivo.
It was also noted that there were a number of contaminating proteins eluted
from the affinity purification columns. Since all the fusion proteins were
generated in the same strain of E. coli it was assumed that most of the
contaminating proteins would be the same in each case and therefore would
have a negligible effect upon overall results.
Although by titration the optimal level of coating was determined as being
10pgmr1 it was difficult to decide how to equilibrate the level of GST. While
the level of total protein coated on the plate would be the same (lO^gml1),
the amount of GST would not be. The fusion proteins can be considered as
whole GST molecules with EspB or Int280 fragments of variable length
attached, hence the multiple band profiles of each fusion protein as
visualised by SDS-PAGE. In effect the level of background subtracted from
the fusion protein readings may actually be too high. To counteract this the
GST could have been coated at half the concentration (5pgml~1) and the
fusion protein at the dilution deemed optimal (10pgml"1). This may have led to
there being more GST in those microtitre wells coated with the GST fusion
protein, and hence too little GST background would have been subtracted.
So long as the method used was consistent and all results were treated the
same way any GST aberrations in the readings would be removed.
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As mentioned previously much work has been done using recombinant
antigens from £. coli 0157, the favoured method being the use of expression
systems that lead to the production of His-tagged rather than GST tagged
proteins. Such a system employed here may have significantly reduced the
level of background observed.
Sequence analysis of the recombinant antigens revealed that the EspB
protein had been generated with two errors and without a stop codon in the
correct position. Instead the stop codon upon the pGEX-4t2 vector provided
the signal to stop translation. As a result the recombinant EspB protein was
generated with an extra sequence of amino acids not present in the native
protein. The two Taq polymerase induced errors resulted in the substitution
of a glutamine residue for a glycine at position 17, and a serine residue for a
threonine at position 196. These errors may have affected the
conformation/antigenicity of the protein and may explain the low level of anti-
EspB antibody detected in the bovine sera.
Experimental infection with E. coli 0157 appears to have little effect upon the
antibody response to the various membrane and secreted proteins. Many of
the calves prior to challenge had detectable levels of antibody (lgG/lgG1) to
these proteins. The period of infection failed to have any effect on the level of
this response. Other calves appeared naive to these proteins prior to
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challenge, in these animals the experimental infection failed to generate an
immune response to any of the proteins examined.
The use of ELISA allowed a more detailed examination of the immune status
of these animals throughout the experimental infection. The levels of all the
bovine immunoglobulin classes were examined using this technique. A
screen of some 260 adult bovine serum samples revealed that in the majority
of cases the level of antibody to Int280 is very low. Of the 223 samples
obtained from Dr Michael Pearce, approximately 180 were found to be
negative for anti-lnt280 IgG. Whether or not these animals had ever come
into contact with E. coli 0157 is unclear. Most of the calves used in the
experimental infections had detectable levels of antibody to Int280 prior to
challenge. This raises the question, why do adult cattle have very low or no
anti-lnt280 antibody when most calves have detectable levels?
It is possible that the regulation of the LEE pathogenicity island is such that
specific environmental conditions are required to bring about expression of
the LEE antigens. Studies by Woodward et al (1999) showed that a bovine
E. coli 0157:H7 isolate was able to extensively colonise the gastrointestinal
tract of gnotobiotic calves. It was noted though that the bacteria were not
adhered to the mucosa and no AE lesions were detected. They postulated
that colonisation of the gastrointestinal tract of these animals by the E. coli
0157 strain used, was achieved through an alternative mechanism. In
contrast, Dean-Nystrom et al (1997) did observe AE lesion formation
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indicative of intimin expression, in neonatal calves (<12h and 30-36h)
experimentally infected with two different E. coli 0157 strains. Woodward et
al (1999) commented that subtle differences between strains yet to be
defined might account for the varying ability of E. coli 0157 to cause disease
in neonatal/gnotobiotic calves.
McNally et al (2001) were able to show that growth media affected the
production of LEE antigens. It is possible that the lack of commensal
organisms in gnotobiotic/very young calves has a dramatic effect upon the
composition of the gastrointestinal secretions, which in turn could affect the
regulation, and production of a number of E. coli 0157 virulence
determinants. If the expression of antigens such as Intimin is affected by
such host factors, changes in the gastrointestinal tract as the calf matures
may explain the lack of a detectable Int280 response among adult cattle.
Calves acquire all their maternal immunoglobulin from the mother's
colostrum; the neonate does not acquire maternal IgG through a placenta, as
human beings. It is vitally important that the calf receives the colostrum as
soon as possible as in the first few hours the wall of the gut is permeable to
large molecules and allows immunoglobulin through. Lissner & Schmidt
(1996) showed that bovine colostra contained antibodies reactive to E. coli
0157 proteins such as verotoxin and haemolysin. In a similar study by
Crivelli et al (2000) human colostra was investigated and found to contain
antibodies reactive to EspB, EspA and Intimin. The passage of bovine
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immunoglobulin from cow to calf via the colostrum could provide the antibody
that was detected in the pre-challenge samples of most of the calves used in
the experimental infections.
Work by Dean-Nystrom et al (1997) showed that the ingestion of colostrum
by calves prior to experimental infection with E. coli 0157:H7 failed to
prevent colonisation and AE lesion formation. However it is possible that the
inoculum used in this study (1010 cfu) was too large to properly assess the
effects of colostrum. In another study Dean-Nystrom et al (2002) were able to
show that three pregnant swine vaccinated with purified Intimin mounted
significant serum and mucosal (colostrum) responses to this antigen.
Furthermore piglets suckling from the vaccinated dams were protected
against colonisation with E. coli 0157. Interestingly a lower dose inoculum
(106 cfu) was used in this study.
It is evident though that in most adult cattle there is no systemic immune
response to Int280. In order for there to be anti-lnt280 IgG in the colostrum a
cow must have had recent exposure to Int280 that generated a systemic
response. The lack of any adult immune response to Int280 would suggest
that this is not the case.
Results described in chapter three show that R3 core LPS is common among
the commensal E. coli of cattle. The association of the R3 core with E. coli
0157 and other VTEC as observed by Currie and Poxton (1999) and Amor et
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al (2000) means that this increased exposure to R3 is likely due in part to
VTEC among the commensal flora. In a study looking at the prevalence of
VTEC in healthy adult cattle, Blanco et al (1996) observed that 10% of the
VTEC isolated from cattle were also positive for the eae gene. Orden et al
(1998) noted similar findings albeit in diarrhoeic calves. It is therefore
possible that a number of bovine commensals harbour the LEE pathogenicity
island, and it is these organisms that provide the constant stimulus to the
mucosal immune system. At birth the neonatal calf is fully immunocompetent
but immunologically naive and is exposed to a wide range of potential
pathogens very quickly (Barington & Parish, 2001). The colostrum provides
protection while the calf begins to produce its own antibody. It is therefore
very likely that LEE positive organisms in the mother's commensal flora
provide the Int280 and EspB challenge that leads to the immune response
we detect in these calves. The porous nature of the gut in this period of the
calfs life would lend itself well to the passage of antigens into the blood
resulting in the generation of a systemic IgG response. As the calf matures
the level of protection offered by the local mucosal immune system
increases, and the barrier to colonisation provided by the commensal flora
improves. If the innate and acquired facets of the mucosal immune system
function well then it is possible that a subsequent re-challenge to the
systemic immune system by a LEE positive organism is less likely. This
would explain the low level of antibody to Int280 among adult cattle, as any
systemic response would be short-lived and possibly undetectable after a
year without constant re-challenge. Colostrum however would contain anti-
187
Int280 antibodies as the mucosal immune system will be constantly exposed
to Int280 and other LEE encoded antigens.
The level of IgA to EspB and Int280 was examined using faecal samples
treated with protease inhibitors to preserve the immunoglobulin. Initially dot
blots were used to detect anti-lnt280 or EspB IgA. Detectable levels of IgA
were found in only a few of the samples investigated. Despite attempts to
process the samples as soon as possible after collection, delays meant that
the exact time between collection and processing was often very variable. It
is likely that protease destruction of IgA prevented detection in many of the
faecal samples. The time taken for faeces to pass through the digestive tract
of a calf is considerable and therefore a degree of protease activity will
already have occurred. Detection could have been improved by starting with
a larger sample of faeces. Filter sterilisation would also have considerably
reduced the protein content of the samples since the membranes used in
these filters are nitrocellulose. Low protein binding filters were unavailable.
ELISA proved a better technique for IgA detection but levels in all the animals
were very low. The level of IgA over the four-week period of experimental
infection did not change in any of the animals.
The LPS of E. coli 0157 was the only antigen found to elicit an immune
response. Four experimentally challenged calves negative for anti-E. coli
0157 LPS IgG prior to challenge were subsequently found to have mounted
a response against the LPS. Chart et al (2002) recently reported the
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detection of anti-E. coli 0157 LPS antibodies in a pregnant woman with
haemolytic uraemic syndrome. Two days after the onset of diarrhoea, anti-
0157 LPS IgM was detected in the sera of the patient. By day ten this
response had diminished and an IgG response began to develop. It is clear
that E. coli 0157 LPS does induce an immune response, although in this
case the development of disease will have facilitated the production of
antibody. However Currie et al (2001) noted that a number of healthy adults
used in their study had anti-0157 LPS IgG, an indication that immune
responses to E. coli 0157 LPS may be acquired in health. Currie et al (2001)
showed that the response to the LPS of E. coli 0157 in health could be
largely attributed to the R3 core and it is unclear whether or not the
responses detected in the experimentally infected calves or in the study by
Chart et al (2002) are core specific or due in part to the O-antigen.
No response was detected in four calves (c87, c108, c117 and c121) and in
two calves (c106 and c140) the response detected was low and did not
change. The results observed in calves c106 and c117 are likely due to the
fact that neither animal was colonised by the E. coli 0157 inoculum. On the
whole there was no correlation between the ability of the inoculum to colonise
and the level of antibody reactive to 0157 LPS. Although no E. coli 0157
was detected in the faeces of calf c81 at any point during the experiment, it
elicited the best response to LPS of all the calves. It would be interesting to
determine at what point during the experimental infection the LPS response
developed. If the IgG response was rapid and developed within three days
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(prior to the first faecal sample) it may have helped prevent colonisation of
the inoculum in this animal. Other animals that shed consistently well
throughout the experiment, for example c95 showed a very muted response
to the LPS.
A study was undertaken to ascertain whether or not the antibodies detected
in the sera of the experimentally infected calves function to prevent AE lesion
formation. Fernandes et al (2001) showed that IgA obtained from human
colostrum inhibited enteroaggregative E. coli from binding to HEp-2 cells by
binding and neutralising the aggregative adherence fimbrial adhesin II. Dean-
Nystrom et al (2002) found that colostrum from dams vaccinated with purified
Intimin contained antibodies reactive to the C-terminal region of Intimin
responsible for receptor binding. Pre-treatment of E. coli 0157 with colostrum
from the vaccinated dams was found to significantly reduce the ability of the
bacteria to form AE lesions on a HEp-2 monolayer.
Without bovine serum E. coli 0157 Zap193 was shown to produce many AE
lesions. The addition of bovine serum had no apparent affect on the ability of
the E. coli 0157 to cause AE lesions. In many cases the bovine serum
appeared to 'improve' the quality and quantity of the lesions observed.
In order to determine if the bovine serum had had any effect upon AE lesion
formation, a method of quantification had to be devised. It was decided that
100 cell nuclei and the number of lesions associated with these cells would
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be counted. Owing to slow image reproduction and the rapidity with which the
fluorescent image diminished, it was almost impossible to count the lesions.
It was also noted that there was an uneven distribution of AE lesions across
the HeLa cell monolayers. While areas of total confluence were devoid of
lesions, many could be seen in areas where the HeLa cells were only
partially confluent. This could be due to a preference E. coli 0157 Zap 193
has for binding to the edge as opposed to the upper surface of a cell. Any
reason for this is unclear.
Far from inhibiting the formation of AE lesions, the addition of bovine serum
from experimentally challenged calves appeared to increase the size of
micro-colonies and the number of the AE lesions observed. This is possibly
due to antibody-mediated agglutination of the bacteria. In vivo opsonization
and agglutination of bacteria by antibody facilitates uptake by macrophages
and phagocytes. On a HeLa cell monolayer however, agglutination of the
bacteria is not followed by phagocytosis and the bacteria are left to sit on the
HeLa cell. Wolff et al (1998) noted that contact with HeLa cells activated the
type III secretion system, it is possible therefore that antibody-mediated
agglutination facilitates contact between large numbers E. coli 0157 and the
HeLa cells and increases the number of AE lesions observed.
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Conclusions
Since 1982 E. coli 0157 has emerged as a serious human pathogen. Cattle
are known to be the reservoir for these bacteria and E. coli 0157 disease in
humans is most often associated with direct contact with animal faeces or
indirectly through the consumption of contaminated food. While adult cattle
appear unaffected by E. coli 0157 and able to transiently carry and shed
(Griffin and Tauxe, 1991), mild disease in very young calves has been noted
(Brown et al, 1997). A number of studies have been able to reproduce EHEC
pathology (microvillus effacement and AE lesion formation) in bovine tissue
explants, colostrum deprived and neonatal calves. Thus the answer to the
question of whether or not cattle are intrinsically resistant to E. coli 0157, is
no. Indeed a close relative of E. coli 0157, E. coli 026, is a well-recognised
bovine and human pathogen, causing similar disease in both (Gunning et al,
2001).
The observation that colostrum deprived, or very young, immunologically
naive calves are susceptible to E. coli 0157 suggests an important role for
the bovine immune system in protection against EHEC disease. The study
outlined in this thesis combined cloning technology with immunological and
molecular detection techniques to examine the role of the bovine
gastrointestinal microbiota and immune response in healthy and
experimentally challenged cattle in the protection against E. coli 0157
associated disease.
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A four-week period of experimental E. coli 0157 infection in 22
conventionally reared male calves failed to stimulate an immune response to
either Int280 or EspB. Many of the calves had antibodies reactive to Int280
prior to challenge and the period of experimental infection did not alter the
level of the response detected. In those animals naive to Int280 prior to
challenge, no response was detected at any point during the experimental
infection. In general there appeared to be less detectable antibody to EspB
than to Int280, although no direct comparisons may be made. In most cases
levels of anti-EspB antibody before, and after challenge did not change.
A study was carried out to determine the distribution of the five core types of
E. coli within two populations of faecal E. coli isolates from healthy humans
and cattle. In accordance with the findings of other studies, R1 core LPS was
the most frequently isolated core type in both populations (Amor et al, 2000,
Gibb et al, 1992). The levels of R2 and R4 core LPS were similar within both
groups of isolates, with R4 making up slightly more of the faecal bovine
isolates. The level of R3 core detected among the bovine isolates was
significantly higher than the level detected among the human isolates.
Studies by Currie and Poxton (1999) and Amor et al (2000) demonstrating an
association between R3 core LPS and VTEC suggest that the significantly
higher level of R3 core LPS among bovine faecal E. coli isolates could be
due to VTEC present in the commensal flora of cattle. Furthermore work by
Blanco et al (1996) showing that a number of bovine VTEC isolates carry the
LEE pathogenicity island, suggests that the elevated level of R3 exposure
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among cattle could be due in part to EHEC in the bovine commensal flora.
This is important when considering the results presented in chapter six which
showed that most adult cattle examined had no detectable antibody to
Int280. This is in contrast to the often-high levels of anti-lnt280 antibody
detected in the sera of a number of the calves prior to experimental
challenge. Although all calves were screened for E. coli 0157 carriage prior
to experimental infection, the production of LEE antigens by other E. coli not
detected may have induced the immune response detected in many of the
animals.
Although a number of studies have shown that bovine, human and porcine
colostra (Dean-Nystrom et al 2002, Lissner et al, 1996, Parissi-Crivelli et al,
2000) contains antibodies reactive to EHEC/EPEC virulence determinants,
for there to be IgG reactive to Int280 in bovine colostra, there must be
constant exposure to this antigen so as to generate memory cells able to
produce antibody. The lack of a systemic response to Int280 among adult
cattle suggests that the incidence of systemic exposure to antigens such as
Int280 is low and that bovine colostra might not contain anti-lnt280 IgG.
One possible explanation for these observations is that at birth calves
encounter a large number of organisms very quickly and will generate
antibody responses against most of the antigens they encounter (Barrington
and Parish, 2001). As mentioned previously it is possible that a number of
these organisms contain the LEE pathogenicity island and hence have the
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capacity to produce Intimin and EspB. Thus in experimentally infected calves,
antibodies detected prior to challenge could have been generated at or soon
after birth upon exposure to the mother's commensal flora. As the mucosal
immunity in these animals develops, systemic challenges may begin to fall off
resulting in the decline of the IgG response detected. This would explain why
adult cattle appear to have little or no antibody reactive to Intimin or EspB.
The constant challenge to the gastrointestinal mucosa will perpetuate the
mucosal immune response and could lead to the production of IgA reactive to
LPS, Intimin and EspB in colostrum.
Work by Hoque et al (2000) linked increased exposure to diarrhoeagenic
enterobacterial species with the development of an anti-core LPS antibody
response that was possibly protective. An investigation of healthy human and
cattle sera showed that in cattle the level of anti-R3 core antibody was
significantly higher than the response to R1, R2 and K12. In humans no
significant differences between the levels of anti-R1, R2 and R3 core LPS
were observed. Currie et al (2000) demonstrated that mucosal immunity to
LPS may play an important role in protection from EHEC disease. It is
possible therefore that the increased exposure to R3 core LPS in cattle leads
to a protective immune response, that provides an effective mucosal
protection. Data presented in this thesis show that LPS was the only antigen
found to stimulate an immune response in any of the experimentally infected
calves. While the role of this immune response is unclear it may play an
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important part in the prevention of EHEC colonisation. Further work is
required to fully characterise this response.
No anti-EspB or Int280 IgA was detected in the faecal antibody preparations
of any of the calves tested. The level of mucosal immunity needs to be
studied and future work should take into consideration the rapid degradation
of IgA in faecal samples. Protease inhibitors should be added to freshly
collected faeces as soon as possible to minimise IgA loss. The use of
protease inhibitor tablets may make this easier.
While recombinant antigens offer an opportunity to examine the immune
response to individual components of a virulence network such as the LEE
pathogenicity island, it should be noted that due to the large GST tag the
antigenicity of the protein could have been altered. The EspB protein was
generated with a number of errors and the low responses detected in the
experimentally infected calves could have resulted from the defects
destroying vital epitopes. Any future work would be recommended to use a
smaller protein tag, for example the His-tag system, which might have less of
an impact on the recombinant conformation.
Owing to the limitations of time it was possible to generate only Int280 from
EDL933 (Int280y). It is possible that other intimin types show varying degrees
of immunogenicity in cattle and could provide an answer as to why E. coli
026 causes bovine disease. It would be interesting to conduct a number of
experimental infections with other E. coli strains expressing different intimin
types.
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The demonstration by Hoey et al (2002) that the receptor for verotoxin, Gb3 is
present on bovine intestinal tissue leads to the possibility that antibody-
mediated protection may neutralise the effects of this toxin in cattle. The
generation of a functional recombinant verotoxin B subunit would be a vital
tool in helping to ascertain a role for any antibody reactive to the toxin.
Although it was not possible to generate recombinant Vt2B here, a number of
studies have achieved it through different means (Gunzer and Karch, 1993,
Acheson and Breucher 1994, Byun et al, 2001). It would be worthwhile
pursuing these ideas and utilising some of the technology to generate a
recombinant B-subunit.
There is hope that an intimin-based vaccine may provide a way of indirectly
avoiding human disease by preventing the colonisation of E. coli 0157 in
cattle. This thesis has shown that despite often-large levels of anti-lnt280 or
EspB IgG, the ability of E. coli 0157 to colonise calves appears unaffected.
The proteolytic Int280 and EspB fragments generated during the protein
expression and purification procedures appeared to exhibit varying degrees
of immunogenicity. This was particularly noticeable with the Int280
fragments. It would be interesting to examine which regions of Intimin are
most immunogenic in cattle. The results of such studies may be able to
pinpoint fragments of intimin that offer vaccine potential. It is possible that
Intimin expression is under considerable regulation in the bovine host and
that other factors for example pili are more important in initial adhesion. Thus
vaccine development should not only look at the possibility of Intimin variants
with differing immunogenicity but other factors that may offer better targets.
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Appendix 1
Buffers and solutions
Phosphate buffered saline (PBS)
Dulbecco A tablets (Oxoid BR14), One tablet in 100ml dH20
Polyacrylamide gel electrophoresis (Laemmli, 1970)
Double strength separating gel buffer (0.75M Tris-HCI, pH8.8, 0.2% w/v
sodium lauryl (dodecyl) sulphate: SDS)
Tris (hydroxymethyl) methylamine 91 g
SDS 2g
PfH20 1000ml
Double strength stacking buffer (0.25M Tris-HCI, pH6.8, 0.2% w/v SDS)
Tris (hydroxymethyl) methylamine 15g
SDS 1g
PfH20 500ml
SDS-PAGE Electrode buffer (0.025M Tris, 0.192M glycine, 0.1%w/v SDS,
pH8.3)
Tris (hydroxymethyl) methylamine 6g




Double strength sample buffer (0.125M Tris-HCI, pH6.8, 4% w/v SDS,
20% v/v glycerol, 2% v/v 2-mercaptoethanol, 0.002% v/v bromophenol
blue)
Tris (hydroxymethyl) methylamine 1.5g
SDS 4g
Glycerol (20% v/v) 25g
2-mercaptoethanol 2ml
Bromophenol blue (0.05% aqueous solution) 4ml
PfH20 100ml
Immunoblotting
Western blotting electrode buffer (0.025M Tris, 0.192M Glycine, 20% v/v
methanol, pH8.3)




Tris buffered saline (TBS: 0.02M Tris-HCI, 0.5M NaCI, 0.25% v/v, pH7.5)




Tween Tris buffered saline (TTBS: 0.02M Tris-HCI, 0.5M NaCI, Tween-
20pH7.5)





3% fish gelatin (v/v) in TBS
Antibody buffer
1% fish gelatin (v/v) in TBS
Horseradish peroxidase (HRP) colour development solution A
4-chloro-1-naphthol 60mg
Methanol 20ml
Horseradish peroxidase (HRP) colour development solution B
Hydrogen peroxide 60pl
TBS 100ml
Solutions A and B were mixed immediately prior to use
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Coomassie Blue stain (Hancock and Poxton, 1988)
SDS-PAGE proten gels were incubated over night in solution one and






























imoter region: bases 2-216
CAP binding site: bases 95-132
RNA polymerase binding site: bases 133-178
Lac repressor binding site: bases 179-199
if transcription: base 179
:everse priming site: bases 205-221
-ccdB gene fusion: bases 217-810
LacZa portion of fusion: bases 217-497
ccdB portion of fusion: bases 508-810
ning site: bases 243-262
iker: bases 262-312
™ Cloning site: bases 294-295
ning site: bases 328-347
orward (-20) priming site: bases 355-370
0 Invitrogen
life technologies
neo (kanamycinl promoter region: bases 1021-1070
neo (kanamycin) resistance gene (ORF): bases 1159-1953
bla promoter region: bases 2062-2156
RNA polymerase binding site: bases 2062-2143
-35 region: bases 2087-2093
bla promoter (P3): bases 2116-2122
Start of transcription: base 2122
Ribosome binding site: bases 2145-2149
bla (ampicillin) resistance gene (ORF): bases 2157-3017







M13 Reverse priming site | T3 priming site
CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTCA GAATTAACCC TCACTAAAGG
GTGTGTCCTT TGTCGATACT GGTACTAATG CGGTTCGAGT CTTAATTGGG AGTGATTTCC
—I Spe I Sse8387 I (Pst I) Pme I EcoR I EcoR I Not I
GACTAGTCCT GCAGGTTTAA ACGAATTCGC CCT1*EH3||EAGGGC GAATTCGCGG
CTGATCAGGA CGTCCAAATT TGCTTAAGCG GGA0H233SSBTTCCCG CTTAAGCGCC
T7 priming site M13 Forward (-20) priminq site
I I I ^
CCGCTAAATT CAATTCGCCC TATAGTGAGT CGTATTACAA TTCACTGGCC GTCGTTTTAC
GGCGATTTAA GTTAAGCGGG ATATCACTCA GCATAATGTT AAGTGACCGG CAGCAAAATG
«quence of pCR®4-TOPO has been compiled from information in sequence databases, published
ices, and other sources. This vector has not yet been completely sequenced. If you suspect an error in




Vector maps and sequence information




















































GGGGGGGCCTCCArT 'COOGG G TTC

































AGCCCCTTAGC G GTTTGA QAT CCATA T CG AACGCG TCC GTT T T AAAaza-A
-AZA
7809BOO8124850 AGCTTTATTCTGGCTCTCAAAAACGGCCTGCTGAATCTGATAGCTTTGCGCCA Q TTTTGT GGT T CTGCAATAGAGTCACC CTTGCCGAGTA ,r~. 880990 ATCGCTTCAAATCAC AT GTAGT G Qualitycolorcoding0-1415-2425-34
>35
ClustalWM l ipleSequenceAlignmentResults:E BpGEXfor/r vequ nces 15630146759 1EspBATGAATACTATTGATAT C CAAGTAACGTGGTTAATTCCG TC GAG GTA ACCG GCT C T ATT TC T90 2SarnpleEspBf-pGexforACTGGTTAATTCCGCTTC GGGA TAC ACCGGC CTTCC GTG AT GCCG TCTG T63 3SampleEspBr-pGexrev0 91105620135165680 1EspBTTATCAATTGATTCAC TGC T C G TGGTAAGG TGATATTGT GC GA C GA C A A CTCC C A GG G180 2SampleEspBf-pGexforTTATCAATTGATTCAC TGC T C GATGG A GTTGAT TTGT GC A C GAAATT AA A CTCC C G TGGTG153 3SampleEspBr-pGexrevTCAAT-GAT-CA-TCTGCTT CTG TGGT AG T-GATATTG AAGCT GC GA -T A A CCG AGATGGTG82 181956210241556270 1EspBACTCTATTGCAGGATTACC ACAAAAAC AT GGCGCAA CTATCA ATT GC GGCCGT T GA CCAGAT A GCT T270 2SampleEspBf-pGexforACTCTATTGCAGGATTA C ACAA AACAATGGCGC A G TCA C CAGGCCGTTTTTG GCCAGAT A GCT TT243 3SampleEspBr-pGexrevACTCTATTGCAGGATTA C ACAA AACAAT GGCGC G T TCA GCAGGCCGT T C GA A GCT T AG172 2718563001314566 1EspBGAAAAAAAAGCCGCGGC CCGCTG TTTGGTTGGC GGAT A TTC T GCAT GT TT TTCT TTGC GC ATGAACAAC360 2SampleEspBf-pGexforGAAAAAAAAGCCGCGGC CCGCT TTTGTTGG GGAT A TTC TCA AT G GTCTT T C TGC AA AA AAC333 3SampleEspBr-pGexrevGAAAAAAAAGCCGCGC CCGCT TTTGGTTGGCGG AT A TTC T CAT G GAT TT TTCTTTTG AA GAA AAC262 36175690402135650 1EspBGCGGCTAAAGGGGCTG TGAG TT CTGAAAAAGCAAGCTCTGCATCTT A CTTGCGGCT AGG GC A AAAGCT450 2SampleEspBf-pGexforGCGGCTAAAG GGCTG TGAG TT CTGAAAAA C GCT T ATCTT CTGCGGCTTCTG GA AAA CT423 3SampleEspBr-pGexrevGCGGCTAAAGGGGCTGT AGATT CTGAAAAAGC GCTCTGCATCTT CTGTGCGGCT AGGC A AAAGCT352 45165680951240 1EspBCTGGTCAAGGCTACGGAAAGTGTTGCTGATGTCG AG AG CAT CAGTGC GA C ATG C CAA A GCC540 2SampleEspBf-pGexforCTGGTCAAGGCTACGGAAAGTGTT CTGATGTCG AGGAG CAT CAGTGC GA C AT C CAC AAGCA C513 3SampleEspBr-pGexrevCTGGTCAAG CTACGGAAAGTGTT GATGTCGCAGAGGAGGCAT CAGTGC T GAGC T GCCACAA AAA CC442
541556701586001563































GCTACTATGTCCATTGCA AAATTACC TCCGGGT A GGG GCCT T GAACTCAATTGGATAGACATCGA GCTCTCC GGT T G'\TCGTTGTACC Qualitycolorcoding■■■■■0-1415-22 3■>35
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GCTTT AGTTAAAC GCGAG CAAATCCGC TC GTGT A TTC A
A
mi
610567897023 AAAGTGCCTCGT GCTTTAAC TCCC TCGCTGAAGTC CT CG CGGA TG TTGT GTCG ACG CA AT /A_ 75067898123 CCCGTGGTTGCCTAGT GA3A CCCAG0OOA •AA/\A _ 88090 AGCATCTKC TTGCG/ATCAG Qualitycolorcoding0-1415-2425-34
>35
ClustalWM l ipleSequenceAlignmentResu ts:Inti iy:pGEXfor/r vequ nces 189190561 20193551 16680 1IntiminCAGGTCGTCGTGTCTGCTAAAA CGCGGAGA G CTT AGCACTTA TGCCA TGCGGTTA AT TT TCAAA CA T1980 2Samplelntf-pGexforCCA CATT8 3Samplelntr-pGexrev0 198195620101242 1550 670 1IntiminACTGAGATTAAGGCTGA A AC CTGCAG AGC AATG TAAGG T C TAA T TCTG T TGAAA G TC GCCA2070 2Samplelntf-pGexforACTGAGATTAAGGCTGA A CAACT AG GC A TG TA GAT TATTAAA TCT C GTT TGAAAC TC GCCA98 3Samplelntr-pGexrevGAGATTAAG-CTTA GACAACTGCAG GC TGGTA GG T CT TAAAT TACT A T ATAAAC TCAGCCA86 20718562100115321 14660 1IntiminGTTAATAATCAATCCG T C T TCAA AAACT TGGGATGTTCCGGTAAG C AACGC A C A CA GGGA G TG TCGT2160 2Samplelntf-pGexforGTTAATAATCAATCCCATTCTCAACAAACTT GG GTTCGGTAAGTCT AACGC G ACGGGA A ATG TCGT188 3Samplelntr-pGexrevGTTAATAATCAATCC- CATTCTC ACAAACT GG ATGTTCGG AAGTCT AC C AC GGG G TCGT175 216175621902022 1356250 1IntiminGCGACGATAACACTAA TT C GTT CGCCG AAAGCGA TGTTAGT C CAGT GTGG GCTGA G TAAGCG T AG C2250 2Samplelntf-pGexforGCGACGATAACACTAA TT C GTT CGCCG AAAGC A TGTTA TGC AC G C GTT G G T A G TA C TGA C278 3Samplelntr-pGexrevGCGACGATAACACTAACTT C GTTCCGCCG AA GC ACTGTTAGT C AC GT AGTATGG G T AGGTTC A T A C265 22516562280193 12564 1IntiminACTTTTTTTGATGAACTGAAAA CAACAAGG GAT T TTGG AACAATG CAGAGCGAGT G CT ATG C C AT2340 2Samplelntf-pGexforACTTTTTTTGATGAACTGAAAA T AC CAAGG GAT TT TTGG A CA G C GACGA T C A TA G C TAT368 3Samplelntr-pGexrevACTTTTTTT ATGAACTGAAAA TGAC CAAGG GAT TT TTGG A CA G C GACG TGCCT ATTG C AA T355 23415562370185402 163 1IntiminGGTCAGTTTAAACTGAAAGCAAGCGGTG TTG TA ATA CAG TA AAA TC GTATC CT G GC TCAGGG2430 2Samplelntf-pGexforGGTCAGTTTAAACTGAAAGCAAGCGGTG TTG TA ATA CATG T C G AAAC GTATC CTGT G GC TC GGG458 3Samplelntr-pGexrevGGTCAGTTTAAACTGAAAGCAAGCGGTG TG T GT C T TTCATG T C GAAAA CAG ATC CG CTT A T A GG445
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ClustalWM ltipleSequencA ignmentRe u ts:V rotoxinpGEXfo /r vseq ences 4516568095124 1verotoxinATGAAGAAGA GTTTATG CGGT23 2SampleVtBf-pGexforCTGAGCCCGT T GTGGTGGCGACCATCCTCCAAAATCGG TCC CGG AT CAT GAGATG T GT83 3sampleVtBr-pGexrevGGGCTGGCAA CCACTTTG TGGTGG GACCATCCT CAAAATG TCC GGAT CATG GATG T GT540 5415567086013 1verotoxinTTTATTTGCATTAGCC G TAATGCAATGG G C G TGTGCA A GT AATTGAT C T ATG ATG C C TT13 2SampleVtBf-pGexforTTTATTTGCATTAGTCTG AAT C AGGCGGC G TGCGCA A GT AATTGAC GTA AG AATG C TT173 3sampleVtBr-pGexrevTTTATTTGCATTAGTC G TA CAATGGCG C G TGCGCA A GTA AATTGAT C GTATG AATGA TT630 6314566079702 1verotoxinTACAGTGAAGGTTGACGGGAAAGAATACTGGACC GTCGC GGAT T CAA C T ACTAA TG CA TTA GA T203 2SampleVtBf-pGexforCACAGTAAAA TGGCCGGAA G ACTGGACCAGTCGCTG AAT T CAAC GTT TG AA GT CTC G TA G AT ACTG63 3sampleVtBr-pGexrevCACAGTAAAAGTGGCGG AA G GTACTGGACCAGTCGC G AATCTGCAA C TACTA TG CA TTA GAAT720 7213565068981 1verotoxinCACAATCAAATCCAGTACCTGTGA AGT CG ATTTG T AAGT CA A TAAG C G270 2SampleVtBf-pGexforCACAATCAAATCCAGT CTGTG T AGGT G ATTTG TGAAGT CAG TAATT ACTGAGGCA ACCTG TC G T353 3sampleVtBr-pGexrevCACAATCAAATCCAGT CTGTG T AGGT G ATTTG TGAAGT CAG TAATC G G AT ACCTG TCG G T810 8112564057890 1verotoxin270 2SampleVtBf-pGexforTGGGTAACAA TGGGATCCCC GGAATTCCC GACTCGAG G AT GT TA T AC TC CCG GC T G443 3sampleVtBr-pGexrevTGGGTAACAAGTGGGATCCCCAGGAATTCCC CGACTC ACCGC TC TGA TA G TC CTCGCGC TTT -899 901156304679 1verotoxin270 2SampleVtBf-pGexforATGACGGTGAAAACCTCTGACACAT CAGCCCG G C GTCACA CTT TC GT AGG C G AGG T533 3sampleVtBr-pGexrev-AGACGGA906
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Figure A4.1: Calf c81. Level of E. coli 0157 shed from an experimentally
infected calf over a four week period (left axis), and the level of anti-lnt280





I ~~| Level of E. coli 0157 shedding (cfu gram'1 faeces)
Figure A4.2: c87. Legend as A4.1
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Figure A4.3: c95. Legend as A4.1














Figure A4.6: c111. Legend as A4.1
Figure A4.7: c117. Legend as A4.1
Figure A4.8: c118. Legend as A4.1
244
Figure A4.9: c121. Legend as A4.1








Figure A4.11: c146. Legend as A4.1
Figure A4.12: Calf c81. Level of E. coli 0157 shed from an experimentally
infected calf over a four week period (left axis), and the level of anti-EspB
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Figure A4.15: c106. Legend as A4.12
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Figure A4.20: c121. Legend as A4.12
Figure A4.21: c140. Legend as A4.12
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Figure A4.23: Calf c295. Level of E. coli 0157 shed from an experimentally infected calf
over a four week period (left axis), and the level of anti-EspB IgA over the same period
(right axis).
Level of E. coli 0157 shedding (cfu gram"1 faeces)
+ Anti-EspB IgA
Figure A4.24: Calf c299. Legend as A4.23
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Figure A4.29: Calf c295. Level of E. coli 0157 shed from an experimentally infected calf
over a four week period (left axis), and the level of anti-INT280 IgA over the same period
(right axis).






























Figure A4.30: Calf c299. Legend as A4.29
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Figure A4.32: Calf c313. Legend as A4.29
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Figure A4.35. Calf c296. Level of E. coli 0157 shed from an experimentally infected calf
over a four-week period
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Figure A4.37. Calf c310. Legend as A4.35
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